European Association for Vision and Eye Research
European University Professors of Ophthalmology

EVER 2018

Annual Congress

October 4-6, 2018

EUPO 2018

Course on Retina, Intraocular Inflammation & Uveitis

October 3-4, 2018

Programme book

Nice, France

www.ever.be
www.eupo.eu

European Association for Vision and Eye Research

EVER 2019

October 17-19 in Nice, France

www.ever.be

Table of contents

Word from the President

Dear Friends for EVER,

It is a great privilege to be the current President of EVER. The executive committee, the EVER board and the logistic staff are working hard to maintain the quality and the attractiveness of this unique meeting in Europe. EVER is a subtle combination of basic and clinical research that is able to satisfy the expectations of both clinicians and researchers, which remains a challenge and one of our greatest ambitions. Listening to your feedback, attendees, speakers and pharma partners included, we have prepared with the commitment of our Program Secretary, Francesca Cordeiro, a new and condensed format for 2018. We do sincerely hope that this alchemy will produce a fruitful and successful meeting for most of you.

I am very heartened by the enthusiasm and the achievements of the young generation to EVER, and I greatly appreciate their contribution. Now we have Gauti Johannesson, representing this new generation and sitting in our EVER board. This year we will have the EUPO course on retina and vitreous diseases during our EVER meeting, another opportunity to welcome our young colleagues.

You are kindly invited to participate to the EVER 2018 meeting from Thursday October 4th to Saturday October 6th in the exceptional venue of Nice. Scientific curiosity, complicity and friendship are the three reasons to attend and learn together.

Alain Bron
President EVER 2018

About EVER

The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress and is an excellent place for networking.

www.ever.be

EVER Membership

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections. Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 scientific sections that best represents his or her primary area of interest.

The benefits of EVER membership are:

- significantly reduced registration fees for annual meeting
- submission of abstracts at annual meeting
- organizing Special Interest Symposia (SIS) and Courses
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 3.324)
- voting rights for the election of the Board Members
- travel supports and poster prizes
- quarterly E-Newsletter

Elections 2018

Cast your vote for the elections of

- Chair of section LC:
  Andrzej Grzybowski and Roy Quinlan
- Chair of section RV:
  Aude Ambresin, Deyar Abd Alkader Ibrahim and Francine Behar-Cohen

They will be elected by online voting. Voting will close on Thursday, October 4, midnight.
The result of the elections will be announced at the General Assembly on Friday, October 5, 19:15 - 19:45.

Website: www.ever.be

On this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2018 meeting and view the status (session, hour, place) of your presentation
- pay on-line and print your invoice
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended

Speakers' affiliation to scientific sections

ACB	Anatomy / Cell Biology
COS	Cornea / Ocular Surface
EOVS	Electrophysiology, physiological Optics, Vision Sciences
G	Glaucoma
IM	Immunology / Microbiology
LC	Lens / Cataract
MBGE	Molecular Biology / Genetics / Epidemiology
NSPH	Neuro-ophthalmology / Strabismology / Paediatric / History
PBP	Physiology / Biochemistry / Pharmacology
PO	Pathology / Oncology
RV	Retina / Vitreous



Download the EVER 2018 Congress App to enhance your congress experience

All congress information in a nutshell:

Information about EVER - Browse sessions by day, type, section, ... - Visit the exhibitors and sponsors - My congress bag: create your personal agenda - Receive the latest news - Make notes - Rate sessions - etc.

EVER - European Association for Vision and Eye Research

www.ever.be

EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. One of the main activities of EVER is the organizing of a high quality research meeting every year at a location chosen for its access and congress facilities. EVER collaborates closely with other societies in organising joint meetings during EVER.

EVER *f* - EVER Foundation

www.ever-f.eu

In 2010, the EVER Foundation was created to raise money to organize EVER *f* Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

Acta Ophthalmologica - EVER's journal

eu.wiley.com

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 3.324)

Composition of the board 2018

Executive committee

Alain BRON
President

Thomas FUCHSLUGER
Secretary General/ Vice President

Steffen HEEGAARD
Treasurer

Francesca CORDEIRO
Programme Secretary

Rafael I. BARRAQUER
President Elect

Peter WIEDEMANN
Vice President Elect

Andrew DICK
Past President

Harminder DUA
EVER liaison

EVER office by Mecodi

Marlene VERLAECKT
Executive Officer

Lies VAN EYCKEN
Executive Assistant

Mieke AKKERS
Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - ever@ever.be

www.mecodi.eu

Website and onsite support

COVR - IT solutions for scientific and medical associations

www.covr.be

Composition of the board 2018

Section chairs

ACB

Kai KAARNIRANTA

Anatomy / Cell Biology

COS

Nora SZENTMARY

Cornea / Ocular Surface

EOVS

Miguel CASTELO-BRANCO

Electrophysiology, physiological Optics, Vision Sciences

G

Sayeh POURJAVAN

Glaucoma

IM

Piergiorgio NERI

Immunology / Microbiology

LC

Rafael I. BARRAQUER

Lens / Cataract

MBGE

Jochen GRAW

Molecular Biology / Genetics / Epidemiology

NSPH

Dominique BREMOND-GIGNAC

Neuro-ophthalmology / Strabismology / Paediatric / History

PBP

Manuel VIDAL SANZ

Physiology / Biochemistry / Pharmacology

PO

Frédéric MOURIAUX

Pathology / Oncology

RV

Peter WIEDEMANN

Retina / Vitreous

EVER representatives in Acta Board

Aki KAWASAKI & Steffen HEEGAARD

Senior advisor

Jean-Jacques DE LAEY

Representative

Stephanie BAILLIF, Local representative France

Venue

EVER 2018 will be held at the Acropolis Convention Center:
1, Esplanade Kennedy
06364 Nice cedex 4
Nice, France

➔ www.nice-acropolis.com

The scientific programme of the EVER congress starts on Thursday, October 4 at 08:30 and concludes on Saturday, October 6 at 18:00.





Congress Information

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee.
Opening hours registration:
- Wednesday Oct. 3 from 07:00-18:00 - *EUPO Course*
- Thursday Oct. 4 from 07:30-18:00
- Friday Oct. 5 from 07:30-18:00
- Saturday Oct. 6 from 07:30-15:30

Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-care, Technician or Nurse, you need to prove your status

Registration fees on-site

	EUR
Member / Course invited speakers	546
Member-in-training	275
Non-member	960
Non-member-in-training	440
Eye-Care / Technician / Nurse	220

Congress Information

Internet access

Wi-Fi internet access is available in the Convention Center. Wifi login code: ever2018

Photographs

It is strictly forbidden to take photographs or videos of the presentations in all lecture halls and posters. Please respect this rule.

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing for not presenting.

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting. In addition coffee & croissants will be served early morning.

CME credits

Continued Medical Education credits
We are pleased to inform you that EVER 2018, Nice, France, 04/10/2018-06/10/2018
has been granted 20 European CME credits (ECMEC®s) by the European Accreditation Council forContinuing Medical Education (EACCME®).

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting.
Participants must make their own arrangements with respect to health and travel insurance.

Publication of the abstracts

The abstracts of the EVER 2018 congress will be published on-line in a special autumn issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

Congress Information

Section Business Meetings

Friday, October 5 from 15:45 to 16:15
EVER Section Business Meetings of the scientific sections

- ACB .....Rhodes 4
- COS .....Rhodes 2
- EOVS .....Rhodes 1
- G.....Rhodes 1
- IM .....Gallieni 1 & 2
- LC .....Hermes
- MBGE.....Gallieni 1 & 2
- NSHP .....Rhodes 2
- PO .....Rhodes 3
- PBP.....Rhodes 3
- RV .....Hermes

The sections

- ACB
- EOVS
- MBGE

will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2019.
Agenda see page 77

EVER General Assembly

Friday, October 5 from 19:15 to 19:45
in room Hermes
FOR MEMBERS ONLY
Agenda see page 85

Prize award ceremony and Closing remarks

Saturday, October 6 from 16:45 to 18:00 in room Hermes
Agenda see page 116

Programme Information

Women 4 EVER

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed. See page 107.

Coffee with Profs

In an initiative to encourage dialogue amongst speakers and EVER members, we have organised a session called "Coffee with Profs". This will be a table of 6-8 "guests" at a table headed by one of the EVER speakers:

- Sally-Anne TSANGARIDES
- Mariya MOOSAJEE
- Chris PURSLOW
- Marcela VOTRUBA
- Aki KAWASAKI
- Fabiana D'ESPOSITO

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.
See pages 41, 68.
Please sign in at the registration desk.

YIA

Young Investigators' award session

The best Rapid Fire abstracts from young authors of each section will be presented in these sessions.

EUPO course

European University Professors of Ophthalmology

Each year EUPO organises a 2 days course for residents in training. This year, the course is on Retina, Intraocular Inflammation & Uveitis and is organized by Prof. Catherine Creuzot and Prof. Bahram Bodaghi.
Wednesday, October 3 + Thursday, October 4 in the morning. The EUPO programme can be consulted in pages 117-120.

Women 4 EVER

Saturday, October 6
from 12:30 to 13:45 in room Gallieni 1+2

Coffee with Profs

Thursday, October 4
from 16:00 to 17:00 in poster area
Friday, October 5
from 14:45 to 15:45 in poster area

YOS session

Thursday October 4
from 17:00 to 18:15 in Rhodes 2
Followed by a cocktail.

YIA sessions

Saturday, October 6
from 14:15 to 15:30 and from
15:30 to 16:45 in Hermes

EUPO

Wednesday October 3
from 08:30 to 18:00 in Hermes
and Thursday October 4

EVER section Travel support

We are pleased to announce that the following 14 members have received an EVER section Travel Support of 500 EUR each:

- ACB - S097 - Giorgia BULLI - Denmark
  Prevention of glutamate-induced retinal ganglion cell death by UCCB01-144 treatment
- COS - S015 - Jan KOSSL - Czech Republic
  Effects of mesenchymal stem cells on production of cytokines by injured cornea in in vitro and in vivo experimental models
- COS - S012 - Lauriane ROUX - France
  Modeling of aniridia-related keratopathy by CRISPR/Cas9 genome editing of human limbal epithelial cells and rescue by recombinant PAX6 protein
- EOVS - 33306/F105 - Maria WAIZEL - Switzerland
  The influence of cataract light scatters on retinal vessel oxygen saturation
- G - F047 - Benjamin DAVIS - United Kingdom
  Neuroprotective Activity of Curcumin Nanocarriers in Rodent Models of Retinal Injury
- G - F045 - Ehtesham SHAMSHER - United Kingdom
  Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer's disease
- IM - 33502/T111 - Sina ELAHI - Switzerland
  Fine-Tuning of therapy in stromal choroiditis using indocyanine green angiography (ICGA)
- LC - S019 - Thibaud GARCIN - France
  Correlations between subjective and objective preoperative assessment of cataract severity
- MBGE - F119 - Khaled EL MATRI - Tunisia
  Clinical and Genetic Characteristics of Leber Congenital Amaurosis in the Tunisian Population: experience of the oculogenetic laboratory LR14SP01
- NSPH - F088 - Rachel EVANS - United Kingdom
  Activation of the phosphoinositide 3-kinase pathway promotes axon regeneration of the optic nerve in vivo
- PBP - 3616/T100 - Francisco Javier VALIENTE-SORIANO - Spain
  Retinal ganglion cells loss and caspase 3 activation after ocular hypertension
- PO - 3143 - Lauge Hjorth MIKKELSEN - Denmark
  High-throughput sequencing reveals no microbial pathogens in ocular adnexal extranodal marginal zone B-cell lymphoma
- RV - 3515/T006 - Pankaj KUMAR - India
  A morphological study and expression patterns of iron regulatory proteins in aging Wistar rats retina after iron overload
- RV - 33506/T027 - Diogo REIS CABRAL - Portugal
  Predictive biomarkers in OCT-Angiography of peripheral nonperfusion in retinal venous occlusions

The Travel Support certificates will be handed over during the Prize Award Ceremony on Saturday, 16:45 in Hermes.

EVER Poster Prizes

Poster Prizes will be awarded for the best posters across all sections.

The winners will be chosen by the poster moderators and will be announced in the Prize Award Ceremony on Saturday, 16:45 - 18:00 in Hermes.
No prize will be given after the congress.
The winners will be waived registration to the EVER congress 2019.

Young Investigators' Award

The best Rapid Fire abstracts from young authors of each section will be presented in these sessions.



Floorplan - Acropolis Convention Center, 2nd floor

Exhibition area



105 - ARVO
113 - Carl Zeiss
101 - Diagnosys UK Ltd
100 - Dice
112 - Experimentica Ltd.
110 - Horus Pharma
109 - Iris Pharma
111 - Metrovision
102 - Novartis Pharma
108 - Quantel-Medical
103 - Santhera Pharmaceuticals
107 - SOE
104 - Thea Pharma
106 - Wisepress

Partners

ARVO

Association for Research in Vision and Ophthalmology - www.arvo.org

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. Since 2005, EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year during EVER and an EVER symposium scheduled during ARVO.

See page 101

EBO

European Board of Ophthalmology ebo-online.org

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress.

EUPO

European University Professors of Ophthalmology - www.eupo.eu

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2018 course is organised in conjunction with the EVER congress in Nice, France.

FAN

European Fluorescein Angiography Club www.fan-int.org

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress.

See page 105

Partners

GDOA

GuangDong Ophthalmologist Association

GuangDong Ophthalmologist Association (GDOA) is the largest organization for eye care professionals in south China. GDOA has over 1000 members divided over 9 different subspecialties such as glaucoma and retina.
See page 63

OOG

The Ophthalmic Oncology Group
www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions.
See pages 89, 102, 106

Optic Nerve Meeting

www.optic-nerve-online.com

Intended for basic scientists and clinicians to address important topics in translational research, including scientists in interdisciplinary areas such as neurology, neurodegenerations and autoimmunity.
Next Optic Nerve Meeting:
Obergurgl, Austria, December 11-13, 2018
See page 58

SOPREF

Société Ophtalmologique Plastique Reconstructrice Esthétique Française
www.sopref.net

See page 106

TFOS

The Tear Film and Ocular Surface Society
www.tearfilm.org

The TFOS DEWS II involved the efforts of 150 clinical and basic science research experts from around the world and it was aimed to achieve a global consensus concerning multiple aspects of Dry Eye Disease.
See page 63

About the programme book

Sessions

BM	Business Meeting
C	Course
CIS	Industry Sponsored Symposium
GA	General Assembly
JM	Joint Meeting
KN	Keynote lecture
SIS	Special Interest Symposium
SOC	Social
POS	Poster session
PS	Plenary session
RF	Rapid Fire session

Symbols

TS	=	EVER section travel support recipient
rf	=	Rapid fire presentation
rf†	=	Best rapid fire presentation
*	=	Conflict of interest disclosed

Scientific sections

ACB	=	Anatomy / Cell Biology
COS	=	Cornea / Ocular Surface
EOVS	=	Electrophysiology, Physiological Optics, Vision Sciences
G	=	Glaucoma
IM	=	Immunology / Microbiology
LC	=	Lens and Cataract
MBGE	=	Molecular Biology / Genetics / Epidemiology
NSPH	=	Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology
PBP	=	Physiology / Biochemistry / Pharmacology
PO	=	Pathology / Oncology
RV	=	Retina / Vitreous Section programme secretaries

Scientific sessions

Francesca M CORDEIRO
Programme Secretary

2018 Section programme secretaries

ACB	Anatomy/Cell Biology Anu KAUPPINEN
COS	Cornea/Ocular Surface Edward WYLEGALA
EOVS	Electrophysiology, Physiological Optics, Vision Sciences Franziska RAUSCHER
G	Glaucoma Eduardo NORMANDO
IM	Immunology/Microbiology Joachim VAN CALSTER Francesco PICHI
LC	Lens and Cataract Ralph MICHAEL
MBGE	Molecular Biology/Genetics/ Epidemiology Petra LISKOVA
NSPH	Neuro-ophthalmology/Strabismus/ Paediatric Ophthalmology/History of Ophthalmology Patrick YU-WAI-MAN
PBP	Physiology/Biochemistry/Pharmacology Neville OSBORNE
PO	Pathology/Oncology Alexandre MOULIN
RV	Retina/Vitreous Jean-Antoine POURNARAS

C EVER 2018 courses

✶ Beginner

✶✶ Intermediate

✶✶✶ Advanced

Thursday, October 4

09:15 - 10:30	Rhodes 2	✶✶✶	EOVS - Basic principles of state-of-the-art ophthalmic instrumentation	p 30
09:15 - 10:30	Rhodes 3	✶	MBGE - I have received a mutation report for my patient, but i don't know what it means!	p 30
09:15 - 10:30	Rhodes 4	✶✶	ACB - How to study mitochondria function, structure and clearance?	p 31
11:30 - 12:45	Rhodes 2	✶✶	COS - Corneal nerves in health and disease	p 34
11:30 - 12:45	Rhodes 4	✶✶	ACB - Proteomics- a tool to find relevant biomarkers for ocular diseases, drug development and safety	p 35
17:00 - 18:15	Rhodes 2	✶	G - Landmark papers in ophthalmology – how to do one!	p 50

Friday, October 5

08:30 - 09:45	Rhodes 2	✶✶	COS - Optical imaging techniques for the cornea and anterior eye segment – pearls and pitfalls	p 55
10:45 - 12:00	Rhodes 2	✶✶	COS - Diagnosis and treatment of infectious keratitis in the clinical practice today	p 59
13:30 - 14:45	Rhodes 3	✶✶✶	PO - Conjunctival tumors	p 66
16:15 - 17:30	Rhodes 3	✶✶	PO - Orbital inflammation	p 79

Thursday
October 4



Thursday, October 4 - Welcome session

PS

8:30 - 8:45 | HERMES

Welcome

Welcome by the EVER President 2018 - Alain BRON

Alain BRON

Acta Ophthalmologica

PS

8:45 - 9:15 | HERMES

EVER-ACTA lecture by Gisèle SOUBRANE

8:45 Introduction by Einar STEFANSSON

1111 8:50 **OCT-A all what we need?**

Gisèle SOUBRANE — Paris

Multimodal imaging (including Fluorescein and ICG Angiography as well as OCTB and Fundus AutoFluorescence) provides morphologic, dynamic and functional information of the retina and of the choroid. Unfortunately, dye-based techniques have drawbacks, such as concealment of vascular detail by dye-leakage, absence of depth-resolution, and adverse reactions to dyes. OCT angiography (OCTA) a non-invasive, dye-free OCT-based imaging technique has shown great potential for visualizing the retinal and choroidal vasculature. It allows volumetric visualization of vasculature based on the motion-contrast generated by flowing erythrocytes and is thus a direct marker for blood flow. The segmentation of the depth resolution permits delineation of individual vascular layers. However, frequent artefacts limit its interpretation. Under-or over-lying vasculature contamination poses a significant challenge. Dynamic flow information is missing . The field of view is small and attempts to increase it result in decreased image quality. Surprisingly, OCTA encounters difficulties to authenticate typical choroidal abnormalities such as PVC. Absence of an OCTA signal does not necessarily imply a complete absence of blood flow, but rather the absence of blood flow above the lowest detectable level. Studies claiming the superiority of OCT A compared to FA for the initial diagnosis always associate another technique either OCT B or ICG A. Nowadays, OCT A is used to assess the presence and maturity of CNV, to identify microaneurysms in the superficial and deep retinal capillary plexus, to identify and quantify macular ischemia . Possibly this technique in conjunction with multimodal imaging will allow an earlier diagnosis and a better therapeutic approach.

Gisèle SOUBRANE

9:15 Award presentation of the Certificate of Honour

Thursday, October 4 - First morning session

JM

9:15 - 10:30 | HERMES

EUPO session 4 - My children cannot see

For details, see page 120

EUPO

SIS

9:15 - 10:30 | RHODES 1

G/ACB - Novel models to study glaucomatous neurodegeneration

Glaucomatous neurodegeneration causes visual disability if it is left untreated. Due to its age-related nature, the number of people with glaucoma will increase and future projections estimate a significant challenge in terms of costs and care of the critical number of visual impaired patients. The condition is related to increased intraocular pressure (IOP), but is classified by loss of the retinal ganglion cells (RGC). Although current IOP-lowering treatments decrease the rate of progression in most patients with glaucoma, the treatments offer no possibility of visual rescue and 15 percent of patients with diagnosed glaucoma will go blind. Previous attempts to rescue the RGCs have been unsuccessful. We believe that the lack of efficacy can be explained by the complexity of the condition as well as absence of ideal models to study the characteristic neurodegeneration. Although animal models of glaucoma have provided valuable information about the disease, there is still no ideal model for studying glaucomatous neurodegeneration due to its complexity. In the present SIS, novel methodologies and models to study the pathophysiology of glaucomatous neurodegeneration will be introduced.

KOLKO M , CORDEIRO M F

1221		9:15	Modelling optic neuropathies using human induced pluripotent stem cell- derived retinal ganglion cells *Daniszewski M, Hewitt A, PEBAY A - Melbourne East*
1222		9:40	Models to study the impact of mitochondrial dysfunction on neurodegeneration *MCMANUS M - Philadelphia*
1223	*	10:05	A model to quantify retinal ganglion cell loss in patients *CORDEIRO M F - London*

Thursday, October 4 - First morning session

C

9:15 - 10:30 | RHODES 2

EOVS - Basic principles of state-of-the-art ophthalmic instrumentation

✶✶✶ Advanced

This course is aimed at providing an overview of the basic principles of various state-of-the-art retinal-imaging systems such as scanning laser ophthalmoscopy, optical coherence tomography, as well as adaptive optics, and discusses how such imaging can even serve as a window into brain mechanisms. The goal is to illuminate for the clinician and scientist the underlying optical concepts and principles of various devices, even when not familiar with the particular technology employed within the instrument, and to demonstrate its potential with applications beyond those of retinal disease diagnosis and follow-up.

IRSCH K , BERNARDES R

1231	9:15	Scanning Laser Ophthalmoscopy – Basic Optical Principles *IRSCH K - Paris*
1232	9:30	Optical Coherence Tomography – Basic Optical Principles *IRSCH K - Paris*
1233	9:45	Optical Coherence Tomography – Machine Learning *BERNARDES R - Coimbra*
1234	10:00	Adaptive Optics – Basic Optical Principles *IRSCH K - Paris*
1235	10:15	Retinal Imaging – a Window into Brain Mechanisms *CASTELO-BRANCO M - Coimbra*

C

9:15 - 10:30 | RHODES 3

MBGE - I have received a mutation report for my patient, but I don't know what it means!

✶ Beginner

Genetics is getting increasingly important in many medical fields including ophthalmology. Patients with both Mendelian and complex disorders such as age-related macular degeneration seek genetic counselling and testing.
This course will provide clinicians and scientists with the basic knowledge to understand mutation reports and pathogenicity evaluations. Practical examples from the ophthalmology field will be given. At the end of the course there will be a short workshop for all attendees.

LISKOVA P , DUDAKOVA L

1241	9:15	Introduction to molecular genetics *DUDAKOVA L - Prague*
1242	9:33	Standards and guidelines for the interpretation of sequence variants *VERDIN H - Ghent*
1243	9:51	Molecular genetics in clinical practice I (Cornea) *LISKOVA P - Prague*
1244	10:09	Molecular genetics in clinical practice II (Retina) *LEROY B - Ghent*

Thursday, October 4 - First morning session

C

9:15 - 10:30 | RHODES 4

ACB - How to study mitochondria function, structure and clearance?

✶✶ Intermediate

Increased oxidative stress seem to be one of the most important factor in normal aging and in the pathogenesis of various age-related retinal diseases. Mitochondria are especially important in the regulation of cellular redox balance, since the reactive oxygen species (ROS) are produced in their electron transport chain. The abundance of ROS can damage cellular components such as DNA and proteins. The aged retina is characterized by an increased level of ROS, accumulation of damaged DNA, proteins and mitochondria and increased low-grade inflammation. Lysosomal autophagy is key clearance system to remove damaged molecules from cells. Mitophagy is a mitochondria-specific selective autophagy that is an essential part of mitochondrial quality control to keep optimal redox balance in cells. In this course key methods to study mitochondria function, morphology and clearance in cell culture, animal models and human material are discussed.

KAARNIRANTA K , BLASIAK J

1251	9:15	Key methods to study mitochondrial function *FERRINGTON D A - Minneapolis*
1252	9:33	Methods to study mitochondrial DNA damage *BLASIAK J - Lodz*
1253	9:51	Mitophagy as a research target *SZÄSZUJFALUSI FELSZEGHY S - Kuopio*
1254	10:09	Mitochondria in the regulation of inflammation *KAUPPINEN A - Kuopio*

SIS

9:15 - 10:30 | GALLIENI 1+2

G/COS - Ocular surface in glaucoma – why bother?

Medical and surgical treatments for glaucoma can cause ocular surface disease (OSD) to an extent that more than half of patient with glaucoma have signs or symptoms of dry eye.
Chronic use of preserved glaucoma drops has been associated with a high incidence of dry eye disease, which is related to the number and type of medications used and can alter treatment compliance and patients' quality of life.
Surgical treatments are also associated with a higher incidence of OSD and subsequent ocular lubricant use. Besides, OSD related to glaucoma medications can also reduce the success rate of filtrating surgeries.
Furthermore, the tear film, one of the eye's optical media, can be affected by IOP lowering medications. Its integrity is of paramount importance for generating reliable and reproducible retinal and optic nerve diagnostic images and for the assessment of disease progression.
This SIS seeks to discuss the negative effects of preserved glaucoma medications and how to manage them, why the ocular surface is so important for the success of glaucoma surgery and how OSD can affect objective imaging parameters for glaucoma progression analysis.

NORMANDO E M , RATNARAJAN G

1261	✶	9:15	Effect of topical medication on the ocular surface *ROUSSEAU A - Le Kremlin Bicêtre*
1262		9:40	importance of ocular surface for the success of glaucoma surgery *RATNARAJAN G - East Grinstead*
1263		10:05	Effect of topical glaucoma treatments on OCT Image Quality *NORMANDO E M - London*

Thursday, October 4 - EVER lecture

PS

11:00 - 11:30 | HERMES

EVER lecture delivered by the Past President

11:00 Introduction by Alain BRON

Andrew DICK

1311 11:05 **Ocular Inflammation**

Andrew DICK — London - Bristol

The management of Ocular Inflammation until recently has lacked high level clinical trial evidence despite years of experience with DMARDs and Biologics. On the backdrop of this data, I will be discussing future approaches no longer quixotic, through our understanding of the immunobiology of experimental models, advances in experimental medicine in man and our increasingly elegant imaging technologies to develop our future approaches that through endophenotypes of uveitis we will target patients appropriately, at the right time and with the right drugs.

11:30 Award presentation of the EVER Certificate of Honour

Thursday, October 4 - Second morning session

JM

11:30 - 12:15 | HERMES

EUPO session 5 - Surgical diseases and miscellaneous

EUPO

For details, see page 120

JM

12:15 - 12:45 | HERMES

EUPO Round table 3 - My job is difficult!

EUPO

For details, see page 120

JM

12:45 - 12:50 | HERMES

EUPO Closure

EUPO

SIS

11:30 - 12:45 | RHODES 1

G/LC - P+p (phaco 'plus' procedures) - revolutionising glaucoma care

The advent of Minimally Invasive Glaucoma Surgery (MIGS) devices has shifted traditional glaucoma treatment paradigms, with phaco 'plus' procedures (P+P) providing earlier opportunities in the treatment of mild to moderate glaucoma, improving control and patient experience.
This highly relevant, contemporary symposium first considers the place of cataract surgery alone +/- goniosynechialysis (GSL), with reference to the landmark 'EAGLE' trial. The speakers will then summarise P+P indications and techniques for the devices most commonly used in Europe, including trabecular outflow (iStent), supra-choroidal trabecular bypass (CyPass) as well as phaco-ECP, an inflow procedure performed alone or in combination with MIGS. The speakers will discuss post-op care, results (evidence-based and real-world experience) and how to avoid common difficulties.
Currently, trabeculectomy & tube surgery are still needed in many patients with moderate and advanced glaucoma; the place of MIGS in the schema of modern glaucoma management will be considered in panel discussion; we encourage attendance from audience members wishing to challenge the faculty to discuss the place of MIGS v traditional surgery in specific clinical cases / scenarios.

BLOOM P , AHMED F

1421		11:30	Phaco alone +/- gonio-synechialysis *PORTEOUS A - London*
1422		11:48	Phaco ECP *BESINIS D - Nea Smyrni*
1423	*	12:06	Phaco iStent *AHMED F - London*
1424		12:24	Phaco Cypass *BLOOM P - London*

Thursday, October 4 - Second morning session

C

11:30 - 12:45 | RHODES 2

COS - Corneal nerves in health and disease

✶✶ Intermediate

Many diseases provoke unpleasant sensations and trophic alterations whose underlying neural mechanisms are not fully understood. The present course offers an overview on the functional mechanisms responsible for sensations evoked in the front of the eye, and on the morphological and functional changes produced by diseases, surgery and infection. The reciprocal influence between corneal nerves and immune cells will be also discussed.

GALLAR J , KOVACS I

1431	11:30	Activity of corneal nerves in health and disease *GALLAR J, Acosta M C - San Juan de Alicante*
1432	11:48	Corneal nerves in keratoconus *KOVACS I, Nagy Z - Budapest*
1433	12:06	Corneal nerves after PRK and CXL treatment *ZSOLT NAGY Z, Popper A - Budapest*
1434	12:24	Immune cells and corneal nerves *HAMRAH P - Boston*

SIS

11:30 - 12:45 | RHODES 3

PBP - Cone photoreception in huma retina: structure and functional evaluation of the human fovea

The organization of the cone photoreceptors in the human fovea, their significance for visual acuity and their impairment in some well-known diseases such as Age related Macular Degeneration (AMD), Stargardt disease, or even dyschromatopsia make the field of cone physiology and restoration attractive for many researchers and ophthalmologist. The advancement of neurophysiological and image technologies has allowed a more precise and objective study of the cellular and morphological organization of human fovea in patients. Moreover, recent advances in neurophysiological techniques have opened the possibility to evaluate the function of the fovea both at the eye a cortex level. The Special Interest Symposium will present recent studies focussing on structure and function of the human fovea and recent approaches treat various types of human retinal diseases. The SIS will provide ample opportunity for interaction among scientists attending the conferences.

DE LA VILLA P , VIDAL-SANZ M

1441	11:30	Structure of the human fovea: from the microscopy to the OCT *CUENCA N, Ortuño-Lizarán I, Pinilla I - Alicante*
1442	11:48	Visual perception in the human fovea: functional evaluation of cone diseases by neurophysiological methods. *DE LA VILLA P, Milla S, Vicente C - Alcala de Henares*
1443	12:06	Macular protection in AMD by Transposon mediated gene delivery *FERNANDEZ-ROBREDO P - Pamplona*
1444	12:24	Evaluation of retinal function by mfVEP *BLANCO R - Barcelona*

Thursday, October 4 - Second morning session

11:30 - 12:45 | RHODES 4

C

ACB - Proteomics - a tool to find relevant biomarkers for ocular diseases, drug development and safety

✶✶ Intermediate

Proteomics, along with other omics, is a potentially valuable tool of personalized medicine and thus helping in selecting the most cost-effective diagnostic and therapeutic options for each patients. This type of personalized approach is becoming more common in the future, since new diagnostic and therapeutic methods are constantly being developed. On the other hand, processing and analyzing of the proteomic samples is becoming easier, more accurate and also cheaper. For these reasons, a lot of effort is currently going into finding potential biomarkers through discovery studies. In addition to sample processing and advanced equipment, proteomic research also requires the work of bioinformaticians as the research methods are yielding increasing amounts of statistical data. Hence, methods of analyzing big data are also increasingly important and therefore researchers in bioinformatics field are both developing new methods and utilizing old ones in order to tackle the growing data. This course will focus on methods of study design, sample processing, mass spectrometry and bioinformatics in diagnostic, therapeutic and safety studies.

UUSITALO H , BEUERMAN R

1451	✶	11:30	New technologies in proteomic research *BEUERMAN R, Zhou L - Singapore*
1452		11:48	Design of clinical efficacy and safety studies based on proteomic analysis *UUSITALO H - Tampere*
1453		12:06	From biomarker discovery to proteomic validation using mass spectrometry *JYLHÄ A - Tampere*
1454		12:24	Bioinformatics in tear fluid proteomics – connecting proteomic and clinical data *NÄTTINEN J - Tampere*

11:30 - 12:45 | GALLIENI 1+2

SIS

IM - Don't miss the diagnosis! How to survive against the worst enemies in your daily practice

In the modern ophthalmology, the introduction of new technologies and the better knowledge on uveitis pathophysiology have helped in understanding the different clinical characteristics of most of the intraocular inflammatory diseases. Consequently, several old concepts were revised and new ones were introduced. The trend at this point is to create the conditions for a better strategy both for the diagnostic procedures and for the treatment choices by using appropriately all the available tools. For such reasons, the multimodal imaging procedures, systemic tests and even biopsies of ocular tissues are part of the daily practice of a uveitis specialist.
In this special interest symposium the main uveitis subsets and masquerade syndromes will be discussed by addressing the critical points for the diagnostic assessment and bringing new concepts on the uveitis classification and the treatment methodology.

NERI P , KHAIRALLAH M

1461	11:30	How ICGA can help in surviving in the jungle of choroidal inflammatory diseases *HERBORT JR. C P - Lausanne*
1462	11:48	How to detect a viral retinitis *KHAIRALLAH M, Khochtali S, Abroug N, Ksiaa I - Monastir*
1463	12:06	How to bare the great imitators *KESTELYN P - Gent*
1464	12:24	How to unmask a masquerade syndrome *NERI P - Abu Dhabi*

Thursday, October 4 - Noon session

CIS

12:45 - 14:00 | RHODES 2

Lunchtime CIS - Nothing to fear about Demodex

JAMES TE

	12:45	How to detect Demodex in the clinical setting *CRAIG J, New Zealand*
	12:57	The on-off relationship between Demodex and dry eye *KAYA S, Austria*
	13:09	How Demodex affects my Blepharitis patients *JAMES T E, United Kingdom*
	13:21	How to manage Demodex Blepharitis with Tea Tree Oil (TTO) *KHAIRALLAH M, Tunisia*
	13:33	Is TTO the killing agent for Demodex? *MERAYO-LLOVES J, Spain*
	13:45	Demodex in my clinical practice *TERZIDOU C, Greece*

Thursday, October 4 - Keynote lecture

KN

14:15 - 14:45 | HERMES

Keynote lecture by Rajendra APTE

14:15 Introduction by Andrew DICK

Rajendra S. APTE

1611 14:20 **An eye on aging and disease**

Rajendra S. APTE — St. Louis

Organismal aging is associated with widespread tissue dysfunction. In the eye, a transition from aging to disease is associated with diverse pathophysiology that ranges from reduced tear production to diseases such as glaucoma and age-related macular degeneration. Understanding the biologic basis of aging and the molecular mechanisms underlying the transition from aging to age-related eye disease is critical in order to find sensitive and specific biomarkers of disease and identifying targeted therapeutic strategies to prevent vision loss. Using genetic mouse models and human data, the role of molecular metabolism, lipid homeostasis and immunity in aging and eye disease will be presented.

14:45 Award presentation of the EVER Certificate of Honour

Thursday, October 4 - First afternoon session

SIS

14:45 - 16:00 | HERMES

RV - Bionic eye - where are we now?

This session is aimed to give an update about the development, current stage and future perspectives of Bionic eye technology. The speakers are the opinion leaders in their field.

LYTVYNCHUK L

1711		14:45	Intraoperative OCT imaging of the Argus II retinal prosthesis and its clinical significance *FALKNER-RADLER C, Lytvynchuck L - Vienna*
1713		15:00	The functional results after Argus II implantation *CINELLI L, Rizzo S - Florence*
1714		15:15	New tacking forceps for fixation of epiretinal prosthesis *LYTVYNCHUK L, Falkner-Radler C, Binder S, Lorenz B - Giessen*
1715	*	15:30	Restitution of visual functions in blind retinitis pigments patients with subretinal implant Alpha AMS *STETT A - Reutlingen*
1716	*	15:45	Innovation and advances in bioelectronic medicine progressing to address atrophic dry AMD with wireless sub-retinal photovoltaic implant *MUQIT M - London*

SIS

14:45 - 16:00 | RHODES 1

G/LC - Simulated ocular surgery - part II

Surgical training in Europe is very different according to each region. National regulations, different settings and allocated resources allow for a great heterogeneity in surgical learning opportunities.
In order to acquire and practice the best surgical skills before starting to operate directly on patients' eyes, simulated surgical training ensures excellent opportunities to build competencies on microsurgery. Simulation based learning enables to learn different surgical procedures, practice various interventions and deal with potential complications in a safe and sustainable educational environment. Besides learning and practicing technical skills, decision-making, teambuilding and communication skills can be trained.
This symposium will give an overview on how surgical teaching is currently being conducted in Europe, how it can be effectively achieved and how simulated surgical training can maximize surgical skills transfer. We will search and interactively discuss solutions on how to best implement this training method in a structured way in European ophthalmological centers.

SUNARIC MEGEVAND G , PRIOR FILIPE H

1721	14:45	The Use of Simulated Ocular Surgery (SOS) eyes in Glaucoma Surgical Training 2 – A U.K. Tertiary Referral Teaching Hospital Experience, One Year Later *MERCIECA K - Manchester*
1722	15:03	UK Trainee Trabeculectomy Outcomes incorporating Simulated Surgery *BHARGAVA A - Manchester*
1723	15:21	The Role of Simulators in Cataract Surgery *RIBEIRO F - Lisbon*
1724	15:39	Six Essential Steps to Develop a Simulation Based Learning Program *PRIOR FILIPE H - Lisbon*

Thursday, October 4 - First afternoon session

SIS

14:45 - 16:00 | RHODES 2

COS/ACB - Aniridia-associated keratopathy (aak): from disease mechanisms to treatments

Aniridia is a multi-faceted condition characterized by underdevelopment of eye structures due to mutations in PAX6 and related genes. The condition is most often congenital and is commonly associated with misdevelopment of the fovea, iris, lens, and cornea often leading to glaucoma, cataract, and a progressive keratopathy called aniridia-associated keratopathy (AAK). AAK has a characteristic phenotype linked to the progressive deterioration of the limbal stem cell niche, that commonly results in inflammation, denervation, vascularization, fibrosis and keratinization. AAK presents numerous challenges for the ophthalmologist and decisions regarding treatment are often difficult. In this SIS, we focus on AAK and present insights into the condition at the molecular and morphologic levels, and describe experiences and outcomes with several surgical interventions for treatment of AAK when corneal transparency has been compromised.

LAGALI N , WYLEGALA E

1731		14:45	Transcriptional analysis of corneal epithelium in AAK and related siRNA-based cell model *LATTA L, Nordström K, Stachon T, Fries F, Szentmáry N, Seitz B, Käsmann-Kellner B - Homburg*
1732		15:00	Unraveling the pathogenesis of AAK - insights from anterior segment imaging in children *LAGALI N, Wowra B, Wylegala E, Fries F, Utheim T, Latta L, Seitz B, Käsmann-Kellner B - Linköping*
1733		15:15	Minimally-invasive surgical treatment of AAK *WOWRA B, Dobrowolski D, Edward W - Katowice*
1734		15:30	Triple procedure for treating advanced AAK with cataract *DOBROWOLSKI D, Wowra B, Grolik M, Wylegala E - Katowice*
1735		15:45	The use of keratoprosthesis in the treatment of AAK *REMEIJER L, Dobrodjnova O, Littink K, Roels D - Rotterdam*

SIS

14:45 - 16:00 | RHODES 3

PBP - Pathogenic role of the microglia in neuroretinal diseases

Microglia, the immunocompetent cells of the central nervous system (CNS), act as neuropathology sensors and are neuroprotective under physiological conditions. Microglia react to injury and degeneration with immune-phenotypic and morphological changes, proliferation, migration, and inflammatory cytokine production. An uncontrolled microglial response secondary to sustained CNS damage can put neuronal survival at risk due to excessive inflammation. A neuroinflammatory response is considered among the etiological factors of the major retinal neurodegenerative diseases like glaucoma, macular degeneration, diabetic retinopathy, and other optic nerve injuries, in which the microglial cells are key players. The aim of the present SIS is to analyze the contribution in retina to microglial-mediated neuroinflammation in the diseases mentioned above.

DE HOZ R , VIDAL-SANZ M

1741		14:45	The Spider Effect: Morphological and Orienting Classification of Microglia in Response to Stimuli in Vivo *JONAS J B - Mannheim*
1742		15:03	The role of microglia in glaucoma *SALOBRAR-GARCIA E, Ramirez A I, De Hoz R, Salazar J J, Ramirez J M - Madrid*
1743	*	15:21	Microglial response to optic nerve injuries *AGUDO-BARRIUSO M, Galindo-Romero C, Boia R, Nadal-Nicolas F M, Ambrosio A F, Vidal-Sanz M, Santiago A R - Murcia*
1744		15:39	The role of the microglia in age-related macular degeneration *LANGMANN T - Cologne*

Thursday, October 4 - First afternoon session

SIS

14:45 - 16:00 | RHODES 4

ACB - Crosstalk of mitochondria and lysosomes in the degeneration of rpe

Retinal pigment epithelial cells (RPE) are constantly exposed to reactive oxygen species (ROS), which may induce damage to proteins, nucleic acids, lipids and cellular organelles. Mitochondria are especially important in the regulation of cellular redox balance, since the ROS are produced in their electron transport chain. In normal circumstances, the amount of ROS is counterbalanced by cellular antioxidant defence. An imbalance between the production and neutralization of ROS by antioxidant defence is associated with increased oxidative stress, which plays an important role in the pathogenesis of many age-related and degenerative diseases, including age-related macular degeneration. Chronic oxidative stress may lead to protein aggregation. Lysosomal autophagy processing of aggregated proteins is important for the cell to maintain its normal functioning and homeostasis. The protein aggregates become double membrane-wrapped organelles called autophagosomes, which become degraded by lysosomal enzymes when they fuse to lysosomes. Crosstalk of antioxidants, mitochondria and lysosomes is central in the regulation of proteostasis in retina.

KAARNIRANTA K , UUSITALO H

1751	14:45	Mitochondrial dysfunction in age-related macular degeneration *FERRINGTON D A - Minneapolis*
1752	15:10	Lysosomes as regulators of protein clearance *SINHA D - Pittsburgh*
1753	15:35	Antioxidants and mitochondria connection in the regulation of autophagy *KAARNIRANTA K - Kuopio*

SIS

14:45 - 16:00 | GALLIENI 1+2

MBGE - Controversies in epidemiology: beneficial or harmful effects of nutritional supplements in the prevention of AMD?

Age-related macular degeneration (AMD) is one of the severe eye disorders of the elderly, caused by genetic, life style and environmental risk factors. Since treatment options are rare, prevention by nutritional supplements are frequently discussed. However, their beneficial or harmful effects might depend on the genetic background of the patients. These aspects will be discussed from different points of view.

GRAW J , MCCARTY C

1761		14:45	Overview of the biological rationale for efficacy of nutritional supplements to prevent AMD *MCCARTY C - Duluth*
1762	*	15:10	Pharmacogenetic influences on nutritional supplementation in prevention of AMD *SCHWARTZ S - Naples*
1763		15:35	Is there a benefit of nutritional supplementation in the prevention of AMD? *LAWRENSON J, Evans J - London*

SOC

16:00 - 17:00 | POSTER AREA

Coffee with Profs - Part I

In an initiative to encourage dialogue amongst speakers and EVER members, we have organised a session called "Coffee with Profs". This will be a table of 6-8 "guests" at a table headed by one of the EVER speakers.

Sally-Anne TSANGARIDES General Manager, Northern Europe Cluster, Santhera Pharmaceuticals
Mariya MOOSAJEE Consultant Ophthalmologist, Moorfields Eye Hospital and Welcome Trust Clinical Research Career Development Fellow, Institute of Ophthalmology, UCL

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

POS

16:00 - 17:00 | POSTER AREA

RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ

T001 Novel retinal artery pulse transit time measurement shows expected blood pressure dependency in rodents
REZAEIAN M, Georgevsky D, Golzan M, Graham S, Avolio A, Butlin M - Sydney

T002 Retinal changes in continuous light: an electron microscopy and NADPH-diaphorase histochemistry evaluation
MAURYA M, Nag T C, Kumar P - Delhi

T003 Effect of raising in complete darkness on pathological and functional readouts in the mouse blight light exposure model
Timonina A, Tenhunen A, CERRADA-GIMENEZ M, Ziniauskaite A, Kaja S, Kalesnykas G, Ragauskas S - Kuopio

T004 Modulation of oxidative stress in the rod outer segment by diterpene manool and sclareol extracted from Salvia tingitana
PANFOLI I, Calzia D, Esposito A, Degan P, Bisio A, Pedrelli F, Schito A, Traverso C E - Genova

T005 Strain differences in the rat streptozotocin-induced model of diabetic retinopathy
JÄÄSKELÄINEN N, Tenhunen A, Thapa R, Ragauskas S, Dunlop T, Ziniauskaite A, Haapaniemi A M, Räsänen H, Kaja S, Kalesnykas G, Cerrada-Gimenez M - Kuopio

T006 A morphological study and expression patterns of iron regulatory proteins in aging Wistar rats retina after iron overload
KUMAR P, Nag T C, Velpandian T, Toy T S, Wadhwa S - New Delhi

T007 Functional and histological evaluation in iodoacetic acid induced photoreceptor degeneration feline model
KIM C, Lee S, Lee S, Nam K - Busan

T008 Protective Effects of Omega-3 Fatty Acids Supplementation Against Retinal Degeneration in Aged C57BL/6 Mice
Prokopiou E, KOLOVOS P, Kalogerou M, Neokleous A, Potamiti L, Sokratous K, Kyriacou K, Georgiou T - Nicosia

T009 Aflibercept inhibits physiological revascularization and pathological neovascularization in the mouse and rat oxygen-induced retinopathy models
VÄHÄTUPA M, Hakkarainen J J, Kaja S, Uusitalo H, Järvinen T A, Uusitalo-Järvinen H, Kalesnykas G - Kuopio

T010 Dose-dependency of intraperitoneally-injected aflibercept in the mouse choroidal neovascularization model
RAGAUSKAS S, Cerrada-Gimenez M, Tenhunen A, Ziniauskaite A, Kaja S, Kalesnykas G - Kuopio

T011 Selected pharmacology of PlGF neutralization over anti-VEGF on retinal gliosis and RGC survival assessed in a diabetic mouse model
ETIENNE I, Van Bergen T, Feyen J - Leuven

T012 The association between macular thickness and axial length
KWON J - Suwon

T013 In vivo retinal cells visible without adaptive optics using a novel full-field OCT
MAZLIN V, Xiao P, Scholler J, Grieve K, Sahel J A, Fink M, Boccara C - Paris

T014 Repeatability of vessel density measurements using optical coherence tomography angiography in retinal diseases
KIM J Y - Daejeon

T015 Macular retinal capillary density and blood flow differences between black and white subjects using optical coherence tomography angiography
SKONDRA D, Chun L - Chicago

T016 Study of macular and optic disk blood flow by angio-OCT in Glucose-6-Phosphate Dehydrogenase (G6PD) deficient men and age-related G6PD-normal subjects
D'AMICO RICCI G, Porcu T, Marzano J, Giancipoli E, Boscia F, Pinna A - Sassari

T017 Choriocapillaris changes during development of CNV – an OCT Angiography quantitative analysis
RODRIGUES C, Cabral D, Coscas F, Pereira T, Cachado F, Geraldes C, Sellam A, Barrão S, Papoila A, Coscas G, Souied E - Lisbon

Thursday, October 4 - Poster session

POS

16:00 - 17:00 | POSTER AREA

RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ

T018	Quantitative OCT-Angiography for neovascular age related macular degeneration: Six months follow-up study *COSCAS F, Cabral D, Rodrigues C, Pereira T, Narotamo H, Geraldes C, Vila-Franca M, Barrão S, Papoila A, Coscas G, Souied E - Creteil*
T019	Macular thickness and volume related to vascular macular capillary in OCTA in patients with Type 1 diabetes with no retinopathy *BARTOLOMÉ I, Orduna-Hospital E, Acha J, Sanchez-Cano A I, Lopez Galvez M I, Perdices-Royo L, Idoate A, Montes P, Ascaso Puyuelo J, Pinilla-Lozano I - Zaragoza*
T020	Correlation between diabetic macular edema and areas of capillary non perfusion detected by optical coherence tomography angiography *ZHIOUA BRAHAM I, Kaouel H, Boukari M, Ammous I, Zhioua R - Tunis*
T021	OCT Angiography findings in maternally inherited diabetes and deafness syndrome *ZHIOUA BRAHAM I, Boukari M, Kaouel H, Ammous I, Mili Boussen I, Zhioua R - Tunis*
T022	OCT-angiography: Deep irregular vascular network predictor of neovascular complication in angioid streaks *EL MATRI K, Falfoul Y, Hassairi A, Maalej R, Maamouri R, Kort F, Chebil A, El Matri L - Tunis*
T023	Optical coherence tomography findings after retinal artery occlusion *BARTOLOMÉ I, Berniolles J, Idoate A, Sanchez Marin J I, Marco S, Montes P, Lopez Sangros I, Karlsruher G, Lazaro A I, Ascaso Puyuelo J, Pinilla Lozano I - Zaragoza*
T024	The EYE-MI pilot study: a prospective acute coronary syndrome cohort evaluated with retinal optical coherence tomography angiography *ARNOULD L, Guenancia C, Gabrielle P H, Bron A, Creuzot C, Cottin Y - Dijon*
T025	Vascular features of surgical macular pathologies in OCT-A imaging *CHRISTODOULOU E, Batsos G, Exarhopoulos D, Parikakis E, Stefaniotou M - Ioannina*
T026	Swept-source OCT and OCT angiography findings in Alport maculopathy. *ZHIOUA BRAHAM I, Smaoui S, Boukari M, Zhioua R - Tunis*
T027	Predictive biomarkers in OCT-Angiography of peripheral nonperfusion in retinal venous occlusions *REIS CABRAL D, Coscas F, Glacet-Bernard A, Pereira T, Geraldes C, Papoila A, Vila Franca M, Coscas G, Souied E - Lisboa*
T028	Effect of early age related macular degeneration on the disk halo size produced by a glare source *PEREZ CARRASCO M J, Contreras I, Alía-González C, Gómez-Palacios V, García-Benítez N, Ciércoles-Rodríguez M, Hurtado-Ceña F J, Puell M C - Madrid*
T029	Structural analysis and evolution of AMD Drusenoid deposits "P", Protein-Cellular Type: study with OCT and Morphology-Structural software *GONZALEZ C - Toulouse*
T030	Structural analysis and evolution of AMD Drusenoid deposits "L", Lipid type: study with OCT and Morphology-Structural software *GONZALEZ C - Toulouse*
T031	Analysis of choroidal structure changes in diabetic patients without diabetic retinopathy: a longitudinal study *FIGUEIREDO R, Luís M E, Hipólito Fernandes D, Cunha J P, Alves M, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Coimbra*
T032	Dietary patterns and age-related macular degeneration in Korean population *KIM Y C, Kang K T - Daegu*

POS

16:00 - 17:00 | POSTER AREA

RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ

T033 Relationship between Macular Thickness and Mesopic Visual Acuity in Early to Intermediate Age-related Macular Degeneration Subjects
PUELL M, Hurtado-Ceña F, Ciércoles-Rodríguez M, García-Benítez N, Gómez-Palacios V, Alía-González C, Pérez-Carrasco M, Contreras I - Madrid

T034 A case report of Outer Retinal Tubulations in Age-Related Macular Degeneration - imaging and histologic correlates
MOURA-COELHO N, Dutra-Medeiros M, Basílio A L, Hipólito Fernandes D, Vieira L, Flores R - Lisbon

T035 Progression of Age Macular Degeneration (AMD) after Cataract Surgery: A Case Series
RAHAYU S, Iwan S - Bandung

T036 Three unusual cases of choroidal neovascular membrane (CNV) formation after pars plana vitrectomy for macular pathology
TSOKOLAS G, Clarke B, Gupta B - Southampton

T037 Early changes in retinal thickness when using intravitreal Ranibizumab for age-related macular degeneration
TOMKINSON C, Mahmood S, Chhabra R - Manchester

T038 Thermo-responsive injectable microgel is able to achieve controlled drug release in the vitreous environment
LIU S, Kearns V, Mcdonald T - Leicester

T039 * Topical Treatment for Ocular Diseases of the Posterior Segment: Non-Invasive Delivery of Large Therapeutics such as Bevacizumab and Ranibizumab
DE COGAN F, Slope L, Berwick M, Peacock A, Scott R, Xu H, Chen M - Birmingham

T040 The probability of over-treatment using the treat-and-extend regimen for wet-AMD
SHIN K H, Jeong S H - Seoul

T041 Retinal oximetry in young patients with type 1 diabetes compared to healthy controls
VEIBY N - Oslo

T042 Retinal neurodegeneration exists in type 1 diabetes prior diabetic retinopathy
ORDUNA HOSPITAL E, Idoipe Corta M, Sanchez Cano A, Perdices Royo L, Acha J, Bartolome I, Cuenca N, Abecia E, Lopez Galvez M I, Pinilla Lozano I - Zaragoza

T043 Retinal neurodegeneration in patients with type 2 diabetes mellitus without diabetic retinopathy
MOURA-COELHO N, Alves M, Dias Santos A, Costa L, Oliveira Santos B, Cunha J P, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Lisbon

T044 Retinal measurements in type 2 diabetic patients without diabetic retinopathy using Spectralis Optical coherence tomography
CIPRÉS ALASTUEY M, Gavin Sancho A, Rodrio Sanjuan M J, Satue Palacian M, Larrea Samper J G, Vilades Palomar E, Orduña Hospital E, Garcia-Martin E - Zaragoza

T045 Subclinical alterations in the visual function of type 2 diabetes mellitus patients without diabetic retinopathy
ORDUNA HOSPITAL E, Viladés Palomar E, Larrea Samper J G, Gavin Sancho A, Satue Palacian M, Cipres Alastuey M, Rodrigo Sanjuan M J, Garcia Martin E - Zaragoza

T046 Retinal measurements in type 2 diabetic patients without diabetic retinopathy using Swetpt-Source Optical coherence tomography Triton device
CIPRÉS ALASTUEY M, Gavin Sancho A, Satué Palacian M, Rodrigo Sanjuan M J, Orduña Hospital E, Vilades Palomar E, Larrea Samper J G, Garcia-Martin E - Zaragoza

T047 Fundus autofluorescence changes in diabetic retinopathy
CHATZIRALLI I, Dimitriou E, Kabanarou S, Chatzirallis A, Xirou T, Theodossiadis G, Theodossiadis P - Athens

Thursday, October 4 - Poster session

POS

16:00 - 17:00 | POSTER AREA

RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ

T048	Carotid-cavernous fistula in a patient with diabetic macular edema. A case report *ASCASO F, Montes P, Karlsruher G, Mateo J, Marco S, Lopez I, Berniolles J, Bartolomé I - Zaragoza*
T049	Dipeptidyl peptidase-4 inhibitors and risk of diabetic retinopathy progression in patients with type 2 diabetes: a population-based cohort study *CHUNG Y R, Ha K H, Kim D J, Lee K - Suwon*
T050	Coexistence of diabetic retinopathy and age-related macular degeneration: Epidemiology and management *CHATZIRALLI I, Dimitriou E, Saitakis G, Chatzirallis A, Theodossiadis G, Theodossiadis P - Athens*
T051	Bariatric surgery and its retinal repercussions – a pilot study *LAIGINHAS R, Guimarães M, Santos-Sousa H, Preto J, Nora M, Chibante-Pedro J, Falcão-Reis F, Falcão M - Alijo*
T052	Automatic Detection of Diabetic Retinopathy using Jointly Trained CNNs *HIJAZI B, Quellec G, Lamard M, Cochener B - Brest*
T053	Evaluation of an Artificial Inteligence clinical decision support suite for Diabetic Retinopathy and Age related macular degeneration screening *TRANOS P, Karassavidou E, Tsirampidou E, Stavrakas P, Chrissafis C - Thessaloniki*
T054	Development and validation of a risk-prediction nomogram for good functional response one year after treatment with anti-VEGF in naive-Diabetic macular edema *GABRIELLE P H, Massin P, Arnould L, Bouche-Pillon J, Maupin E, Bron A, Kodjikian L, Creuzot C - Dijon*
T055	Combining sub threshold laser therapy and anti-VEGF injections in diabetic macular edema *EL MATRI L, Falfoul Y, Chebbi Z, Hassairi A, El Matri K, Chebil A - Tunis*
T056	Analysis of factors related to early macular edema recurrence after intravitreal dexamethasone implant treatment in diabetic macular edema *KIM K T, Chae J B, Kim D Y - Cheongju*
T057	Eficacy and safety of corticosteroid implant (Fluocinolone Acetonide (FAc) 0.2 µg/day,Iluvien ®) for management of Diabetic Macular Edema (DME): a real-life study *VIEIRA M, Pereira J, Santos M, Arruda H, Sousa J - Leiria*
T058	Three year real-life outcomes from the use of the fluocinolone acetonide implant (Iluvien) in the treatment of refractory DMO *KARATSAI E, Ali Y, Taylor S - Guildford*
T059	Evidences of new risk factors for retinal vein thrombosis *FRUSCHELLI M, Gelmi M C, De Bartolo G, Hadjistilianou T, Bocchia M, Gozzetti A, Calzoni P, Puccetti L - Siena*
T060	Differentiated approach to the management of patients with retinal occlusions. *MALGIN K, Zagrebneva M - Orenburg*
T061	Comparison of the efficacy of intravitreal Bevacizumab and Dexamethasone implant in patients with macular edema by branch retinal vein occlusion according to macular perfusion type *CHOI C W - Iksan-si*
T062	Pseudophakic cystoid macular edema responding to the combination of topical and systemic treatment as first-line therapy (case-series study) *PANFILOVA A, Arslanov G, Chistyakova N, Dal N, Krasavina M, Onishchenko E, Khudainazarova V - Saint-Petersburg*
T063	Acute Endophthalmitis after Cataract Surgery: 164 Consecutive Cases Treated at a Referral Center in South Korea *JEONG S, Chung J, Chang Y - Seoul*

POS

16:00 - 17:00 | POSTER AREA

RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ

T064 Endophthalmitis rate following intravitreal injection of anti-VEGF and the impact of post-injection topical antibiotics
HORNER F, Chavan R - Birmingham

T065 Acute endophthalmitis after intravitreal injections of corticosteroids or anti-vascular growth factor agents. A nationwide study in France from 2012 to 2015
BAUDIN F, Benzenine E, Mariet A S, Bron A, Daien V, Korobelnik J F, Quantin C, Creuzot C - Dijon

T067 Syphilitic placoid chorioretinitis: Clinical features and therapeutic response in two cases
ASCASO F, Karlsruher G, Montes P, Marco S, Lopez I, Berniolles J, Bartolome I, Lara F, Minguez E - Zaragoza

T068 A case of total retinal detachment associated with AIDS-related cytomegalovirus retinal necrosis: the role of combined surgery
VOLHA Y, Imshenetskaya T - Minsk

T069 Post-hoc comparison of best-corrected visual acuity improvement in study and untreated fellow eyes with active non-infectious uveitis of the posterior segment in the SAKURA program
BODAGHI B, Pavesio C, Abraham A - Paris

T070 Case series: Ozurdex® for macular edema in uveitis
SOUSA F, Mano S, Marques R, Leal I, Prates-Canelas J - Lisbon

T071 Risk Factors for Central Serous Chorioretinopathy: Multivariate Approach in a Case-Control Study
CHATZIRALLI I, Kabanarou S, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P - Athens

T073 The effect of eplerenone in chronic central serous chorioretinopathy refractory to PDT therapy
PARIKAKIS E, Karagiannis D, Batsos G, Kontomihos L, Ktena E, Peponis V - Kifissia, Athens

T074 Histopathologic analysis as a tool for understanding the pathogenetic mechanisms in posterior pole pathologies
CHRISTODOULOU E, Batsos G, Goussia A, Parikakis E, Stefaniotou M - Ioannina

T075 Optical Coherence Tomographic Changes of Subretinal Proliferation in Rhegmatogenous Retinal Detachment with Scleral Buckling
KIM Y C, Kang K T - Daegu

T076 The role of disorganization of inner retinal layers as predictive factor in patients with epiretinal membrane
XIROU T, Garnavou-Xirou C, Kabanarou S, Gkizis I, Bitza P, Koutropoulou N, Kontou E, Chatziralli I - Glyfada

T077 Longitudinal Evaluation of Retinal Structure in Patients with Idiopathic Epiretinal Membrane Using Optical Coherence Tomography
LEE M Y - Uijeongbu-Si

T078 The effect of internal limiting membrane peeling in treatment of idiopathic epiretinal memebrane
CHANG Y S, Song S H, Jeong S H - Daejeon

T079 Retinal detachment following elective macular surgery
GRAJEWSKI L, Carstens J, Krause L - Dessau

T080 The incidence of rhegmatogenous retinal detachment in France from 2010 to 2016: seasonal and geographical variations
BEN GHEZALA I, Benzenine E, Mariet A S, Gabrielle P H, Bron A, Quantin C, Creuzot C - Dijon

Thursday, October 4 - Poster session

POS

16:00 - 17:00 | POSTER AREA

RV - Retina/Vitreous

Poster T001-T096

SOUBRANE G , DE LAEY JJ

T081		Localized versus 360-degree laser photocoagulation with pars plana vitrectomy in the management of primary rhegmatogenous retinal detachment *RYOO N K, Kim S Y, Woo S J, Park K H - Seongnam-Si*
T082		Surgical treatment of macular holes using platelet rich plasma *MALGIN K, Lomukhina E - Orenburg*
T083		Surgery for macular telangiectasia type 2 with lamellar hole or macular hole in Asians: Affirmative results and mechanisms *LEE S C, Hwang D J, Moon B G, Kong M, Sohn J H - Bupyeong-gu*
T084		Our experience two steps surgical treatment of optic disk pit maculopathy *VOLHA Y, Imshenetskaya T, Markevich V, Vaskevich G - Minsk*
T085		Pars plana posterior capsulectomy during combined pars plana vitrectomy and cataract surgery *KIM Y C - Daegu*
T086		Augmented field of view for ocular endoscopy using deap learning *THIERY T, Lamard M, Guerre A, Quellec G, Cochener B - Brest*
T087		Structural impact of arrested foveal development in preterms *SJÖSTRAND J, Popovic Z - Mölndal*
T088		Is that a torpedo near the fovea? Torpedo maculopathy a case report *BERNIOLLES J, Batolome Sese I, Ramiro Millan P, Ascaso Puyuelo F J, Marco Monzon S, Montes P, Sierra Garcia M E - Zaragoza*
T089		Retinal biomarkers for Alzheimer's and Parkinson's diseases *BERNARDES R, Nunes A, Castelo-Branco M - Coimbra*
T090		Changes in the retina in the evolution of Alzheimer's disease *SALOBRAR-GARCIA E, De Hoz R, Salazar J J, Ramirez A I, Lopez-Cuenca I, Yubero R, Gil P, Ramirez J M - Madrid*
T091		Age Macular Degeneration - Alzheimer Disease: Ophthalmic exam - MCI in-between correlations. 5 years evolution *GONZALEZ C - Toulouse*
T092		Contribution of multimodal imaging in traumatic maculopathy *ELBANY S, El Chehab H, Thibaud M, Maelle R, Agard E, Verrecchia S, Kodjikian L, Dot C - Lyon*
T093		Characterization of Retinal Structure in CNGB3-associated Achromatopsia *GEORGIOU M, Kalitzeos A, Litts K M, Singh N, Kane T, Hirji N, Mastey R, Kumaran N, Dubra A, Carroll J, Michaelides M - London*
T094	*	Mild Cone-rod dystrophy and sensorineural hearing loss with CEP250 mutation in a Japanese family *GOCHO K, Kubota D, Takahashi H, Kameya S - Inzai*
T095		Morpho-functional relationship and follow up of retinal dystrophy in subjects with Joubert syndrome using OCT and electrophysiology *FALCIONE A, Ruberto G, Bertone C, Signorini S, Guagliano R, Bianchi P E - Pavia*
T096		Diagnosis of pattern dystrophy in a case with multiple sclerosis (MS) on fingolimod (Gilenya) treatment and progressive dyschromatopsia *GARNAVOU-XIROU C, Xirou T, Vasileias D, Boutouri E, Tsamis D, Ragkousis A, Gkizis I, Anastasakis A, Terzidou C, Kabanarou S - Ashford*

POS

16:00 - 17:00 | POSTER AREA

PBP - Poster Session: Physiology/Biochemistry/Pharmacology in Poster area

Poster T097 - T109

SCHMETTERER L , STEFANSSON E

T097	Effect of flicker stimulation on retinal and optic nerve head blood flow as measured by Laser Speckle Flowgraphy *SCHMIDL D, Fondi K, Bata A, Luft N, Witkowska K, Werkmeister R, Schmetterer L, Garhofer G - Vienna*
T098	Evaluation of sex differences in flicker light induced vasodilation and central retinal thickness in healthy young subjects. *SZEGEDI S, Malin A G, Witkowska K J, Fondi K, Bata A M, Schmidl D, Garhofer G, Schmetterer L - Vienna*
T099	Effects of focal light-emitting diode (LED)-induced phototoxicity in the albino rat retina *MIRALLES DE IMPERIAL OLLERO J A, Di Phierdomenico J, Gallego-Ortega A, Villegas-Perez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia*
T100	Retinal ganglion cells loss and caspase 3 activation after ocular hypertension *VALIENTE-SORIANO F J, Sánchez-Migallón Carreras M C, Agudo-Barriuso M, Vidal-Sanz M - Murcia*
T101	Unilateral optic nerve axotomy at different distances from the optic disk cause the same course of retinal ganglion cells death *GALINDO-ROMERO C, Lucas-Ruiz F, Albadalejo-García V, Ros-Alcobas L, Vidal-Sanz M, Agudo-Barriuso M - Murcia*
T102	Different aetiologies cause distinct patterns of cone degeneration *GARCÍA-AYUSO D, Di Pierdomenico J, Martínez-Vacas A, Hadj-Said W, Hernandez-Muñoz D, Marie M, Agudo-Barriuso M, Vidal-Sanz M, Picaud S, Villegas-Pérez M P - Murcia*
T103	Microglial cell inhibition improves photorreceptor survival in two animal models of inherited retinal degeneration *DI PIERDOMENICO J, García-Ayuso D, Agudo-Barriuso M, Vidal-Sanz M, Villegas-Pérez M P - Murcia*
T104	Retinal response to hypoxia: new insight on the functional role of beta3 adrenoceptors *DAL MONTE M, Cammalleri M, Filippi L, Bagnoli P - Pisa*
T105	VEGF-induced VEGF release in the retina in response to oxidative stress *DAL MONTE M, Amato R, Lulli M, Rossino M G, Cammalleri M, Casini G - Pisa*
T106	Acute high-fat feeding exacerbates retinal degeneration in a mice model of retinitis pigmentosa *LAX P, Kutsyr O, Noailles A, Maneu V, Cuenca N - San Vicente del Raspeig*
T107	Metallothionein-mediated neuroprotection of retinal ganglion cells using FLOREC retinal explants culture *MACHOWICZ J, Wojtyniak A, Witek P, Kocot E, Wawrzonkowski P, Ajeleti M, Pietrucha-Dutczak M, Lewin-Kowalik J, Smedowski A - Katowice*
T108	Refinement for mouse EAE-model *TENHUNEN A, Cerrada-Gimenez M, Thapa R, Jääskeläinen N, Nevalainen T, Kankkunen A, Partanen P, Mering S - Kuopio*
T109	Laponite clay for long term delivery dexamethasone intravitreal inyections *RODRIGO M J, Prieto E, Garcia-Martin E, Idoipe M, Vispe E, Fraile J M, Mayoral J A, Martinez T, Subias M, Lopez A, Polo V - Zaragoza*

Thursday, October 4 - Poster session

POS

16:00 - 17:00 | POSTER AREA

IM - Immunology/Microbiology

Poster T110-T123

WILLERMAIN F , DICK A

T110 Suclinical signs persistance in Vogt-Koyanagi-Harada disease (VKHD) patients treated with early high-dose corticosteroids and immunosuppressive therapy
YAMAMOTO TAKIUTI J H, Lavezzo M M, Sakata V M, Kanenobu C, Morita C, Oyamada M K, Hirata C E - Sao Paulo

T111 Fine-Tuning of therapy in stromal choroiditis using indocyanine green angiography (ICGA)
ELAHI S, Gillmann K, Gasc A, Jeannin B, Herbort Jr C P - Lausanne

T112 Treatment of corticosteroid resistant Grave's orbitopathy with tocilizumab
GRIVET D, Perillat N, Gain P, Thuret G - Saint-Etienne

T113 EYS606 for the Treatment of Non-Infectious Uveitis (NIU)
BUGGAGE R - Paris

T114 Aciclovir-resistant HSV1 keratitis : a clinical and virological study
ROUSSEAU A, Burrel S, Gueudry J, Deback C, Bordereau S, Mouriaux F, Labalette P, Bazard M C, Gabison E, Bourcier T, Schweitzer C, Labetoulle M - Le Kremlin Bicêtre

T115 Association between visual function and quality of life in patients with Vogt-Koyanagi-Harada disease
YAMAMOTO TAKIUTI J H, Missaka R F, Souto F M, Marchiori B M, Caetano V M, Takiuti J T, Lavezzo M M, Oyamada M K, Hirata C E - Sao Paulo

T116 In vitro antimicrobial activity of a new ophthalmic solution containing povidone-iodine 0.6% (IODIM®)
PINNA A, Donadu M G, Usai D, D'Amico-Ricci G, Boscia F, Zanetti S - Sassari

T117 Interleukin-33 regulates mitochondrial function in the retinal pigment epithelium maintaining immune homeostasis
SCOTT L, Vincent E, Dick A, Theodoropolou S - Bristol

T118 Efficacy of a colloidal silver-based topical solution on microbial biofilms
BLANCO A R, Marino A, D'Arrigo M, Nostro A - Napoli

T119 Clinical follow-up of uveitis patients treated with TNF-alpha inhibitors and causes of treatment discontinuation
LE A, Judice Relvas L, Makhoul D, Draganova D, Lefebvre P, Bazewicz M, Caspers L, Nubourgh I, Vanderhulst J, Goffin L, Ferster A, Postelmans L, Willermain F - Rognée

T120 Clinical characteristics and complications in intermediate uveitis: analysis of 15-years experience in a tertiary center for uveitis in Belgium
VANCLOOSTER A, Tack M, Sys C, Leroy B P, De Schryver I - Gent

T121 Epidemiology in paediatric non-infectious uveitis treated with tumor necrosis factor-alpha inhibitors: a retrospective study
Van Slycken M, VAN SLYCKEN A, Leroy B P, De Schryver I, Dehoorne J - Ghent

T122 Adalimumab in the management of Acute Zonal Occult Outer Retinopathy: a case report
STOCKMAN M, Sys C, Balikova I, Leroy B, De Zaeytijd J, De Schryver I - Roeselare

T123 Visual electrophysiological assessment in birdshot chorioretinits treated with anti-TNF-α
CLAEYS M, De Zaeytijd J, Sys C, Neu F, Leroy B P, De Schryver I - Ghent

Thursday, October 4 - Second afternoon session

SIS

17:00 - 18:15 | HERMES

RV - Oct-angiography biomarkers in choroidal and retinal disease

ZOGRAFOS L , COSCAS F

1811	17:00	OCT-A biomarkers for the macular surgical pathologies *POURNARAS C - Genève*
1812	17:15	Structural versus Angiography OCT in AMD *COSCAS F, Cabral D, Coscas G, Souied E - Creteil*
1813	17:30	OCT-A in radiation induced maculopathy *ZOGRAFOS L - Lausanne*
1814	17:45	New insight on choroidal vasculature: multimodal morphofunctional approach *LUPIDI M, Cagini C, Coscas F, Cardillo Piccolino F, Coscas G - Perugia*
1815	18:00	3 D OCT angiography in choroid layer *REIS CABRAL D, Coscas F, Pereira T, Narotamo H, Geraldes C, Vila-Franca M, Papoila A - Lisboa*

SIS

17:00 - 18:15 | RHODES 1

G - Laser treatments for glaucoma-old headlines or breaking news?

In recent years there has been a shift in the treatment of glaucoma to promote early & minimally invasive intervention. There is a drive to reduce dependency on topical medication given the known low rates of persistence with & adherence to topical treatment regimes. Studies suggest that minimising dependence on glaucoma drops for treatment effect can significantly improve quality of life. Laser treatments offer safe and effective pressure lowering and with increasing patient acceptance of laser as a primary treatment option this SIS will offer clinicians a review of the laser modalities available and late breaking news on new uses for traditional treatments.

CRAWLEY L , AMEEN S

1821	17:00	ECP- reducing inflow from the inside *CRAWLEY L - London*
1822	17:18	micropulse diode laser trabeculoplasty- subthreshold is the new threshold *AMEEN S - London*
1823	17:36	ALPI- Post EAGLE to PI or not to PI *BESINIS D - Nea Smyrni*
1824	17:54	SLT- revolution or evolution *PORTEOUS A - London*

Thursday, October 4 - Second afternoon session

C

17:00 - 18:15 | RHODES 2

G - Landmark papers in ophthalmology – how to do one!

✶ Beginner

This course will include four lectures covering personal reflections of established researchers on important steps that lead to the publication of a landmark paper. The lectures will include topics such as the importance of study design, important factors involving patient recruitment, how to get the money through grant applications, journal selection etc. Participants will have the opportunity to have an informal discussion with the lecturers at the end of the session. Participants can then continue to mingle and get to know each other over some drinks and food.

JÓHANNESSON G

1831	17:00	Study design - making the most of your resources when planning a trial *BOWMAN R - London*
1832	17:18	Mitochondria to money, how to get that funding *VOTRUBA M - Cardiff*
1833	17:36	Keeping your trial on track - when to start recruiting, how to keep things moving and when to stop *ROSA A, Oliveira M, Martins A - Coimbra*
1834	17:54	End points for the 21st century and making your research understandable to the general public *THOMPSON D - London*

SIS

17:00 - 18:15 | RHODES 3

PO - Genetic predisposition syndromes in ophthalmology

Ophthalmology recognizes many syndromes, some of which have a known genetic basis. It is important to recognize the association between an eye disease and the systemic syndrome, as the presence of a germ line mutation may not only affect other organs of the patient, but may also be important for family members and offspring. Several important genetic predisposition syndromes will be discussed.

KIVELÄ T , MOURIAUX F

1841	17:00	Von Hippel-Lindau tumor predisposition syndrome *SCHALENBOURG A - Lausanne*
1842	17:15	Xeroderma pigmentosum tumor predisposition syndrome *TBD*
1843	17:30	BAP1-TPDS: a wide-ranging tumor predisposition syndrome *KIVELÄ T, Turunen J A, Repo P, Järvinen R S, Lehesjoki A E - Helsinki*
1844	17:45	Familial adenomatous polyposis and associated differential diagnosis of RPE lesions *KIILGAARD J F - Copenhagen*
1845	18:00	Second cancers in survivors of hereditary retinoblastoma *VAN HOEFEN WIJSARD M, Fabius A W, Van Leeuwen F E, Moll A C - Amsterdam*

Thursday, October 4 - Second afternoon session

SIS

17:00 - 18:15 | RHODES 4

ACB - Ocular surface as a target for drug development

In the maintenance of the fine homeostasis of ocular surfaces, cornea, conjunctiva and lacrimal glands are interacting via nervous system, growth factors and cytokines regulating several mechanisms like tear fluid secretion, cell differentiation, tissue regeneration, inflammation and wound healing. Ocular surface problems are clinically common, quality of life reducing and potentially vision threatening conditions. Currently it is estimated that there are nearly 350 million patients world wide suffering from dry eye only and the direct costs of it is $ 3,8 billions. Ocular surface is also a potential target of adverse events of topical medical therapies and several ocular intervention.This SIS is focusing on ocular surface as a potential target for drug development and safety issues including proteomic approach.Tear proteomics is a novel approach to study the mechanisms involved in disease processes and to find clinically relevant biomarkers for diagnostics and for the development of novel therapeutic interventions in clinical studies.

UUSITALO H , BEUERMAN R

1851		17:00	The utility of proteomics for understanding the pathophysiology of dry eye *STERN M E - Irvine*
1852		17:15	Ocular surface disease and dessicating stress *CALONGE M, Pinto-Fraga F J, Fernandez I, Gonzalez-Garcia M J, Enriquez De Salamanca A, Lopez-Miguel A - Valladolid*
1853		17:30	Large data sets in Proteomics and new insights into eye disease *BEUERMAN R - Singapore*
1854	*	17:45	Standardization of preclinical testing platforms for topical ophthalmic drugs *KALESNYKAS G, Hakkarainen J J, Ziniauskaite A, Thapa R, Tenhunen A, Mering S, Kaja S - Kuopio*
1855		18:00	Ocular surface and proteomic safety biomarkers in topical medication *UUSITALO H - Tampere*

SIS

17:00 - 18:15 | GALLIENI 1+2

MBGE - Grand rounds in animal & human genetics

This SIS will provide a forum to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics, with the specific aim to stimulate interaction between human and mouse ophthalmic geneticists. The format is simple, informal and is comparable to that of the Grand Rounds in departments of ophthalmology around the World.
All EVER participants are invited to come and discuss cases during this session. All of us will learn!

LEROY B , GRAW J

1861		17:00	Human Case *LISKOVA P, Kousal B, Petra H, Kolarova H, Honzik T - Prague*
1862		17:18	Animal Case *ROUX M, Guimond A, Herault Y - Illkirch*
1863		17:36	Animal Case *AMARIE O, Fuchs H, Gailus-Durner V, Hrab De Angelis M, Graw J - Neuherberg*
1864		17:54	Human Case *LEROY B - Ghent*

Thursday, October 4 - Evening session

SIS

18:15 - 19:30 | RHODES 2

What does TFOS DEWS II bring to your clinical practice?

ROLANDO M

	18:15	What's new in TFOS DEWS II? *ROLANDO M - Italy*
	18:33	Proteomics in tear fluid *GRUS F - Germany*
	18:51	Breaking the chain: inflammation in dry eye *SHORTT A - United Kingdom*
	19:09	A new weapon for chronic dry eye co-presenter Dr. Quintas *EMESZ M - Austria* *QUINTAS A - Portugal*

Friday
October 5

Friday, October 5 - First morning session

SIS

8:30 - 9:45 | HERMES

RV - Ischemic ocular diseases: raise the red flag!

Theme: ocular ischemic diseases: from pole to pole
The SIS will adress clinical consequences of ischemia in various ocular pathologies . The participants will receive useful clinical tips to manage such pathologies.

AMBRESIN A , POURNARAS J

2111		8:30	Peripheral ischemia in diabetes: anti VEGF, PRP? *AMBRESIN A - Lausanne*
2112		8:42	Blood flow dysfunction in glaucoma *SCHMIDL D - Vienna*
2113		8:54	Techniques of phacoemulsification and vitreoretinal surgeries in ischemic eyes *POURNARAS J A - Lausanne*
2114		9:06	Choroidal and retinal occlusive vasculitis *VAUDAUX J - Lausanne*
2115		9:18	Acute ischemic retinal disease *MANTEL I - Lausanne*
2116		9:30	Ischemic optic neuropathies: does the origin of ischemia matter? *TBC*

SIS

8:30 - 9:45 | RHODES 1

G - Maximising information extraction from biological data

Big Data describes an approach to research where the aim is to extract all available information from a data source and therefore overcome some of the limits of conventional sampling based approaches. This multidisciplinary SIS presents recent developments in techniques to maximise information extraction from pre-clinical and clinical imaging datasets. The use of these practices to yield novel mechanistic insights into neurodegenerative processes in glaucoma will be discussed in addition to techniques that can be ultimately exploited for the development of novel diagnostic and therapeutic approaches in patients.

DAVIS B , NORMANDO E M

2121		8:30	RGC cell size and susceptibility to loss in rodent glaucoma models *DAVIS B, Guo L, Ravindran N, De Groef L, Cordeiro M F - London*
2122		8:45	Improving information extraction from visual field data *NORMANDO E M - London*
2123		9:00	Neurodegeneration in the Brain – Before or after the retina? *JOLLY J, Sheldon A, Alvarez I, Ip B, Maclaren R, Bridge H - Oxford*
2124	*	9:15	Cortical anomalies in response to RGC damage: how do they affect the visual field and how should we measure them? *REDMOND T - Cardiff*
2125		9:30	Image analysis and data science for vessel network analysis in the retina *DE BOEVER P - Mol*

Friday, October 5 - First morning session

C

8:30 - 9:45 | RHODES 2

COS - Optical imaging techniques for the cornea and anterior eye segment – pearls and pitfalls

✶✶ Intermediate

Within the last 25 years more and more classical diagnostic techniques such as ultrasound were augmented or superseded by optical based diagnostic techniques. Amongst those we find Placido based corneal topography, Scheimpflug or OCT based tomography of the anterior segment of the eye, confocal microscopy of the cornea or specular microscopy of the corneal endothelium.

In this course we will give guidelines how to read and to interpret measurements of these instruments. The audience will get a comprehensive insight how to read the specific output parameters of these modern diagnostic tools and how to use them for instrument-assisted diagnosis. The interpretations will be illustrated and emphasized by typical clinical examples.

SZENTMARY N , WYLEGALA E

2131	8:30	Placido-based corneal topography and Scheimpflug-based corneal tomography *LANGENBUCHER A, Szentmáry N, Daas L, Wylegala E, Eppig T - Homburg*
2132	8:45	High resolution anterior segment OCT CASIA 2 for corneal and anterior segment diagnosis *WYLEGALA E - Katowice*
2133	9:00	Confocal microscopy for diagnosis of infectious processes in the cornea *DAAS L, Szentmáry N, Flockerzi E, Langenbucher A, Seitz B - Homburg*
2134	9:15	Measurement of corneal biomechanics using the high-speed Scheimpflug system CORVIS *EPPIG T, Szentmáry N, Spira-Eppig C, Langenbucher A, Seitz B - Homburg/Saar*
2135	9:30	Analysis and interpretation of specular microscopy measurements of the corneal endothelium *SZENTMARY N, Tóth G, Butskhrikidze T, Hager T, Langenbucher A, Seitz B - Budapest*

SIS

8:30 - 9:45 | RHODES 3

IM - Therapeutic update: biologic agents in uveitis

The treatment of non infectious uveitis continues to remain a challenge for many ophthalmologists. Unfortunately, in spite of a multitude of highly unfavourable systemic effects, corticosteroids are still regarded as the mainstay of treatment for many patients with chronic and refractory non infectious uveitis. However, with the success of other conventional and biologic immunomodulatory agents in treating systemic inflammatory and autoimmune conditions, interest in targeted treatment strategies for uveitis is increasing. Multiple clinical trials on steroid-sparing immunosuppressive agents and biologic agents have already been completed, and many more are ongoing. This symposium highlights the results and implications of these clinical trials investigating novel treatment options for non infectious uveitis.

VAN CALSTER J , BODAGHI B

2141		8:30	Introduction / clinical trial results of TNF alfa blocking agents *VAN CALSTER J - Leuven*
2142	✶	8:48	Role of other biologics in adult uveitis patients *WILLERMAIN F - Bruxelles*
2143		9:06	Biologics in childhood uveitis *DICK A - Bristol*
2144		9:24	New molecules under development *BODAGHI B - Paris*

Friday, October 5 - First morning session

SIS

8:30 - 9:45 | RHODES 4

LC/RV - New approaches in myopia diagnosis, prevention and treatment

Myopia is a global problem, being particularly prevalent in the urban areas of East Asia. It is progressing at faster than predicted rates for reasons that are still unknown. Besides the direct economic and social burdens, associated ocular complications from pathologic myopia may lead to significant visual impairment and blindness due to various pathologies in the macula, peripheral retina and the optic nerve. The epidemiology of myopia is characterized by increasingly early onset, combined with high myopia progression rates. In fact, with prevalence of myopia above 80% and high myopia over 20%, it is crucial to control this degenerative disease. New generation optical coherence tomography (OCT) technologies, including enhanced depth imaging (EDI-OCT), swept source OCT (SS-OCT) and OCT angiography, have led to a greater insight in pathophysiology of high-grade myopia. The aim of this symposium is to provide an update on diagnostic tools, interventions to slow the onset of myopia and retard its progression, as well as a review on current treatment options and their efficacy.

GRZYBOWSKI A , ASCASO F

2151		8:30	Myopia epidemiology *MORGAN I - Ainslie*
2152		8:45	OCT angiography in myopia *ASCASO F - Zaragoza*
2153	*	9:00	Myopic CNV – current diagnosis and management *SCHWARTZ S - Naples*
2154		9:15	Myopia control with Atropine in Europe *KLAVER C, Tan E, Tideman W, Polling J R - CA Rotterdam*
2155		9:30	Other strategies of Myopia control *GRZYBOWSKI A - Olsztyn*

SIS

8:30 - 9:45 | GALLIENI 1+2

MBGE/NSPH - Understanding retinal ganglion cell loss — from genes to disease mechanisms

Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a key clinical feature. The commonest causes worldwide are mutations in mitochondrial DNA (causing Leber's hereditary optic neuropathy: LHON) and OPA1 mutations (causing Autosomal Dominant Optic Atrophy: ADOA). Based on published data from different geographical populations, 60-80% of patients with ADOA have mutations in the OPA1 gene. Although inherited optic neuropathies are considered as 'orphan' diseases, grouped together, the prevalence is about 1 in 10,000 – representing an important cause of blindness in both the paediatric and young adult population. Recent trials of drugs and gene therapy in patients with LHON, have shown the first glimmer of hope for the treatment of this group of patients. At this exciting time, this SIS will focus on disease mechanisms and clinical phenotyping and potential avenues towards novel and effective therapies.

VOTRUBA M , YU-WAI-MAN P

2361		8:30	The pathogenic mechanisms of mitochondrial optic neuropathies studied in iPSCs-derived neurons *CARELLI V - Bologna*
2362		8:48	Retinal vascular changes in mitochondrial optic neuropathy *BARBONI P - Bologna*
2363		9:06	What have metabolism studies taught us about ADOA pathophysiology and possible future therapies? *LENAERS G, Reynier P, Chao De La Barca M, Bocca C, Kouassi Nzoughet J, Charif M - Angers*
2364		9:24	Novel strategies to treat autosomal dominant optic atrophy *VOTRUBA M - Cardiff*

Friday, October 5 - Keynote lecture

KN

9:45 - 10:15 | HERMES

Keynote lecture by Leonard LEVIN

9:45 Introduction by Francesca M CORDEIRO

Leonard LEVIN

2211 9:50 **The Axon is dead: long live the Axon!**

Leonard LEVIN — Montreal

In 2002 Martin Raff and colleagues wrote a seminal paper identifying an axonal self-destruction program as separate for the more familiar programs for somal loss. Given that so many central nervous system diseases begin (and usually end) with axonal injury and degeneration, several laboratories focused on dissecting the mechanisms by which these processes occur. More recently, we have developed an ability to identify the very earliest signals associated with axonal degeneration. Coupled with the development of pharmacological therapies that might protect axons ("axoprotection") and the availability of animal models where axon degeneration is severely inhibited, we are in a golden age of axon biology and therapy.

10:15 Award presentation of the EVER Certificate of Honour

Friday, October 5 - Second morning session

SIS

10:45 - 12:00 | HERMES

RV - Laser photocoagulation of capillary macro-aneuvrysms in retinal vascular diseases

During diabetic macular edema (DME) and retinal vein occlusion (RVO), it has recently been shown that focal vascular anomalies (capillary macro-aneurysms) may play a central role. Indeed, their prevalence is estimated to be around 30% of cases (Dupas, unpublished data).
The systematic detection of macro-aneurysms followed by their OCT-controlled photocoagulation is of interest because it may diminish the need for intravitreal injections. We subsequently developed a procedure called Indocyanine green-Guided Targeted Laser photocoagulation (IGTL) which combines the detection of macro-aneurysms by ICG angiography, their photocoagulation by laser. We have shown that targeted photocoagulation of those macro-aneuvrysms may improve vision while decreasing retinal edema, with low need for intra vitreal injection (Paques et al, BJO 2016).
The proposed SIS intends to re-assess the role of photocoagulation in chronic macular edema management, while discussing indications and treatment modalities.

DUPAS B , PAQUES M

2311	10:45	Capillary macroaneurysms in retinal vascular diseases : an overview *PAQUES M - Paris*
2312	11:03	Laser photocoagulation of macroaneurysms; clinical cases in DME *DUPAS B - Paris*
2313 *	1:21	Macroaneurysms and their photocoagulation in other diseases *DELYFER M N - Bordeaux*
2314	11:39	Technological developments for improving indocyanine-guided laser photocoagulation *MEIMON S - Paris*

SIS

10:45 - 12:00 | RHODES 1

G - EVER Obergurgl optic-nerve-conference symposium 2017

The EVER optic nerve conference takes place every year in Obergurgl in the austrian alps. This conference explores the current state of our understanding of research related to optic nerve and neurodegeneration and regeneration. Topics identify the crucial challenges and promising future research directions for boosting visual function in optic nerve disease.
To stimulate ideas and discussion, leading experts from a variety of fields emphasize a cross-sectional, interdisciplinary approach. The conference bring together clinicians and basic scientists from different fields and highlight translational research providing a platform for networking and stimulating discussions. In this special interest symposium SIS some of the topics of the Obergurl optic nerve conference 2017 will be presented.

GRUS F , CROWSTON J

2321	10:45	Redox-dependent signaling in axonal degeneration *LEVIN L - Montreal*
2322	11:00	Seeing is believing : live imaging of microvascular pathology in glaucoma *DI POLO A - Montreal*
2323	11:15	Ageing, neuronal metabolism and mitochondria in glaucoma *WILLIAMS P - Bar Harbor*
2324	11:30	Mitochondrial genetic variation and its implications for glaucoma *KHAWAJA A - London*
2325	11:45	MeCP2 association with glaucoma and protein interactions in the retina *FUNKE S - Mainz*

Friday, October 5 - Second morning session

C

10:45 - 12:00 | RHODES 2

COS - Diagnosis and treatment of infectious keratitis in the clinical practice today

✶✶ Intermediate

We summarize up-to-date diagnostic and treatment options of infectious keratitis using literature data and clinical examples. In the clinical practice, most commonly bacterial, herpetic, mycotic and acanthamoeba keratitis occur. Beside slitlamp examination, for diagnostic purpose, corneal sensitivity is analysed. We routinely perform in vivo confocal microscopy, polymerase-chain-reaction (PCR) and histological examination of the corneal sample. As conservative treatment we use primarily topical moxifloxacin or cephazolin with fortified tobramycin or gentamycin in bacterial, topical antiviral gel (in some cases in combination with systemic antiviral treatment) in part in combination with topical corticosteroids in herpetic, voriconazole or amphotericin-B in mycotic, and topical-triple-therapy (diamidine, biguanid and antibiotics) in acanthamoeba keratitis. In case of early diagnosis and initiation of topical therapy, most cases of infectious keratitis recover successfully. However, beside conservative treatment, amniotic membrane transplantation, crosslinking and penetrating keratoplasty therapy may be necessary in well-selected cases and well-defined details.

SZENTMARY N , SEITZ B

2331	10:45	Bacterial keratitis – standard treatment? *MÓDIS L - Debrecen*
2332	11:00	"Herpetic keratitis" – a chameleon *SEITZ B - Homburg*
2333	11:15	Aciclovir resistant herpetic keratitis - diagnosis and treatment *REMEIJER L, Verjans G - Rotterdam*
2334	11:30	Acanthamoeba keratitis – when to use conservative and surgical treatment? *SZENTMARY N, Laurik-Feuerstein K L, Daas L, Shi L, Langenbucher A, Seitz B - Budapest*
2335	11:45	Mycotic keratitis – the threat of today? *DAAS L, Szentmáry N, Flockerzi E, Langenbucher A, Seitz B - Homburg*

SIS

10:45 - 12:00 | RHODES 3

IM/PO - Uveitis: translational insights in invasive diagnostics

Patients with intraocular inflammation can present with very difficult diagnostic challenges. Over the last years, our understanding of the underlying mechanisms of uveitis has grown and the possibilities of immunologic and microbiologic testing have increased. As a result, it has become clear that uveitis entails a multitude of diseases. Although some eyes are inflamed due to local ocular immune phenomena, many of them are ocular manifestations of systemic diseases. The spectrum of disease pathogenesis is highly diverse, including trauma, infectious diseases, autoimmunity and neoplasia. Hence, an accurate diagnosis is the cornerstone of adequate treatment. Even after a profound workup, a precise diagnosis cannot be found in up to 30% of the patients. Fortunately, new yet invasive diagnostic techniques are being developed, such as the determination of inflammatory mediators and the cellular reaction on ocular fluid samples.

VAN CALSTER J , VAN GINDERDEUREN R

2341	10:45	Introduction / surgical techniques / Outcome in 2018 *VAN CALSTER J - Leuven*
2342	11:03	Future in translational research: proteomics? *DICK A - Bristol*
2343	11:21	Uveitis and histopathology in 2018 *VAN GINDERDEUREN R - Leuven*
2344	11:39	Translational research in lymphoma *NERI P - Abu Dhabi*

Friday, October 5 - Second morning session

SIS

10:45 - 12:00 | RHODES 4

LC - Optical and refractive changes with aging

This Special Interest Symposium will give an overview about the refractive development from childhood to adulthood, highlighting the unresolved questions which will define future research. We will cover the topics of eye modelling and will focus on age related changes in the cornea and crystalline lens.

MICHAEL R , ROZEMA J

2351	*	10:45	The physics of light scattering changes with aging *VAN DEN BERG T J - Amsterdam*
2352		11:00	Clinical and research applications of modelling ocular biometry *ROZEMA J - Edegem*
2353		11:15	Optical quality of the cornea and its age-related changes *NAVARRO R - Zaragoza*
2354		11:30	Refractive development of the lens and it's relation to cataract type *MICHAEL R, Pareja Aricó L A, Barraquer R I - Barcelona*
2355		11:45	Multiple stages of refractive development *MORGAN I - Ainslie*

SIS

10:45 - 12:00 | GALLIENI 1+2

LC/MBGE - Cholesterol, oxysterols and eye disease

Cholesterol and its derived oxysterols are associated with a range of different eye diseases. Cholesterol deposits are found in eye tissues as a result of mutations in cholesterol-processing enzymes (eg Smith-Lemli-Opitz syndrome (SLOS)) and in these cases they are associated with lens cataract. Statin use is also linked to cataract incidence. Recently though it is the identification of cholesterol metabolism as a risk factor for Age Related Macular Degeneration that has sparked most interest in this oxysterol and its metabolism. Indeed, finding a number of oxysterols in drusen including, 7keto-cholesterol, which also correlates with age related cataract evidences the close association between cholesterol, its derivatives and oxidized products and the maintencance of eye health. The retina exhibits both concentration and oxysterol specific cytotoxic responses and yet oxysterols have also emerged as potential therapeutic leads for cataract. The importance of cholesterol to lens (Subczynski/Raguz) and retinal (Fliesler) homostasis as well as its link with AMD (Curcio) and cataract (Uwineza/Quinlan) will be presented. Gender and Early Career Investigator balance is a factor in speaker selection.

QUINLAN R

2161		10:45	Cholesterol oxidation and cataract *UWINEZA A, Cummins I, Kalligeraki A, Jarrin M, Ainsbury E, Quinlan R - Durham*
2162		11:03	SLOS, oxysterols and retinal homeostasis *FLIESLER S - Buffalo*
2163		11:21	Cholesterol dependent homeostasis in the lens - a biophysical perspective *SUBCZYNSKI W - Milwaukee*
2164		11:39	Cholesterol and the extracellular deposits of age-related macular degeneration (AMD) *CURCIO C - Birmingham*

Friday, October 5 - European Ophthalmology Heritage lecture

PS

12:00 - 12:30 | HERMES

European Ophthalmology Heritage lecture by Jean-Jacques DE LAEY

12:00 Introduction by Alain BRON

Jean-Jacques DE LAEY

2411 12:05 **A brief history of cataract surgery**

Jean-Jacques DE LAEY — Gent

Although the Eber's papyrus dating from 1525 BC possibly mentions cataract, it is by no way certain that the ancient Egyptians performed cataract surgery. Sushutra is considered the father of Indian surgery. He is probably the first to mention cataract surgery. His technique of lens couching may have reached Rome via Alexandria. In his book "De Medicina" Celsius gives a precise description of lens couching and this technique will remain the standard operation for cataract surgery till the 18th Century. It was often performed by itinerant surgeons, one of the most famous being Chevalier John Taylor who operated unsuccessfully on Bach. Jacques Daviel, who will become surgeon-oculist to king Louis XV describes in the Mémoires de l'Académie de Chirurgie in 1753 his first extracapsular cataract extraction for which he performed an inferior corneal incision. Although this first eye was lost by endophthalmitis Daviel continued to experiment with this technique and claimed that by 1756 he had performed 434 cataract extractions of which 354 were "perfectly successful". Whereas couching still had its firm supporters like Scarpa, resulting in what was sometimes called "The Hundred Years War", Daviel's technique became gradually universally accepted. A guillotine type corneal knife was designed by Guerin (1769) and later by Dumours and Dumont (1760). The most successful cataract knife was however that of von Graefe. Further improvements were the introduction of corneal sutures by Williams in 1866, phenol asepsis by Lister in 1869 and especially local anaesthesia with cocaine by Koller in 1888. The next important steps will be the introduction of intraocular lenses by Ridley in 1949 and of phacoemulsification by Charles Kelman in 1962.

12:30 Award presentation of the EVER Certificate of Honour

Friday, October 5 - Noon session

CIS

12:30 - 13:30 | HERMES

Lunchtime CIS

GuangDong Ophthalmologist Association (GDOA) is the largest organization for eye care professionals in south China. GDOA has over 1000 members divided over 9 different subspecialties such as glaucoma and retina.

Friday, October 5 - Noon session

CIS

12:30 - 13:30 | RHODES 3

Innovations & Novel Products in Ophthalmology (INPO)

FUCHSLUGER T

2511	12:30	Fluorescence Lifetime Imaging Ophthalmoscopy *KATAYAMA Y - Germany*
2512	12:45	Novel ophthalmic applications of neurokinin 1 receptor antagonists *FERRARI G - Italy*
2513	13:00	Laponite clay as a carrier for controlled drug delivery system for intravitreal injections *RODRIGO MJ - Spain*
2514	13:15	Articor - a biosynthetic material for ocular surface reconstruction *FUCHSLUGER T - Germany*

Friday, October 5 - Noon session

SIS

12:30 - 13:30 | RHODES 1

COS/MBGE - TFOS DEWS II: Dry Eye redefined

This SIS will summarize the main findings and novelties presented in the TFOS DEWS II report, including the updated definition and classification, evidences on epidemiology and pathophysiology, the proposed diagnostic algorithm and therapeutic approach.

VILLANI E , SULLIVAN D A

2521	*	12:30	TFOS DEWS II Definition and Classification Report *VILLANI E - Milan*
2522		12:40	TFOS DEWS II Epidemiology and Pathophysiology Reports *SULLIVAN D A - Boston, MA*
2523		12:50	TFOS DEWS II Pain & Sensation Report *BELMONTE C - Alicante*
2524	*	13:00	TFOS DEWS II Iatrogenic Dry Eye Report *MESSMER E M - Munich*
2525		13:10	TFOS DEWS II Diagnostic Methodology Report *PULT H - Weinheim*
2526		13:20	TFOS DEWS II Management and Therapy Report *BARABINO S - Sanremo*

Friday, October 5 - First afternoon session

SIS

13:30 - 14:45 | HERMES

RV - Macular interface surgery

AIM: To present all the new facts regarding macular interface pathology
METHODS: We will provide lectures and questions and answers in the field of macular interface pathophysiology, macular hole, ERM, Vitreomacular Traction Sundrome, New Techniques, New Instrumentation.
RESULT: We believe that at the end of rhe session we will provide all the necessary knowledge for a safer and better management of the macular interface pathology.
CONCLUSION: Macular interface pathology is a good proportion of a Vitreoretinal Surgeon's every day activity. The more you know the better management you can provide.

PAPPAS G , POURNARAS J

2611	13:30	Macular hole management *VIESTENZ A - Halle (Saale)*
2612	13:45	ERM management *TRANOS P - Thessaloniki*
2613	14:00	New Instrumentation *POURNARAS J A - Lausanne*
2614	14:15	Macular interface surgery complication and management *STAPPLER T - Lausanne*
2615	14:30	20 Questions and answers regarding macular interface pathology and surgery *PAPPAS G - Heraklion*

SIS

13:30 - 14:45 | RHODES 1

G/IM - The latest update on uveitic glaucoma

Uveitic glaucoma is a common complication which afflicts up to 20% of these patients. Uveitic glaucoma is a challenging task for the ophthalmologist. The treatment is longitudinal and the type of inflammation affects the choice of topical glaucoma medication, IOP control, cataract development, surgical decision making, and medical management after glaucoma surgery. This SIS tries to review the latest update on management and offers some recommendations on treatment options.

POURJAVAN S , NERI P

2621	13:30	The incidence of Glaucoma in uveitic patients *NERI P - Abu Dhabi*
2622	13:48	The pathophysiology and medical management of uvitic glaucoma *POURJAVAN S - Brussels*
2623	14:06	Surgical options and management in uvitic patients *VAN CALSTER J - Leuven*
2624	14:24	Glaucoma, surgical treatment in uveitic and JIA patients *KESTELYN P - Gent*

Friday, October 5 - First afternoon session

SIS

13:30 - 14:45 | RHODES 2

COS - New approaches for unmet needs in anterior segment diseases

This symposium discusses novel basic scientific and translational approaches regarding unmet needs in anterior segment diseases.

FUCHSLUGER T , FERRARI G

2631	13:30	Nerves in the cornea: proper functioning and healing potential *FERRARI G - Milan*
2632	13:45	Novel biomaterials for ocular surface surgery *THIEME D, Fuchsluger T, Schubert D W - Erlangen*
2633	14:00	Inhibition of apoptosis for the treatment of corneal endothelial diseases *FUCHSLUGER T - Erlangen*
2634	14:15	Link between genetic and functional analyses in pseudoexfoliation glaucoma *BERNER D - Erlangen*
2635	14:30	TFG-ß1 and LOXL1 affect the Pseudoexfoliation syndrome pathology *LIRAVI P - Erlangen*

C

13:30 - 14:45 | RHODES 3

PO - Conjunctival tumors

✶✶✶ Advanced

We describe benign and malignant conjunctival tumors with their clinical and histological aspects
We summarise the practical management of benign conjunctival lesions, the surgical approach of conjunctival tumors and the management of epithelial and melanocytic malignancies. We give all the indications of radiotherapy and local chemotherapy and guidelines for follow up of patients
Rare tumors of the conjunctiva will also be described

DESJARDINS L , MOULIN A

2641	13:30	Conjunctival tumors: clinics and pathology *MOULIN A - Lausanne*
2642	13:42	What to do in case of papilloma or nae *SCHALENBOURG A - Lausanne*
2643	13:54	Principles of surgical approach of conjunctival tumors *CASSOUX N - Paris*
2644	14:06	Management of epithelial malignancies (radiotherapy and local chemotherapy) *DESJARDINS L - Paris*
2645	14:18	Management of malignant conjunctival melanoma (radiotherapy and local chemotherapy) *ZOGRAFOS L - Lausanne*
2646	14:30	Rare conjunctival tumors:(choristomas, neurinomas , sebaceous carcinomas.....) *MATET A - Paris*
2647	14:42	High-throughput sequencing reveals no microbial pathogens in ocular adnexal extranodal marginal zone B-cell lymphoma *MIKKELSEN L H, Mollerup S, Hansen A, Heegaard S - Copenhagen*

Friday, October 5 - First afternoon session

SIS

13:30 - 14:45 | RHODES 4

PBP/ACB - Modern tools to examine the retina

The Special Interest Symposium will present recent studies focussing on modern techniques to identify and study specific populations of retinal neurons, alterations in blood supply and fate of cell transplants following several experimental situations mimicking common retinal diseases. The SIS will provide ample opportunity for interaction among scientists attending the conferences.

VIDAL-SANZ M , SALINAS NAVARRO M A

2651		13:30	New approaches to study retinal pericytes *ALARCÓN-MARTÍNEZ L - Montreal*
2652		13:48	Cell Tracking: The key to understanding the phenomena after photoreceptor transplantation *ORTÍN-MARTÍNEZ A, Tsai E L S, Comanita L, Tachibana N, Gurdita A, El-Sehemy A, Nickerson P E, Wallace V A - Toronto*
2653		14:06	Population of Pituitary Adenylate Cyclase-Activating Polypeptide and Melanopsin-Expressing Retinal Ganglion Cells in the Albino Adult Rat Retina *SALINAS NAVARRO M A, Nadal Nicolas F M, Agudo-Barriuso M, Vidal-Sanz M - El Palmar*
2654	*	14:24	Choosing the best marker to identify retinal ganglion cells *GALINDO-ROMERO C, Nadal-Nicolas F M, Lucas-Ruiz F, Marsh-Armstrong N, Vidal-Sanz M, Agudo-Barriuso M - Murcia*

SIS

13:30 - 14:45 | GALLIENI 1+2

MBGE - New insights in ocular developmental dysgenesis

The symposium aims i) to reveal novel phenotypes or phenotypes-genotypes correlations; ii) to bring samples of mutations in coding regions and impairing the gene function and iii) to question an intriguing regulatory mechanism in congenital microcoria.
-Describing the X-linked BCOR gene role in two different syndromes with eye defects the OFCD syndrome, which occurs exclusively in females and a severe recessive microphthalmia syndrome, in males.
-Reporting a wide spectrum of eye anomalies with different modes of inheritance of FOXE3 mutations demonstrating correlations between the mutation type, the mode of inheritance and the phenotype severity.
-Evidencing mutations pattern in non-coding regions of PAX6 in 3/4 of 27 patients suffering aniridia without coding sequence mutations.
-Studying 13q32.1 deletions encompassing TGDS & GPR180 in Congenital microcoria (MCOR). The role of both genes and elements regulating the expression of neighboring genes in MCOR was addressed in transgenic mouse lines with variable deletions of the region. Molecular analysis clearly shows iris-specific modification of distant genes expression, suggesting a regulatory landscape modification and the fate of embryonic cells involved in iris formation.

CALVAS P , ROZET J

2661		13:30	Pathogenic variants in the X-linked BCOR gene cause two different syndromes *RAGGE N - Oxford*
2662		13:48	FOXE3 mutations correlations between mutation types, inheritance pattern, and phenotype severity *PLAISANCIE J, Ragge N, Dollfus H, Kaplan J, Lehalle D, Francannet C, Morin G, Colineaux H, Calvas P, Chassaing N - Toulouse*
2663		14:06	PAX6 non-coding regions variants leading to aniridia spectrum *Plaisancié J, Tarilonte M, Ramos P, Dollfus H, Blanco-Kelly F, Kaplan J, Fares-Taie L, Francannet C, Goldenberg A, Rozet J M, Ayuso C, Chassaing N, Calvas P, CORTON PEREZ M - Madrid*
2664		14:24	Is the modification of the 13q32.1 regulatory landscape the cause of congenital microcoria? *FARES-TAIE L, Nedelec B, David P, Gerber S, Crippa S, Passet B, Vilotte J L, Chassaing N, Kaplan J, Kostic C, Calvas P, Rozet J M - Paris*

Friday, October 5 - Coffee with Profs and Poster session

SOC

14:45 - 15:45 | POSTER AREA

Coffee with Profs - Part II

In an initiative to encourage dialogue amongst speakers and EVER members, we have organised a session called "Coffee with Profs". This will be a table of 6-8 "guests" at a table headed by one of the EVER speakers.

Chris PURSLOW Head of Medical Affairs, Thea Pharmaceuticals, UK & Ireland
Marcela VOTRUBA MA BM BCh PhD FRCOphth Head of School & Consultant Ophthalmologist, School of Optometry & Vision Sciences, Cardiff University
Aki KAWASAKI Hôpital Ophtalmique Jules Gonin, Dept. of Neuro-Ophthalmology, Lausanne, Switzerland
Fabiana D'ESPOSITO MD, PhD Ophthalmologist, Ophthalmic Genetics, Honorary Senior Lecturer, Imperial College, London, UK, Consultant, Western Eye Hospital, Imperial NHS Trust, London, UK Visiting Professor, University of Naples "Federico II", Italy, Magi Euregio, Bolzano, Italy

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

POS

14:45 - 15:45 | POSTER AREA

G - Glaucoma

Poster F001-F050

YAP T , DAVIS B

F001		Diagnostic accuracy of a new thresholding glaucoma screening programme using temporally modulated flicker *JINDAL A, Fidalgo B, Ctori I, Tyler C, Lawrenson J - London*
F002		Transconjunctival bleb sutures for post-trabeculectomy hypotony *RULE E, Beer F, Manns R, Ambrose I, Walker L, Lockwood A, Kirwan J - Portsmouth*
F003		The Role of the αvβ3 Integrin in Lamina Cribrosa Cells and the Possible Role in Glaucoma Pathogenesis *HOPKINS A, Murphy R, Irnaten M, Wallace D, Brennan D, Clarke A, O'Brien C - Dublin*
F004		Intravitreal rituximab for the treatment of ocular lymphoma and glaucoma *LOCKWOOD A, Farnworth D, Rainsbury P, Balendra S - Portsmouth*
F005		Peripapillary microvasculature and Lamina cribrosa: is there a role in the diagnosis of primary open-angle glaucoma? *RODRIGUES C, Sousa Silva R, Cabral D, Rodrigues P, Marques M, Camacho P, Valadares J, Segurado J, Fernandes J, Barrão S - Lisbon*
F006	*	Results from an international observatory survey on the management of glaucoma treatments and its impact on the ocular surface disease (OSD), an ECOS-G (European Club of Ocular Surface in Glaucoma) initiative. *KOLKO M, Iliev M E, Benitez Del Castillo J M, Thygesen J, Baudouin C - Glostrup*
F007		Incidence and prevalence of glaucoma in native and immigrant groups living in Denmark *HORWITZ A, Klemp M, Torp-Pedersen C, Kolko M - Copenhagen*
F008		Comparing the mid-term efficacy and safety of the Stegmann Canal Expander Canaloplasty with the prolene suture Canaloplasty in cases of open angle glaucoma *ADLJU R, Brazitikos I, Stangos A, Mameletzi A, Sunaric Mégevand G - Geneva*
F009		Anatomical position of the raphe in the human retina *JANSONIUS N, Schiefer U - Groningen*
F010		Effects of acute ocular hypertension on the adult rat retina: in vivo an ex vivo retinal analysis. *GALLEGO ORTEGA A, Segura-Castro P, Gómez-Serna C, De La Villa P, Di Pierdomenico J, Bernal-Garro J, Villegas-Pérez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia*

POS

14:45 - 15:45 | POSTER AREA

G - Glaucoma

Poster F001-F050

YAP T , DAVIS B

F011	rf	Peripapillary vascular analysis from optical coherence tomography angiography to differentiate glaucoma and normal eyes *MARQUES M, Cabral D, Rodrigues P, Alves S, Valadares J, Barrão S - Lisboa*
F012		Potential metabolic markers in glaucoma and their regulation in response to hypoxia *TIEDEMANN D, VOHRA* R, Marie Dalgaard L, Vibæk Jensen J, Hildegaard Bergersen L, Vidiendal Olsen N, Hassel B, Abbas Chaudhry F, Kolko M - Copenhagen*
F013	*	The effect of the Valsalva maneuver on the retinal veins *STODTMEISTER R, Stroehla H, Spoerl E, Pillunat L E, Terai N - Rodalben*
F014		Noninvasive intracranial pressure assessment using otoacoustic emissions: an application in glaucoma *LOISELLE A, De Kleine E, Van Dijk P, Jansonius N M - Groningen*
F016		XEN gel stent to treat intraocular hypertension induced by Dexamethasone-implant intravitreal injections: about 5 cases *REZKALLAH A, Mathis T, Denis P, Kodjikian L - Lyon*
F017		Quantitative evaluation of peripapillary microvasculature in Pseudoexfoliation Syndrome *RODRIGUES C, Sousa Silva R, Cabral D, Rodrigues P, Marques M, Camacho P, Joana V, Segurado J, Fernandes J, Barrão S - Lisbon*
F018		Retinal blood supply and oxygen extraction as a function of blood pressure status and vascular dysregulation assessed by optical coherence tomography-angiography and dual-wavelength retinal oximetry *PAPPELIS K, Jansonius N - Groningen*
F019		Long-term follow-up of transscleral cyclodiode for rubeotic glaucoma *WALKER L, Weston K, Rule E, Lockwood A - Portsmouth*
F020		Comparison of 1-year outcomes of XEN implantation alone vs combined phacoemulsification-XEN surgery at a Tertiary Center of Ophthalmology in Portugal *MOURA-COELHO N, Hipólito Fernandes D, Crisóstomo S, Basílio A L, Tavares Ferreira J, Dutra-Medeiros M, Sa Cardoso M, Gomes T - Lisbon*
F021		Prevalence of unknown ocular hypertension, pre-perimetric glaucoma and glaucoma in patients seen in primary refraction center in France *CHAMARD C, Villain M, Causse A, Bentaleb Y, Pelen F, Baudouin C, Daien V - Castelnau Le Lez*
F022		Above Tenons Conjunctival dissection – A modification for Trabeculectomy Surgery *SRIKANTHA N, Macgregor C, Kirwan J, Lockwood A - Winchester*
F023		Modeling the circadian pattern of intra-ocular pressure *DEFORCE F, Renault D, Cattaert T, Aptel F - Sint Agatha Berchem*
F024		Long term postoperative refractive outcomes of combined cataract and glaucoma surgery *CHUNG J K - Seoul*
F025	*	Nutritional oral supplement containing L-arginine, L-citruline, α-lipoic acid, vitamin B2, vitamin B12, folic acid and Gingko biloba in primary open angle glaucoma patients - a prospective, randomized, controlled study. *WASYLUK J, Krajewska M, Oseka M, Sobol M, Prost M - Warszawa*
F026		Clinical implications of reactive epiretinal patches in open-angle glaucoma *KIM E K, Park H Y L, Park C K - Seoul*
F027		Clinical course of prematurity with enlarged cup to disc ratio - 24 months retrospective consecutive case series *JIN S W - Busan*

Friday, October 5 - Poster session

POS

14:45 - 15:45 | POSTER AREA

G - Glaucoma

Poster F001-F050

YAP T , DAVIS B

F028 *

EEvaluation of a 24 Hour Circadian Rhythm Model for Intraocular Pressure after Implant with a Supraciliary Micro-Stent

VERA L F, Vontress M, Sarangapani R - Milan

F029 *

EComparing the predicted efficacy of one versus two supraciliary micro-stents for lowering intraocular pressure in glaucoma patients using an ocular computational fluid dynamic model

VERA L F, Missel P, Sarangapani R - Milan

F030

Association between autonomic dysfunction and retinal nerve fiber layer thinning in healthy subjects

JUNG Y H, Shin J A - Seoul

F031

Long term follow-up of patients with plateau iris syndrome after treatment with argon laser peripheral iridoplasty

TSOKOLAS G, Tzamos G, Datta A - Southampton

F032

The promoter polymorphism -308G>A in the gene of Tumor necrosis factor alpha and the risk for open-angle glaucoma in Bulgarians

VLAYKOVA D, Dzhelebov D, Tacheva T, Dimov D, Kurzawski M, Drozdzik M, Vlaykova T - Stara Zagora

F033

An unusual case of neo-vascular glaucoma in the post-partum period secondary to severe peripheral retinal ischaemia

STAHL M, Sheck L, Anastasia T, Yang E, Pal B - Slough

F034

Comparison between the 24-2 new grid program of the Compass fundus automated perimeter and the 24-2 program of the Humphrey field analyser

FENOLLAND J R, Alves Chaves M, Sendon D, Charpentier S, Manchart T, Renard J P, Giraud J M - Saint Mande

F035

Changes in circumpapillary retinal nerve fibre layer thickness after phaco surgery only in patients with primary angle closure glaucoma

OH W H, Kim B G, Kim J S - Seoul

F036

Altered Antioxidant-Oxidant Status in the Peripheral Blood of Patients with Low-Tension Glaucoma and Ocular Hypertension

LANGBØL M, Baskaran T, Dalgaard L, Vibæk Jensen J, Tiedemann D, Toft-Kehler A K, Kolko M - Copenhagen

F037

Bilateral activation of retinal microglia: quantitative analysis of the area the retina occupied by IBA-1 + cells in the nerve fiber layer-ganglion cell layer at different time points after laser-induced ocular hypertension in mice

SALAZAR J J, De Hoz R, Fernandez-Albarral J A, Ramirez A I, Salobrar-Garcia E, Rojas B, Triviño A, Aviles-Triguero M, Vidal-Sanz M, Ramirez J M - Madrid

F038

Bilateral activation of retinal microglia: quantitative analysis of the microglia cell number at different time points after laser-induced ocular hypertension in mice

DE HOZ R, Fernandez-Albarral J A, Ramirez A I, Salazar J J, Salobrar-Garcia E, Rojas B, Triviño A, Valiente-Soriano F J, Villega-Perez M P, Ramirez J M - Madrid

F039

Visual field changes after epiretinal membrane surgery in glaucomatous eyes

LEE K S, Kim Y - Gyeonggi-do

F040

Comparison of vessel diameters during hypoxia in patients with low tension glaucoma, ocular hypertension and age-matched control

BASKARAN T, TIEDEMANN D, Langbøl M, Vohra R, Jensen P S, Bek T, Jensen P K, Olsen N V, Kolko M - Copenhagen*

F041 *

Reactive astrocytosis alters gene expression of ECM components in primary optic nerve head astrocytes

KAJA S, Stubbs E, Rao V, Kalesynkas G, Ghosh A - Kuopio

POS

14:45 - 15:45 | POSTER AREA

G - Glaucoma

Poster F001-F050

YAP T , DAVIS B

F042 ISY (satISfaction surveY): First real-life data of use of a preservative-free multidose glaucoma device (EasyGrip® delivery system) in 5 European countries
DENIS P, Erb C, Puska P, Skov J, Chen E, Klyve P, Duch S - Lyon

F043 Three better than two? A twin study to examine the accuracy of IOP measurement
MANZAR H, Simcoe M, Hammond C - London

F044 Amniotic membrane transplantation and conjunctival autograft for repair of leaking glaucoma filtering bleb
BARTOLOMÉ I, Berniolles J, Marco S, Lopez Sangros I, Montes P, Karlsruher G, Idoate A, Sanchez Marin J I, Perez Garcia D, Martinez Morales J, Ascaso Puyuelo J, Ibañez J - Zaragoza

F045 Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer's disease
SHAMSHER E, Davis B, Dev P, Grgic L, Somavarapu S, Guo L, Cordeiro F - London

F046 Glaucoma drainage devices: making surgery simpler
MANNS R, Rule E, Ambrose I, Hunter G, Lockwood A - Portsmouth

F047 Neuroprotective Activity of Curcumin Nanocarriers in Rodent Models of Retinal Injury
DAVIS B, Guo L, Pahlitzsch M, Balendra S, Shah P, Ravindran N, Malaguarnera G, Sisa C, Shamsher E, Hamze H, Noor A, Sornsute A, Somavarapu S, Cordeiro M F - London

F048 Combined phacocanaloplasty for open-angle glaucoma and cataract
Perez Garcia D, IBANEZ J, Martinez Morales J, Ascaso J, Garces A - Zaragoza

F049 Implant of micro-stent cypass in glaucoma
Perez Garcia D, MARTINEZ MORALES J, Ibanez J, Ascaso J, Isabel B, Berniolles J, Marco S, Lopez I - Zaragoza

F050 Just how broken are we? Neck and back pathology among ophthalmologists
HUNTER G, Macgregor C, Ambrose I, Manns R, Lockwood A - Portsmouth

Friday, October 5 - Poster session

POS

14:45 - 15:45 | POSTER AREA

NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

Poster F051-F098

BARBONI P , CARELLI V

F051 Management of congenital dacryocystocele, complicated by early post-natal dacyrocystitis
TSAKIRIS K, Quinn A G - Exeter

F052 Brushfield spots and Wölfflin nodules unveiled in dark irides using near-infrared light
POSTOLACHE L, Parsa C - Brussels

F053 Ophthalmic Manifestations of Tuberous Sclerosis: A Tertiary Hospital Experience
MANO S, Marques R, Sousa F, Fonseca A, Pinto F, Campos F - Lisbon

F054 Orbital exenteration with superficial temporalis muscle flap: an innovating approach
BENNEDJAI A, Bremond-Gignac D, Kolb F, Bennis Y, Picard A, Kadlub N - Paris

F055 Association between myopia and optic nerve head drusen in children
Lee S K, Lim D H, LYU I J - Seoul

F056 Vascular Complications of Optic Nerve Head Drusen
TEIXEIRA F, Esteves Marques R, Mano S, Couceiro R, Pinto F - Lisboa

F057 Screening and follow-up of acute ROP: reproducibility and diagnostic accuracy of fluorescein angiography
GUAGLIANO R, Barillà D, Bertone C, Maffia A, Verticchio Vercellin A C, Periti F, Plaitano C, Tinelli C, Arpa C, Bianchi P E - Pavia

F058 Suspecting a goldenhar syndrome: a case report
MARCO MONZON S, Lopez I, Karlsruher G, Montes P, Bartolome I, Ramiro P, Castillo J, Ascaso J - Zaragoza

F059 Retinal layer thinning in Parkinson's disease: a meta-analysis of optical coherence tomography studies
CHRYSOU A, Jansonius N, Van Laar T - Groningen

F060 Macular and papillary morphometric evaluation with SD-OCT in children affected by mild-severe refractive errors
ARPA C, Bianchi P E, Barillà D, Bertone C, Milano G, Plaitano C, Periti F, Verticchio A, Tinelli C, Guagliano R , Manzoni F - Cabiate

F061 Optical coherence tomography outcomes in patients with Friedreich ataxia: a longitudinal study
ROJAS LOZANO M P, Ferreras A, De Hoz R, Ramírez A I, Salobrar-Garcia E, Muñoz Blanco J L, Urcelay J L, Salazar J J, Ramirez J M - Madrid

F062 Anterior Segment swept-source Optical Coherence Tomography evaluation of patients submitted to lateral recti hang-back recession surgery
REIS CABRAL D, Pereira T, Rodrigues P, Vila-Franca M, Camacho P, Oliveira Rodrigues C, Seldon R, Braz F, Varandas G - Lisboa

F063 Spectral-Domain Optical Coherence Tomography findings in 64 patients with aniridia : a retrospective study
DARUICH-MATET A, Bremond-Gignac D - Paris

F064 Inner retinal layers of the retina predict visual cortical thickness and structural connectivity in early Alzheimer's Disease
CASTELO-BRANCO M, Jorge L, Alves C, Canário N, Santiago B, Santana I, Quental H, Reis A, Ambrosio F, Bernardes R - Coimbra

F065 Is the OCT useful in monitoring idiopathic intracranial hypertension?
SOUSA F, Lopes P, Marques R, Pinto F - Lisbon

F066 Ability of Swept-source OCT to detect retinal changes in patients with bipolar disorder
GAVIN SANCHO A, Cipres Alastuey M, Satue Palacian M, Rodrigo Sanjuan M J, Orduna Hospital E, Vilades Palomar E, Larrea Samper J G, Garcia-Martin E - Zaragoza

POS

14:45 - 15:45 | POSTER AREA

NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

Poster F051-F098

BARBONI P , CARELLI V

F067 Optical Coherence Tomography as a Diagnostic Tool for Detecting Mild Cognitive Impairment in Parkinson's Disease
SUNG M S - Gwangju

F068 Optical coherence tomography angiography of the foveal avascolar zone and vessel density in children: comparison between preterm and full term patients
PERITI F, Plaitano C, Toma C, Guagliano R, Bertone C, Barillà D, Vandelli G, Bianchi A, Arpa C, Vulpetti A, Tinelli C, Bianchi P E - Piacenza

F069 The ability of Spectral domain Optical coherence tomography to detect retinal changes in patients with essential tremor: is neurodegeneration an underlying cause?
SATUE M, Vilades E, Orduna E, Gavin A, Cipres M, Rodrigo M J, Larrea G, Garcia-Martin E - Zaragoza

F070 Evaluation of visual function and retinal changes caused by Multiple sclerosis after a 10-year follow-up
SATUE M, Orduna E, Vilades E, Gavin A, Cipres M, Rodrigo M J, Larrea G, Garcia-Martin E - Zaragoza

F071 Evaluation of retinal thickness asymmetry in patients with multiple sclerosis against healthy controls
VILADES E, Orduna Hospital E, Larrea Samper J G, Rodrigo Sanjuan M J, Cipres Alastuey M, Gavin Sancho A, Satue Palacian M, Garcia Martin E - Zaragoza

F072 Retinal thinning in patients with multiple sclerosis: evaluation of the pattern of retinal loss during disease progression
VILADES E, Orduna Hospital E, Larrea Samper J G, Rodrigo Sanjuan M J, Ciprés Alastuey M, Gavin Sancho A, Satué Palacian M, Garcia Martin E - Zaragoza

F073 Changes in the Vision, Visual Field and Retina by OCT in Early ALS Patients: a longitudinal study
ROJAS LOZANO M P, Ferreras A, Ramirez A I, De Hoz R, Salobrar-García E, Salazar J J, Muñoz-Blanco J L, Urcelay J L, Ramirez J M - Madrid

F074 Vision involvement in optic neuritis and non-optic neuritis eyes in patients with multiple sclerosis or neuromyelitis optica spectrum disorder
ROJAS LOZANO M P, Cadena M, Cuello J P, García-Domínguez J M, Martinez Ginés M - Madrid

F075 Ganglion cell layer complex measurement in the evaluation of an optic chiasm compression
CHARPENTIER S, Fenolland J R, Sendon D, Thomas Lavaud A, Manchart T, Renard J P, Garcia C, Dolz M, Bordier L, Giraud J M - Saint Mande

F076 Retina, a mirror of the brain: an association between macular and cerebral structural integrity over age
JORGE L, Canário N, Quental H, Bernardes R, Castelo-Branco M - Coimbra

F077 OCT- Angiography: perspectives of differential diagnostics of pathology optic nerve
IOYLEVA E, Kabanova E - Moscow

F078 Woman –ophthalmologists in the past
POLAK A - Lublin

F079 The development of anatomy of the eye and its optics
POLAK A, Grzybowski A - Lublin

F080 Creators of Polish ophthalmology in 19thc and their achievements
POLAK A, Grzybowski A - Lublin

F081 Pseudo-Foster Kennedy syndrome due to uncontrolled Diabetes Mellitus
RAHAYU S, Kartika A, Setioadji B, Handayani R - Bandung

F082 Visual function and retinal changes in patients with bipolar disorder
GAVIN SANCHO A, Cipres Alastuey M, Satue Palacian M, Rodrigo Sanjuan M J, Orduña Hospital E, Vilades Palomar E, Larrea Samper J G, Garcia-Martin E - Zaragoza

Friday, October 5 - Poster session

POS

14:45 - 15:45 | POSTER AREA

NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History

Poster F051-F098

BARBONI P , CARELLI V

F083 Early prognostic factor for irreversible damage by optical coherence tomography in patients with ethambutol-induced optic neuropathy
KIM E W, Park C K, Bae H W, Lee S Y, Kim S A, Lee K H, Kim C Y - Seoul

F084 Optic nerve biopsy in unexplained progressive optic neuropathy
VAN LINT M, De Vin T, De Keizer R, Vandewalle E, Cassiman C, Appeltans A - Jette

F085 Maintained treatment with idebenone increases the probability and magnitude of visual acuity recovery in patients with Leber's hereditary optic neuropathy (LHON)
LLORIA X, Silva M, Catarino C, Rudolph G, Lob F, Von Livonius B, Klopstock T - Liestal

F086 Natural history findings from a large cohort of patients with Leber's hereditary optic neuropathy (LHON): New insights into the natural disease-course
SILVA M, Lloria X, Catarino C, Klopstock T - Pratteln

F087 Long-term maintenance of visual acuity in patients with Leber's hereditary optic neuropathy treated with idebenone
LLORIA X, Silva M, Rudolph G, Lob F, Von Livonius B, Catarino C, Klopstock T - Liestal

F088 Activation of the phosphoinositide 3-kinase pathway promotes axon regeneration of the optic nerve in vivo
EVANS R, Pearson C, Cave J, Deshpande S S, Conceição R, Fawcett J, Eva R, Martin K, Barber A C - Cambridge

F089 Statins ameliorate the ultrastructural alterations in the optic nerve in a rabbit model of hypercholesterolemia
RAMIREZ A I, Fernandez-Navarro J, De Hoz R, Rojas B, Salazar J J, Triviño A, Ramirez J M - Madrid

F090 Silent sinus syndrome: a rare clinical entity
PEREZ GARCIA D, Ibañez Alperte J, Martinez Morales J, Ascaso Puyuelo J - Zaragoza

F091 Neurodegeneration in non-proliferative diabetic retinopathy: new biomarkers and their relation to vasculopathy and visual function
NGUYEN A, Naso S, Kardon R, Abdulghafor M, Kawasaki A - Lausanne

F092 Evaluation of multifocal visual evoked potentials in patients with multiple sclerosis using Retiport device
LARREA SAMPER J G, Viladés Palomar E, Orduna Hospital E, Rodrigo Sanjuan M J, Gavin Sancho A, Ciprés Alastuey M, Satue Palacian M, García Martín E - Zaragoza

F093 Evaluation of the multifocal electrorretinogram in patients with multiple sclerosis using Retiport deviced
LARREA SAMPER J G, Viladés Palomar E, Orduna Hospital E, Rodrigo Sanjuan M J, Gavin Sancho A, Ciprés Alastuey M, Satue Palacian M, García Martín E - Zaragoza

F094 Sarcomere remodeling following strabismus surgery
HOCHHARD K, Vicente A, Pedrosa Domellöf F - Umeå

F096 Accomadative convergence pupillary eye system and psychological status of healthy school aged children
BUSHUYEVA N, Pasechnikova N, Shakir D, Ushan O - Odessa

F097 Acute facial asimmetry as the presentig sign of an underdiagnosed entity
MARCO MONZON S, Isabel L, Montes P, Karlsruher G, Berniolles J, Ramiro P, Perez D, Dominguez A, Ascaso J - Zaragoza

F098 A software based measurement of horizontal muscles insertion
MARQUES M, Cabral D, Rodrigues P, Santos C, Traz F, Seldon R, Varandas G - Lisboa

POS

14:45 - 15:45 | POSTER AREA

EOVS - Electrophysiology, physiological Optics, Vision Sciences

Poster F099-F115

ROZEMA J, LAWRENSON J

F099	New analysis of the Farnsworth D-15 test *EVANS B, Barbur J, Rodriguez-Carmona M - London*
F100	The Rayleigh equation: reasons for a standard in application *KRASTEL H, Kirchhübel R, Bischoff P, Jonas J B - Neckargemünd*
F101	Uncorrected refractive error and associated risk factors among socially vulnerable older adult population living in Armenia *GILOYAN A, Harutyunyan T, Petrosyan V - Yerevan*
F102	Corneal astigmatism distribution at Indonesia National Eye Center Cicendo Eye Hospital *SUGANDA R, Renata Musa I, Wahyu M S, Virgana R - Jakarta utara*
F103	Conservative Treatment of Newly Diagnosed Keratoconus *MRAZOVAC D, Jandrokovic S, Zimak Z, Petricek I - Zagreb*
F104	A new reaction time test (Ocusweep® Reaction Time Test) for assessing visual performance and compliance *TIGCHELAAR I, Mäntysalo T, Leinonen M - Turku*
F105	The influence of cataract light scatters on retinal vessel oxygen saturation *WAIZEL M, Türksever C, Todorova M G - Basel*
F106	Correlating macular inner retinal layer thickness with photopic and mesopic contrast sensitivity in healthy young and older subjects *PUELL M, Palomo-Álvarez C, Pérez-Carrasco M - Madrid*
F107	Different retinal layers thickness measurements change with age in healthy eyes *RODRIGO M J, Vilades E, Orduna E, Gavin A - Zaragoza*
F108	Measurement of macular ganglion cell–innerplexiform layer with spectral-domain optical coherence tomography in patients with optic nerve head drusen and papilledema *IOYLEVA E, Kabanova E, Krivosheeva M - Moscow*
F109	Spectral optical coherence tomography with multiple sclerosis. Regression analysis *IOYLEVA E - Moscow*
F110	Electrophysiology and retinal thickness alterations in patients with multiple sclerosis with and without previous optic neuritis *ORDUNA HOSPITAL E, Vilades Palomar E, Rodrigo Sanjuan M J, Gavin Sancho A, Cipres Alastuey M, Larrea Samper J G, Satue Palacian M, Garcia Martin E - Zaragoza*
F111	Pattern electroretinogram steady-steate in dyslexis and normal readers *CELLINI M, Campos E C - Bologna*
F112	Investigating the movement of the centre of the multifocal hexagonal stimulus array using an electroretinogram function *SUZUKI N, Yamane K - Numazu*
F113	The effect of sustained eye rotation upon central and peripheral axial length in young, adult myopic subjects *ALKHALDI S, Seidel D, Gray L - Glasgow*
F114	Indications for electrostimulation method in the treatment of children with concomitant non-accomodative strabismus *BOYCHUK I, Mazur V - Odessa*
F115	Maximum human objectively measured pilocarpine stimulated accommodative amplitude *GRZYBOWSKI A, Schachar R A, Gaca-Wysocka M, Schachar I H, Pierscionek B K - Olsztyn*

Friday, October 5 - Poster session

POS

14:45 - 15:45 | POSTER AREA

MBGE - Molecular Biology/Genetics/Epidemiology

Poster F116-F131

LISKOVA P , DAVIDSON A

F116 Clinical and Genetic Characteristics of enhanced S-cone syndrome in a Tunisian cohort: experience of the oculogenetic laboratory LR14SP01
FALFOUL Y, Turki A, Habibi I, Hassairi A, El Matri K, Chebil A, Schorderet D, El Matri L - Tunis

F117 Novel CDHR1 mutation causing cone rod dystrophy
FALFOUL Y, Habibi I, Turki A, Hassairi A, El Matri K, Chebil A, Schorderet D, El Matri L - Tunis

F118 Phenotype in homozygous and heterozygous carriers of BEST1 mutations in autosomal recessive Bestrophinopathy
EL MATRI K, Falfoul Y, Habibi I, Turki A, Chebil A, Schorderet D, El Matri L - Tunis

F119 Clinical and Genetic Characteristics of Leber Congenital Amaurosis in the Tunisian Population: experience of the oculogenetic laboratory LR14SP01
EL MATRI K, Falfoul Y, Habibi I, Turki A, Hassairi A, Chebil A, Schorderet D, El Matri L - Tunis

F120 Novel C8ORF37 mutation causing cone rod dystrophy
EL MATRI L, Falfoul Y, Habibi I, Turki A, El Matri K, Chebil A, Schorderet D - Tunis

F121 NMNAT1 mutation causing retinitis pigmentosa
EL MATRI L, Habibi I, Falfoul Y, Turki A, Hassairi A, El Matri K, Chebil A, Schorderet D - Tunis

F122 A possible novel TGFBI mutation Ser591Phe in a Finnish family with lattice corneal dystrophy
JAAKKOLA A M, Järventausta P, Repo P, Kivelä T, Turunen J - Helsinki

F123 Ocular manifestations in S77T transthyretin-related familial amyloid polyneuropathy
BUNOD R, Cauquil C, Bourenane H, Adam C, Barreau E, Labetoulle M, Adams D, Rousseau A - Le Kremlin-Bicêtre

F124 On the day cataract operation cancellations: A prospective audit
BALENDRA S, Srikantha N, Evans A - London

F125 The 100,000 Genomes Project and the Western Eye Hospital Experience
D'ESPOSITO F, Miodragovic S, Normando E, Bonetti P, Cordeiro M F - London

F126 miRNAs as putative biomarkers for recurrent hemorrhage after PPV
MAMMADZADA P, Gudmundsson J, Kvanta A, Andre H - Stockholm

F127 Heritability of corneal curvature and Pentacam topometric indices: a population based study
YEKTA A A, Hashemi H, Khabazkhoob M, Heydarian S, Ostadimoghaddam H, Derakhshan A, Heravian J, Azimi Khorasani A, Momeni-Moghaddam H, Yekta R - Mahhad

F128 Mapping of proteomic profile and effect of the spongy layer in the human amniotic membrane
NAZARI HASHEMI P, Bisson A, Chaventre F, Guillou C, Cosette P, Boyer O, Muraine M - Rouen

F129 Cornea donation for research versus for transplantation: a one year prospective study of acceptance rates in a French University Hospital
GARCIN T, Pugniet J L, Peyragrosse T, Barallon M, Rogues F, Acquart S, Thuret G, Gain P - Saint Etienne

F130 Vision-Related and Health-Related Quality of Life in Patients with Giant Cell Arteritis
NÍ MHÉALÓID Á, Conway R, Molloy E, Murphy C C - Dublin

F131 Does the presentation of orbital cellulitis exhibit seasonality?
AMBROSE I, Rule E, Manns R, Hunter G, Lockwood A - Portsmouth

Friday, October 5 - Section Business Meetings

BM

15:45 - 16:15

Section Business Meetings

Agenda

1. Report of the chair of section

2. Report of the programme secretary

3. Next year's meeting:

    • Nomination of the 2019 section programme secretary (different from the section chair)

    • Proposals of 2019 Special Interest Symposia (SIS)

    • Proposals of 2019 Courses

    • Proposals for 2020 Keynote speakers

4. Comment on the EVER activities

5. Other business

In addition to the agenda:

- all sections will nominate nominate candidates for the election of the new treasurer 2019 - 2023

- the sections ACB, EOVS and MBGE will nominate at least 2 candidates for section chair 2019 - 2023

ACB	Gallieni 1+2
COS	Rhodes 2
EOVS	Rhodes 1
G	Rhodes 1
IM	Rhodes 4
LC	Hermes
MBGE	Rhodes 4
NSPH	Rhodes 2
PBP	Rhodes 3
PO	Rhodes 3
RV	Hermes

Friday, October 5 - Second afternoon session

SIS

16:15 - 17:30 | HERMES

RV - Advanced oct and oct-angiography in challenging cases

OCT angiography (OCT-A) as a new non-invasive imaging technology that enables the monitoring of the macular retinal and choroidal circulation. OCT-A allows a detailed detection either of the macular retinal capillaries plexus as well as the subretinal choroidal neovascularisation.
The correlation of OCT-A with OCT longitudinal or "en face" sections resulted to a better understanding of the pathologic features of the macular degenerative or vascular pathologies. OCT-A became a useful imaging modality in the evaluation and management of macular hemodynamic changes observed during the evolution of the retinal ischemic micronagiopathies and the treatment and follow up of the maculopathies related to a subretinal neovascularisation. Applications of OCT and OCT-A were focused on the evaluation of particular cases of the retinal or the optic nerve head pathologies.
The aim of the symposium is to organize an interactive discussion on the new imaging aspects for the detection and management of the most common maculopathies, as well as an interactive discussion of typical clinical cases.

POURNARAS C , ZOGRAFOS L

2711		16:15	Hand handled OCT in paedriatic ocular oncology *STATHOPOULOS C, Gaillard M C, Munier F - Lausanne*
2712		16:30	Evaluation of small particles in motion in diabetic macular edema *MANE V, Couturier A, Dupas B, Bonnin S, Gaudric A, Tadayoni R - Paris*
2713	*	16:45	OCT-A evaluation in glaucoma *PUECH M, Aimadaly M - Paris*
2714		17:00	Evaluation of the retinal pigment epithelium defects with OCT-A *ZOGRAFOS L - Lausanne*
2715		17:15	Multimodal imaging of diabetic retinopathy, the role of OCT angiography *POURNARAS C - Genève*

SIS

16:15 - 17:30 | RHODES 1

G - Neuroprotection in glaucoma – challenges and opportunities

Glaucoma is a degenerative optic neuropathy characterised by retinal ganglion cell (RGC) loss for which intraocular pressure modulation remains the only clinically modifiable risk factor. Neuroprotective therapies seek to slow or prevent RGC death via an IOP independent mechanism. Despite some early promise, recent clinical trials assessing the efficacy of neuroprotective therapies have had mixed results. This session seeks to discuss recent pre-clinical developments in this field to spark discussions regarding methods to overcome challenges in the design and translation of future neuroprotective therapies to the clinic.

DAVIS B , DE GROEF L

2721	*	16:15	Neuroprotective efficacy of a multi-loaded micro particulate drug delivery system in an ocular hypertension model of glaucoma *ARRANZ-ROMERA A - Madrid*
2722		16:30	Evidence for MMP-3 as neuroprotection target at the crossroad of inflammation and neurodegeneration *DE GROEF L, Lefevere E, Salinas-Navarro M, Andries L, Geeraerts E, Van Hove I, Movahedi K, Moons L - Leuven*
2723		16:45	Assessment of memantine loaded PEGylated biodegradable nanoparticles in a rodent glaucoma model *SÁNCHEZ-LÓPEZ E, Davis B M, Guo L, Espina M, Silva A M, Souto E B, Ravindran N, Ettcheto M, Camins A, Garcia M L, Cordeiro M F - Barcelona*
2724		17:00	Evaluation of topical curcumin nanoparticles in of rodent glaucoma models *DAVIS B, Pahlitzsch M, Balendra S, Shah P, Ravindran N, Malaguarnera G, Sisa C, Guo L, Noor A, Sornsute A, Somavarapu S, Cordeiro M F - London*
2725		17:15	Neuroprotection in glaucoma – outstanding challenges *NORMANDO E M - London*

Friday, October 5 - Second afternoon session

SIS

16:15 - 17:30 | RHODES 2

COS - Translational concepts in ophthalmology

This symposium will discuss current translational concepts in cornea, glaucoma, and retinal pathologies. Innovative surgical and non-surgical therapies will be presented.

JUENEMANN A , SEITZ B

2731		16:15	Cold plasma - a novel approach to treat therapy-resistant corneal infections *FUCHSLUGER T - Erlangen*
2732		16:30	Laser systems in corneal surgery *SEITZ B, Langenbucher A - Homburg*
2733		16:45	Trace elements in glaucoma *HOHBERGER B - Erlangen*
2734	*	17:00	Development of antifibrotics for glaucoma surgery - synergy of molecular biology and bioinformatics *JUENEMANN A, Stahnke T, Gajda-Derilo B, Struckmann S, Möller S, Barrantes I, Hamed M, Stachs O, Füllen G - Rostock*
2735	*	17:15	Electronical subretinal implants - recent developments *STETT A - Reutlingen*

C

16:15 - 17:30 | RHODES 3

PO - Orbital inflammation

** Intermediate

The spectrum of orbital inflammatory disease (OID) ranges broadly from specific disease diagnoses, for example, Wegener's granulomatosis or sarcoïdosis, to nonspecific inflammation that may involve one or multiple structures of the orbit as anterior orbit, muscle (myositis), lacrimal gland, diffuse or posterior orbit. Mimics of idiopathic OID must be considered in a comprehensive differential diagnosis and include malignancies (metastasis and lymphomas). Idiopathic OID may be secondary to an underlying systemic inflammatory disease, which must be diagnosed in order to develop a comprehensive therapeutic plan, or may represent localized pathologic processes without systemic involvement. Thus, pathologist's role is important. Therapeutic options for inflammatory diseases are focused on corticosteroids.

MOURIAUX F , KIVELÄ T

2741	16:15	Clinical features and differential diagnosis of orbital inflammation *MOURIAUX F - Rennes*
2742	16:33	Pathology of orbital inflammation *KIVELÄ T, Tynninen O - Helsinki*
2743	16:51	Biopsy of orbital inflammation *ECKSTEIN A, Mattheis S, Pförtner R, Esser J - Essen*
2744	17:09	Imaging of orbital inflammation *LAGIER J - Nice*

Friday, October 5 - Second afternoon session

16:15 - 17:30 | RHODES 4

SIS

ACB/COS - Scleral contact lenses: hands on - fitting, maintenance & clinical advantages - it's no magic !

Scleral Contact Lenses are a high-tech and versatile medical tool for the treatment in many different scenarios of ocular surface dysfunction and disease. This reaches from irregular corneas of any kind, e.g. high astigmatism, keratoconus and keratoglobus, over recurrent wounding of the epithelium and stem cell deficiency to the improvement of scars and corneal opacities, to cases of severe dry eye disease, and Sclerals have even proven to be useful in ocular infections. Still, the practical application of this enormously useful tool is limited because conventional wisdom seems to know that they are just too difficult to fit and to use for the ordinary clinician. Therefore, the aim of the present SIS is to explain – in a kind of "Hand On" Approach – in detail and in concrete specific patient settings, how a Scleral Contact Lens is practically fitted and obtained, how it is managed by the patient himself and supported by the clinician and which clinical advancements have occurred in specific concrete patients.

KNOP E

2751		16:15	Which pitfalls does ocular anatomy have in store for the application of Scleral Contact Lenses? *KNOP E - Berlin*
2752		16:30	How do I fit a Scleral contact lens in a specific patient? *NAU C - Minnesota*
2753		16:45	The DOs and DON´T s of Scleral Lens fitting *NAU A - Boston*
2754		17:00	Which concrete advantages have Sclerals provided for my patient? *CARRASQUILLO K G - Needham*
2755	*	17:15	Is it possible to run a self-supporting Scleral Contact Lenses practise? *MEKKI M B - Algiers*

16:15 - 17:30 | GALLIENI 1+2

SIS

MBGE - Gene regulation in eye development and disease

This SIS will cover studies of transcriptional regulation in multiple ocular tissues, including the lens, retina, and retinal pigment epithelium and will link these studies to cataract, glaucoma, and retinal degenerations. State-of-art methods, including single cell RNA-seq, ChIP-seq, genome editing by CRISPR-Cas9, and differentiation of ES and iPS cells will be discussed. Studies of eye development are driven by dissecting the critical roles of specific DNA-binding transcription factors and regulation of their activities by extracellular signaling in specific compartments of the eye. Organization of gene regulatory networks that govern vertebrate eye development will be also presented. Critical gaps and novel research opportunities in our understanding of gene function during normal and abnormal eye development will be summarized and discussed in the context of understanding of ocular cell and tissue homeostasis. Collectively, these proposed presentations will add novel insights into understanding of eye development, regenerative potential of multiple ocular tissues, and rational design of therapies to prevent and/or delay onset of age-related eye diseases.

CVEKL A , KOZMIK Z

2761	16:15	Gene regulation and lens development: Insights from single-cell RNA-seq analysis *CVEKL A, Mcgreal R, Yilin Z, Phil W, Larry D, Deyou Z - Bronx*
2762	16:33	The role of Meis family transcription factors in retina development *KOZMIK Z, Fujimura N, Antosova B - Prague*
2763	16:51	The molecular role of the Six6 transcription factor in glaucoma *SKOWRONSKA-KRAWCZYK D, Nguyen Huu V A, Jabari M, Rocha L - La Jolla*
2764	17:09	Transcriptional networks regulating timing and differentiation of the retinal pigmented epithelium *ASHERY-PADAN R - Ramat Aviv, Tel Aviv*

Friday, October 5 - Keynote lecture

KN

17:30 - 18:00 | HERMES

Keynote lecture by Christine CURCIO

17:30 Introduction by Catherine CREUZOT

Christine CURCIO

2811 17:35 **Microarchitecture and timeline of geographic atrophy: the x,y,z,t of AMD**

Christine CURCIO — Birmingham, USA

Population-based eye pathology and clinicopathologic correlation have validated at the subcellular level features of age-related macular degeneration (AMD) newly appreciated in optical coherence tomography (OCT). Clinical OCT has advanced through signal averaging, eye-tracking, integration with multimodal imaging, frequent imaging during the course of anti-VEGF therapy, and new high-resolution histology. Clarified AMD pathologies include subretinal drusenoid deposit (extracellular deposits distinct from sub-RPE drusen), outer retinal tubulation (a neurodegeneration and gliosis), a catalogue of RPE morphology at all AMD stages, landmarks of atrophy like refractile drusen and persistent basal laminar deposit, Friedman lipid globules, and clinicopathologic correlation of major neovascularization subtypes. Combined with experimental re-creation of sub-RPE deposits in vitro, it is possible to see the growth of drusen in vivo and the migration and death of RPE off the top, as a precursor to drusen-related atrophy. Thus, the targeting of drusen is motivated, to forestall atrophy as well as neovascularization. AMD is more approachable than ever, as imaging fills in missing pieces and targetable precursors to end-stages are found.

18:00 Award presentation of the EVER Certificate of Honour

Friday, October 5 - Evening session

SIS

18:00 - 19:15 | HERMES

RV - Adaptive optics: clinical applications and beyond

Cellular-scale imaging of the eye is a growing area for clinicians. Adaptive optics-enhanced fundus imaging has been developed for two decades and its technical maturity enables us to trace outlines of the major clinical applications. New techniques are being developed in parallel such as Doppler holography and full field OCT which also enables novel insights into the fine structural and functional aspects of the retina and other ocular tissues such as the cornea. In this SIS a multidisciplinary panel of speakers (physicists-computer scientists-ophthalmologists) will present the latest advances in the medical use of new imaging techniques. Emphasis on clinical pertinence and mulltimodal imaging will allow clinicians but also physicists interested in the field to appreciate the related opportunities

PAQUES M , GRIEVE K

2911	18:00	Clinical use of flood-illumination adaptive optics fundus camera ophthalmoscopy *PAQUES M - Paris*
2912	18:10	Structural and functional imaging of ocular tissues with full-field OCT *GRIEVE K, Scholler J, Xiao P, Mazlin V, Thouvenin O, Fink M, Sahel J A, Paques M, Boccara C - Paris*
2913	18:20	Adaptive optics scanning laser ophthalmoscopy: clinical applications *MERINO D - Barcelona*
2914	18:30	Adaptive optics in the eye as window to brain function *DUBIS A, Houston S, Nunez Do Rio J, Greenwood J - London*
2915	18:40	High speed adaptive optics angiography *Meimon S, GOFAS E - Paris*
2916	18:50	Adaptive Optics for inherited retinal disease clinical trials *MOOSAJEE M, Dubis A - London*
2917	19:00	Infrared autofluorescence in adaptive optics ophthalmoscopy for imaging retinal pigment epithelial cells in health and disease *ROSSI E A, Ferguson D R, Paques M, Sahel J A, Grieve K - Pittsburgh*

SIS

18:00 - 19:15 | RHODES 1

NSPH - From Francisco de Goya´s eyesight difficulties to famous one-eyed warriors

Historic ocular disorders, like tracoma, first described on papyrus about 1927 BC in Ancient. Egypt. Old ophthalmological therapies, such as cryosurgery and aesthetic blepharoplasty. Famous doctors like the Polish ophthalmologist Tadeusz Krwawicz and well recognized patients, such as the Spanish painter Francisco de Goya or certain monocular warriors: Hannibal, Philip of Macedon, Date Masamune, Duke of Urbino and Admiral Nelson. We will take a look at six topics, all of which show the importance of eyes along the history.

GRZYBOWSKI A , ASCASO F

2921		18:00	Influence of eyesight difficulties in the late work of the Spanish painter Francisco de Goya (1746-1828) *ASCASO F - Zaragoza*
2922		18:15	Tadeusz Krwawicz , MD, PhD – inventor of cryo-surgery *GRZYBOWSKI A, Kanclerz P - Olsztyn*
2923		18:30	The System of Fighting Trachoma in Poland (1928-1939) *POLAK A, Rejdak R - Lublin*
2924	*	18:45	Famous monocular warriors *SCHWARTZ S - Naples*
2925		19:00	Aesthetic blepharoplasty through the ages *PAPADAKIS M - Wuppertal*

Friday, October 5 - Evening session

18:00 - 19:15 | RHODES 2

SIS

COS - Keratoconus – from molecularbiological background through corneal stabilization to keratoplasty

Keratoconus is a multifactorial disease with an incidence of 1/2000. This symposium discusses pathophysiology and molecularbiological background of keratoconus as much as earliest device-based diagnostics and stage-related therapy. We focus on surgical treatment options, which stabilize the cornea in order to delay or even avoid the necessity of lamellar or penetrating keratoplasty.

SZENTMARY N , SEITZ B

2931	18:00	New aspects on the pathophysiology and molecularbiological background of keratoconus *STACHON T, Latta L, Seitz B, Langenbucher A, Szentmáry N - Homburg*
2932	18:15	Changes of the subbasal nerve plexus in keratoconus *FLOCKERZI E, Daas L, Seitz B - Homburg*
2933	18:30	Device-based earliest instrument guided diagnosis of keratoconus *EPPIG T, Spira-Eppig C, Szentmáry N, Langenbucher A, Seitz B - Homburg/Saar*
2934	18:45	Intracorneal ring segments (INTACS) – long-term results of the first 100 keratoconus patients *DAAS L, Langenbucher A, Seitz B - Homburg*
2935	19:00	Excimerlaser-guided deep anterior lamellar keratoplasty (DALK) or penetrating keratoplasty (PKP) in advanced keratoconus *SEITZ B - Homburg*

SIS

18:00 - 19:15 | RHODES 3

PO - Intravitreal pharmacotherapy in ocular oncology

Intravitreal pharmacotherapy is widely used in ocular oncology, mainly for the treatment of vitreous invasion of intraocular tumors and the prevention and treatment of neovascular glaucoma related to ocular radiotherapy. This therapeutic approach is applied both in pediatric and adult ocular oncology. Thanks to intraocular pharmacotherapy, it was possible to improve the eye retention probability as well as the functional results following conservative management of uveal melanomas and to resolve the problem of conservative management of retinoblastomas with vitreous seeding.

ZOGRAFOS L , DESJARDINS L

2941	18:00	Intravitreal chemotherapy for vitreal seeding for retinoblastoma *HADJISTILIANOU T - Sienna*
2942	18:10	Intravitreal anti-VEGF in pediatric ocular oncology *STATHOPOULOS C, Munier F, Gaillard M C, Beck-Popovic M - Lausanne*
2943	18:20	Intravitreal pharmacotherapy for the prevention of neovascular glaucoma *SCHALENBOURG A - Lausanne*
2944	18:30	Intravitreal anti-VEGF for the treatment of irradiation induced optic neuropathy and maculopathy *ZOGRAFOS L - Lausanne*
2945	18:40	Intravitreal chemotherapy in ocular lymphomas *CASSOUX N - Paris*
2946	18:50	Intravitreal anti-VEGF for the treatment of intraocular vascular tumors *KIVELÄ T - Helsinki*
2947	19:00	Intravitreal steroids for ocular tumors: indications and limits\r *MATET A - Paris*

Friday, October 5 - Evening session

SIS

18:00 - 19:15 | RHODES 4

ACB/COS - Keratoconus in all its states under a contact lens

Keratoconus is a typically progressive and often severe form of corneal ectasia that can occur inherited but also secondary to different types of ocular surface disease often in conjunction with ocular allergy and types of chronic inflammation that weaken the structure of the collagenous tissue matrix. Due to the irregular shape of the cornea and the often high dioptric impact, the visual rehabilitation in keratoconus can typically not be made by glasses. Therefore contact lenses of the rigid type and often scleral contact lenses are the mainstay of conservative therapy in keratoconus patients. Due to the typically progressive nature of keratoconus if is often not only the visual rehabilitation that is of interest but also the potential inhibition of progression of this corneal ectasia in order to prevent or to delay the necessity of a potential penetrating keratoplasty. The aim of the present SIS is to elucidate and to discuss, which types of contact lenses are suitable for which patients in order to provide them a suitable therapeutic approach in keratoconus and to delay progression of the disease.

KNOP E , MEKKI M B

2951		18:00	Keratoconus – more than a simple morphological change of corneal shape *KNOP E - Berlin*
2952		18:15	Which patient and which eye is suitable for which type of lens ? *CARASQUILLO K - Needham*
2953		18:30	Which lens fit the best for which patient ? *NAU C - Minnesota*
2954		18:45	What do we know of indications and outcome of corneal crosslinking – alternative or in addition to Scleral Lenses ? *NAU A - Boston*
2955	*	19:00	After SURGERY CXL or ICRS implantation or after graft (DALK or PK) ? *MEKKI M B, Yahiaoui S, Titah O, Taibi A - Algiers*

SIS

18:00 - 19:15 | GALLIENI 1+2

NSPH - Understanding ocular anterior dysgenesis phenotype genotype

Ocular Anterior Dysgenesis refer to a wide group of anterior segment diseases that are genetically determined. Clinically there is a large spectrum of findings from posterior embryotoxon to more severe forms such as aniridia, kerato-irido-lenticular dysgenesis as Peters anomaly, primary congenital glaucoma or Axenfeld-Rieger syndrome. The new molecular information is challenging the traditional thinking that was usually guided by the histopathological findings. Our understanding of anterior segment phenotype has improved with new techniques of anterior segment imaging and early genotype-phenotype correlations. Recent advances in genetics help us for a better understanding of the underlying of ocular development mechanisms. An overview of the innovating diagnosis, imaging and treatment is summarized.

BREMOND-GIGNAC D , ATILLA H

2961		18:00	What's new in ocular anterior dysgenesis imaging? *BREMOND-GIGNAC D - Paris*
2962		18:15	Ocular phenotype of ocular anterior dysgenesis *ROBERT M, Bremond-Gignac D - Paris*
2963		18:30	Classification of ocular anterior dysgenesis: new insights *ATILLA H - Ankara*
2964		18:45	Congenital cataract: new insights *SAUER A - Strasbourg*
2965		19:00	Corneal transplant and pediatric ocular anterior dysgenesis *DAIEN V - Montpellier*

Friday, October 5 - General Assembly

GA

19:15 - 19:45 | HERMES

EVER General Assembly

MEMBERS ONLY

Agenda

1. President's address by Alain Bron
2. Minutes of the General Assembly 2017
3. Report of the Secretary General, Thomas Fuchsluger
4. Report of the Programme Secretary, Francesca Cordeiro
5. Report of the Treasurer, Steffen Heegaard:
    - approval of the accounts 2017
    - discharge to the directors
    - approval budget for 2018
6. Results of the elections 2018
7. Presentation of the board 2019
8. Future congresses
9. Miscellanea
10. Handover of chain of office

Saturday
October 6



Saturday, October 6 - First morning session

SIS

8:30 - 9:45 | HERMES

RV - Controversies in new technology for the diagnosis and management of retinal and choroidal disease

Technological advances in Ophthalmology have been extraordinary in recent years with the introduction of new equipment and new techniques. Such an introduction, however, is not always accompanied with enthusiasm but also scepticism, especially when well established diagnostic or therapeutic approaches that have been shown to be essential in patient care are challenged or presumably replaced. In this special interest symposium, the pros and cons of new technology and the challenges in its implementation in relation to standard practice will be examined in the form of three separate debates involving OCT angiography, intraoperative OCT and 3D vitrectomy respectively. The first debate will address the important question as to whether OCT angiography can replace fluorescein angiography in clinical practice. Vasilios Papastefanou will argue in favour of this and Irini Chatziralli will argue against. The second debate will address 3D vitrectomy and whether it can replace conventional vitrectomy. Jean-Antoine Pournaras will argue in favour and Tina Xirou will argue against. The third debate will address whether intraoperative OCT is or not of clinical use. Odysseas Georgiadis will argue in favour and Evgenia Kontou will argue against.

PAPASTEFANOU V , XIROU T

3111	8:30	OCT angiography can replace fluorescein angiography in clinical practice - For *PAPASTEFANOU V - London*
3112	8:42	OCT angiography can replace fluorescein angiography in clinical practice - Against *CHATZIRALLI I - Athens*
3113	8:54	3D vitrectomy can replace conventional vitrectomy - For *POURNARAS J A - Lausanne*
3114	9:06	3D vitrectomy can replace conventional vitrectomy - Against *XIROU T - Glyfada*
3115	9:18	Intraoperative OCT: Is it of clinical use? - For *GEORGIADIS O, Da Cruz L - London*
3116	9:30	Intraoperative OCT: Is it of clinical use? *KONTOU E - Athens*

SIS

8:30 - 9:45 | RHODES 1

G - Ocular imaging in glaucoma

Since the introduction of the first ophthalmoscope it has become rapidly clear that imaging of the eye is critical for diagnosis and for monitoring of eye disease. This holds also true for glaucoma. Although the diagnosis of glaucoma is still clinical, the fast technical development of new and sophisticated instruments for the non-invasive and in-vivo assessment of ocular structures allows now the evaluation of the most critical components, such as the optic nerve head and the ganglion cell layer in unprecedented high resolution. Further, new tools such as OCT angiography, wide field OCT imaging or functional imaging may have the potential to open new horizons for the early identification of risk patients. However, despite the progress that has been made, several questions are still not sufficiently answered. One important issue is that the association between structural changes and loss of function in the progressing patients is still not well understood. In this SIS, new developments in ocular imaging and their application in the field glaucoma will be discussed. Further, the potential role of functional imaging will be covered and limitations in our current understanding the structure function relationship will be elaborated.

GARHOFER G , SCHMETTERER L

3121	8:30	Value of OCT Angiography in glaucoma *LABBE A - Paris*
3122	8:48	Wide Field OCT angiography in glaucoma *SCHMETTERER L - Singapore*
3123	9:06	Functional imaging of the retina: New way to assess ocular disease *GARHOFER G - Vienna*

Saturday, October 6 - First morning session

SIS

8:30 - 9:45 | RHODES 2

COS - Visual rehabilitation in keratoconus beyond keratoplasty

Nowadays, modern, minimally invasive, interventional approaches are employed for visual rehabilitation in patients with keratoconus, thereby significantly reducing the need for keratoplasty. Corneal collagen crosslinking (CXL), implantation of intracorneal ring segments, combined treatment modalities including corneal surface ablation together with CXL, as well as the use of toric phakic intraocular lenses, have revolutionized our concept of visual rehabilitation in patients with keratoconus. These interventional procedures are able to achieve satisfactory visual outcomes with remarkable safety, improving the quality of life in patients with keratoconus.
This Special Interest Symposium aims to provide a comprehensive overview of the above-mentioned treatment approaches, highlighting recent advances, controversial issues and the current state, as well as emphasizing on pearls and pitfalls for young physicians and anterior segment surgeons. The speakers are international leaders in the field with vast experience in the topics that will be discussed, and they will offer an in-depth insight into the challenging, but also fascinating treatment algorithm for visual rehabilitation in keratoconus.

GATZIOUFAS Z , SZENTMARY N

3131	8:30	CXL and visual rehabilitation in keratoconus: myths and reality *HAMADA S - Caterham*
3132	8:48	Intracorneal ring segment implantation in keratoconus: an evidence-based approach *GATZIOUFAS Z - Basel*
3133	9:06	Corneal surface ablation and CXL for visual improvement in keratoconus: when, what and how. *KANELLOPOULOS J - Athens*
3134	9:24	Toric phakic IOL implantation in keratoconus: indications and outcomes. *COCHENER B - Brest*

8:30 - 9:45 | RHODES 3

JM

OOG Ocular Oncology Group I - Ocular adnexa, imaging and intraocular tumors

HEEGAARD S , KIVELÄ T

3141	8:30	Use of ocular ultrasound for diagnosis of orbital lesions *SOUSA F, Mano S, Teixeira F, Pinto F - Lisbon*
3142	8:35	Evisceration with autogenous scleral graft and bioceramic implantation within the modified scleral shell: 133 cases over 17 years *NADAL J, Daien V, Villain M - Nimes*
3144	8:55	Assessing eye color Inside and out *MADIGAN M C, Cao D, Ton H T T - Sydney*
3145	9:05	The role of chemotherapy in malignant ocular medulloepithelioma *SHERIFF I, Karaa E K, Chowdhury T, Scheimberg I, Duncan C, Reddy M A, Sagoo M S - London*
3146	9:15	Choroidal osteoma in old age (an unexpectedly difficult diagnosis) *Krastel H, KALTAKJI F, Schlichtenbrede F - Neckargemünd*
3147	9:20	Neonatal Retinoblastoma *HADJISTILIANOU T, Barchitta M, Esposti G, Defrancesco S, Fruschelli M - Sienna*
3148	9:30	An "unexplainable" progressive regression of vitreous seeding in advanced retinoblastoma. *HADJISTILIANOU T, Barchitta M, Defrancesco S, Esposti G, Menicacci C - Sienna*

Saturday, October 6 - First morning session

SIS

8:30 - 9:45 | RHODES 4

ACB/RV - Functional hypoxia in the eye: a role for hypoxia-inducible factors

Hypoxia contribute to specific functions in ocular tissues, in both physiological and pathological conditions. The molecular roles of hypoxia-inducible factors (HIF) signaling in the eye will be illustrated, particularly in vascularization, and avascularity, of the different tissues. Studies on HIF-mediated responses and functions in models of ocular pathologies have been increasing during the previous years, and will be elaborated. Furthermore, the impact of hypoxia and HIFs will be addressed in a bench-to-clinic translational perspective.

ANDRE H , KAUPPINEN A

3151		8:30	Who's driving? Investigating the role of the HIF-1/PKM2 axis in the Warburg effect in mammalian retina *PEET D, Kittipassorn T, Wood J, Mammone T, Haydinger C, Casson R - Adelaide*
3152	*	8:45	Non-invasive imaging of retinal oxygen metabolism *STEFANSSON E, Hardarson S, Olafsdottir O - Reykjavik*
3153		9:00	Methylation-dependent control of HIF-1/VEGF axis in a mouse model of oxygen-induced retinopathy. Potential role of the glial water channel Aquaporin-4 *PISANI F, Cammalleri M, Dal Monte M, Locri F, Mola M G, Nicchia G P, Frigeri A, Bagnoli P, Svelto M - Bari*
3154		9:15	Rod-specific inactivation of Vhl leads to HIF-dependent retinal degeneration *GRIMM C, Barben M, Schori C, Samardzija M - Schlieren*
3155		9:30	Hypoxia and eye: from bench to bedside *ARJAMAA O - Turku*

SIS

8:30 - 9:45 | GALLIENI 1+2

MBGE - The role of non-coding variants in ocular disease

Decreasing costs of whole-exome sequencing and copy number variation analysis has enabled the identification of vast number of disease-causing mutations and novel genes implicated in ocular disease over the past few years. Despite these state of the art technologies many patients still lack their molecular diagnosis. Attention in the field of human genetics field has now turned to understanding the pathological relevance of non-coding variants within the human genome. This special interest symposium will discuss the recent discoveries in the field of non-coding variation and mechanisms on how these variants can lead to ocular pathology.

LISKOVA P

3161	*	8:30	Antisense therapy for Fuchs endothelial corneal dystrophy ameliorates TCF4 repeat-expansion mediated toxicity *DAVIDSON A - London*
3162		8:48	Posterior polymorphous corneal dystrophy – a disease caused by dysregulation of transcription factors involved in epithelial-to-mesenchymal transition *LISKOVA P - Prague*
3163		9:06	The non-coding morbid genome of inherited retinal diseases *DE BAERE E - Ghent*
3164		9:24	Whole genome analysis of inherited retinal disease patients reveals non-coding mutations intractable to other detection strategies *ARNO G, Carss K J, Niblock M, Waseem N, Cheetham M E, Michaelides M, Moore A T, Raymond F L, Webster A R - London*

Saturday, October 6 - Ophthalmic Research lecture

Ophthalmic Research
Journal for Research in Experimental and Clinical Ophthalmology

PS

9:45 - 10:15 | HERMES

Ophthalmic Research lecture

9:45 Introduction by Alain BRON

3211 9:50 **DARC Development and Translation**

Francesca M CORDEIRO — London

The DARC Technology (Detection of Apoptosing Retinal Cells) is a revolutionary technique that enables direct visualization of nerve cells through labelling of the apoptotic process with fluorescently-labelled Annexin V (ANX776). DARC has successfully completed Phase 2 clinical trials, with development supported through the Wellcome Trust, and is an example of basic science to clinical translation. DARC has potential to monitor and assess multiple neurodegenerative conditions, with Phase 2 including patients with age-related macular degeneration (AMD), optic neuritis (ON) and Down's Syndrome (a model of Alzheimer's (AD)) in addition to glaucoma. Moreover, its use as an exploratory endpoint in clinical trials of new therapies is an exciting prospect.

Francesca M CORDEIRO

10:15 Award presentation of the Certificate of Honour

Saturday, October 6 - Poster session

POS

10:15 - 11:15 | POSTER AREA

COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N

S002 An innovative bioreactor allows corneal storage for up to 3 months
GARCIN T, Gauthier A S, Crouzet E, Herbepin P, Perrache C, He Z, Thuret G, Gain P - Saint Etienne

S003 Using the angular backscattered light to assess transparency of human corneal grafts after treatment by various anti-edematous eye drops
GIL M, Dubald M, Guerin C, Georges G, Siozade Lamoine L, Deumie C, Ho Wang Yin G, Hoffart L - Saint Laurent du Var

S004 Characterization of corneas following different time and storage methods for use as a source of stem-like limbal epithelial cells
RODRIGUEZ M, Romano-Ruiz P, Etxebarria J, Andollo N - Barakaldo

S005 Processed human umbilical cord lining as transplant for sclera defect: an in vivo study
BARNOUIN L, Michel A, Douet J Y, Robin M C, Regnier A - Mions

S006 Development of secured amniotic membranes as ophthalmologic allografts
BARNOUIN L, Michel A - Mions

S007 Effects of a hydrocortisone plus sodium hyaluronate solution on wound healing and inflammatory biomarkers in corneal epithelial cells
BUCOLO C, Lazzara F, Fidilio A, Platania C B M, Zasa G, Drago F - Catania

S008 A synthetic metalloporphyrin SOD mimetic protects corneal epithelial cells from oxidative stress-induced damage in vitro and in vivo
THAPA R, Žiniauskaitė A, Ghosh A K, Tenhunen A, Ragauskas S, Kalesnykas G, Hakkarainen J J, Kaja S - Kuopio

S009 Effect of Biphalin on Corneal Epithelial Wound Healing
YILDIZ E, Özer B, Gedar M, Mollica A, Sahin A - Istanbul

S010 The effect of estrogen and dihydrotestosterone on hyperosmolarity-induced expression and production of IL-1β, TNF-α and IL-8 through MAPK pathway in human corneal epithelial cells
ÖZER B, Yildiz E, Sahin A - Istanbul

S011 Novel model for corneal permeability in vitro testing through the combined use of collagen-based hydrogels with stratified corneal epithelial cells
ZINIAUSKAITE A, Cepla V, Valiokas R, Kalesnykas G, Hakkarainen J J - Kuopio

S012 Modeling of aniridia-related keratopathy by CRISPR/Cas9 genome editing of human limbal epithelial cells and rescue by recombinant PAX6 protein
ROUX L, Concordet J P, Zhou J H, Ferrigno O, Aberdam D - Paris

S013 Aniridia-Related Keratopathy in naïve corneas and after keratolimbal allograft
VICENTE A, Byström B, Pedrosa Domellöf F - Umeå

S014 Anti-inflammatory properties of corneal stroma-derived stem cells: Potential as a topical therapy for the ocular surface
SIDNEY L, Orozco Morales M L, Marsit N, Mcintosh O, Hopkinson A - Nottingham

S015 Effects of mesenchymal stem cells on production of cytokines by injured cornea in in vitro and in vivo experimental models
KOSSL J, Hermankova B, Javorkova E, Bohacova P, Zajicova A, Holan V - Prague

S016 Comparison of calcium signalling between native and cultured human corneal endothelium after mechanical stimulation
LAPAJNE L, Schollmayer P, Hawlina M, Andjelic S - Ljubljana

POS

10:15 - 11:15 | POSTER AREA

COS - Cornea/Ocular Surface

✶✶ Intermediate

Poster S001-S080

FUCHSLUGER T , SZENTMARY N

S017 Verification of splicing alteration caused by a novel SLC4A11 intronic mutation using an autologous induced pluripotent stem cell-derived corneal endothelial-like cell model
BREJCHOVA K, Dudakova L, Skalicka P, Vachova V, Dobrovolny R, Liskova P - Prague

S018 ✶ Corneal endothelial follow-up after intracameral injection of lidocaine, tropicamide and phenylephrine for mydriasis during cataract surgery
GAIN P, Crouzet E, Khatib W, Thuret G - Saint-Etienne

S019 Phenotype-genotype correlation of p.R124S mutation in granular type 1 corneal dystrophy of Tunisian origin
FALFOUL Y, Bouyacoub Y, Munier F L, Sayeb M, Ouederni M, Chargui M, El Matri L, Abdelhak S, Cheour M - Tunis

S020 Keratoendotheliitis Fugax Hereditaria is Caused by a Mutation in the NLRP3 Gene
TURUNEN J, Wedenoja J, Repo P, Järvinen R S, Jäntti J, Mörtenhumer S, Riikonen A, Lehesjoki A E, Majander A, Kivelä T - Helsinki

S021 Gonococcus: A Rare Cause of Infective Conjunctivitis
JONES R, Vakros G - Manchester

S022 The study of conjunctival bacterial flora isolated in patients undergoing intravitreal injection and cataract surgery
KANG J, Nam K Y, Lee S U, Lee S J - Busan

S023 Bilateral acute corneal melting secondary to nonsteroidal anti-inflamatory drugs
LÓPEZ SANGRÓS I, Marco S, Montés P, Karlsruher G, Ascaso F J, Del Buey M A - Zaragoza

S024 Clinical Outcomes for the Treatment of Corneal Blindness using an Epidescemetic Keratoprothesis
VEGA-ESTRADA A, Al-Shymali O, Alio J - Alicante

S025 Non-contact millimeter-field imaging of in vivo corneal cells by full-field OCT
MAZLIN V, Xiao P, Grieve K, Sahel J A, Fink M, Boccara C - Paris

S026 Use of ultra high-frequency ultrasound VevoMD (70 MHz) in ophthalmology
TRONE M C, Perrot J L, Grivet D, Cambazard F, Cinotti E, Gain P, Thuret G - Saint-Etienne

S027 Management of Salzmann's nodular degeneration by scleral contact lenses
TRONE M C, Perillat N, Thuret G, Gain P - Saint-Etienne

S028 Evaluation of the impact of tear layer thickness in scleral lenses on the optical quality of the eye by means of Optical Quality Analysis System (OQAS)
TRONE M C, Garcin T, Thuret G, Gain P - Saint-Etienne

S029 Diclofenac release from LbL coated silicon based contact lenses
PRIOR FILIPE H, Silva D, Sousa H, Gil H, Moutinho G, Alvarez-Lorenzo C, Saramago B, Serro A P - Lisbon

S030 Novel Polymeric Inserts Comprising Nanomicelles for Topical Ocular Delivery of Cyclosporine-A
TERRENI E, Monti D, Chetoni P, Burgalassi S, Tampucci S, Chipala E, Alany R G, Al-Kinani A A - Pisa

S031 ✶ Cyclosporine pharmacokinetics in healthy volunteers after ocular administration of OTX-101, a novel nanomicellar cyclosporine formulation
ROLANDO M, Weiss S L, Arntz R, Justice A, Kramer W G, O'connor P - Genoa

S032 Prevalence and clinical patterns of ocular complications associated with anti PD-1/PDL-1 anticancer immunotherapy
BITTON K, Barreau E, Rémond A L, Bodaghi B, Michot J M, Champiat S, Mateus C, Marabelle A, Couret C, Best A L, Labetoulle M, Rousseau A - Villejuif

Saturday, October 6 - Poster session

POS

10:15 - 11:15 | POSTER AREA

COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N

S033 Ocular pharmacokinetics profile of different hydrocortisone ophthalmic formulations
BUCOLO C, Salomone S, Piazza C, Blanco A R, Drago F - Catania

S034 The impact of long term glaucoma medications on structure and function of meibomian glands
SCEMLA B, Labetoulle M, Andrieu S, Lambotin C, Barreau E, Rousseau B, Rousseau A - Paris

S035 Efficacy and tolerability of Blephademodex® in patients with demodex blepharitis
KHAIRALLAH M, Riadh M, Serge D - Monastir

S036 Gender Differences in Symptoms and Signs of Dry Eye Disease in a Norwegian Cohort of Patients
TELLEFSEN S, Badian R A, Stojanovic A, Paaske Utheim T, Aas Utheim Ø, Tashbayev B, Raeder S, Chen X - Oslo

S037 Clinical signs in dry eye: a multicentric cross-sectional study
CANTALAMESSA E, Villani E, Nucci P, Rolando M - Milan

S038 Comparison of Ocular Surface Index Score and Clinical Dry Eye Disease Parameters in the Young (aged 0-19) and the Elderly (aged 80-99)
UTHEIM O, Raeder S, Badian R, Chen X, Tashbayev B, Utheim T P - Oslo

S039 Failure to validate the fluorescein breakup patterns classification in an italian sample of dry eye patients
CANTALAMESSA E, Villani E, Luccarelli S V, Lucentini S, Rolando M, Nucci P - Milan

S040 Developement of a safe and biocompatible powder to be reconstituted as keystone for dry eye syndrome treatment
Barnouin L, MICHEL A - Mions

S041 Effect of a new topical soft steroid hydrocortisone phosphate 0.335% on treatment of dry eye disease
SHORTT A - London

S042 All-in one automated measurement of ocular surface parameters: interferometry, tear meniscus, non-invasive break-up time and meibography
COURRIER E, Trone M C, Renault D, Lambert V, Lazreg S, Thuret G, Gain P - Saint Priest en Jarez

S043 Effect of a new opthalmic hydrocortisone and sodium hyaluronate formulation on two experimental dry eye models
BUCOLO C, Lazzara F, Fidilio A, Platania C B M, Blanco A R, Drago F - Catania

S044 Blinking during exercise affects tear osmolarity
Wylegala A, WYLEGALA E - Katowice

S045 The effect of eliminating tear evaporation on tear osmolarity
ALZAMIL H, Madden L, Pearce E I - Glasgow

S046 Impact of preserved and preservative-free latanoprost on the survival of conjunctival goblet cells
AHMAD MOUHAMMAD Z, Taul Brændstrup C, Begun X, Nagymihály R, Heegaard S, Petrovski G, Kolko M - Copenhagen

S047 Ocular surface involvement on GVHD patients
LAZREG S, Renault D - Blida

S048 Ocular surface temperature, blinking rate and corneal sensitivity in young contact lens wearers
Pastor-Zaplana J Á, Morales-Villellas M, Monteserín-Rodríguez M, GALLAR J, Acosta M C - San Juan de Alicante

S049 Corneal surface temperature decrease during the interblink interval is greater in Sjögren's syndrome
Merino M L, Belmonte J, Acosta M C, Rosas J, Belmonte C, GALLAR J - San Juan de Alicante

POS

10:15 - 11:15 | POSTER AREA

COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N

S050 Corneal Sub basal nerve plexus 10 years after LASIK
CANADAS SUAREZ P, Aranda R, Rodero A, García-González M - Valladolid

S051 Immunolabeling of nerves by anti-neurofilament and anti-βIII-Tubulin in the different compartments of the human ocular surface
HE Z, Lambert V, Forest F, Bergandi F, Garcin T, Perrache C, Gain P, Thuret G - Saint-Etienne

S052 First case of immunohistochemical study of a corneal button after treatment by recombinant Neuronal Growth Factor (cenegermin).
THURET G, Lambert V, Trone M C, Forest F, Gain P, He Z - Saint-Etienne

S053 Orbital biomechanical changes in Graves' disease and Thyroid eye disease: application of Corvis ST
VIEIRA M, Neves A, Carvalheira F, Batista A, Santos M, Sousa J - Leiria

S054 Longitudinal evaluation of corneal biomechanical parameters in a 7-11 years old Iranian population
YEKTA A A, Hashemi H, Momeni-Moghaddam H, Khabazkhoob M, Zarei-Ghanavati S, Ostadimoghaddam H, Heravian J, Yekta R - Mahhad

S055 Corneal scattering and biomechanical behavior in eyes with Fuchs' endothelial dystrophy
KETABI SHADVAR S, Gros-Otero J, Katsanos A, Rodrigo Rey S, Castaño Martin B, Garcia-Gonzalez M, Teus M A - Alcobendas

S056 Corneal posterior surface characterization in normal and keratoconus patients according to the degree of visual limitation
VEGA-ESTRADA A, Jorge A - Alicante

S057 Late onset corneal haze after corneal collagen crosslinking for progressive keratoconous
PARIKAKIS E, Peponis V, Kontomihos L, Kontadakis G, Batsos G, Tsilioni A, Ktena E, Karagiannis D - Kifissia, Athens

S058 Dynamics of local antioxidant status in patients with keratoconus after various protocols of ultraviolet crosslinking of the cornea.
EMIN U, Bikbov M, Bikbova G, Khalimov A, Usubov E - Ufa

S059 Riboflavin levels in the aqueous humour of the rabbit's eye with standard UV corneal cross-linking in different Epi-Off areas
EMIN U, Bikbov M, Bikbova G, Khalimov A, Shevchuk N, Usubov E - Ufa

S060 The effects of corneal collagen cross-linking and the discrepancy between epithelium on and epithelium off treatment – Results from the Portsmouth population cohort
MACGREGOR C, Hunter G, Maycock N, Lockwood A, Jayaswal R - Portsmouth

S061 Testing ANN: a neural network to guide keratoconus treatment with ICRS
VEGA-ESTRADA A, Jorge A - Alicante

S062 Effect of intracorneal ring segment implantation on tear film properties in patients with keratoconus
SAGRI D, Thabit A, Elalfy M, Hamada S, Goldblum D, Scholl H, Gatzioufas Z - Zurich

S063 In vivo biocompatibility of a new intrastromal inlay for spherical ametropia and presbyopia correction, in a rabbit model
CROUZET E, Castignoles F, Dommanget C, Perrache C, Forest F, Trone M C, Thuret G, Gain P - Saint Priest en Jarez

S064 Epidemiologic study of dry eye disease (DED) in pre-surgery refractive patients
YANCHENKO S - Krasnodar

S066 Results of treatment of transient dry eye syndrome with increasing of intraocular pressure in the patient after LASIK
Bikbov M, KHIKMATULLIN R, Usubov E, Zaynetdinov A - Ufa

Saturday, October 6 - Poster session

POS

10:15 - 11:15 | POSTER AREA

COS - Cornea/Ocular Surface

Poster S001-S080

FUCHSLUGER T , SZENTMARY N

S067 Effect of laser-assisted subepithelial keratectomy with mitomycin C on corneal optical density measured with confocal microscopy
CANADAS SUAREZ P, Drake P, Laucirika G, Teus M - Valladolid

S068 Morphological and refractive consequences of traumatic loss of LASIK corneal flap
ASCASO F, Montes Rodríguez P, Karlsruher Riegel G, López I, Marco S, Berniolles J, Bartolomé M I, Del Buey M A - Zaragoza

S069 Dropmeter interest in clinical trials
RENAULT D, Garhöfer G, Courrier E, Lambert V, Garcin T, Rebika H, Thuret G, Gain P - Clermont-Ferrand

S070 * The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): overview of possible applications
THURET G, Crouzet E, Garcin T, Herbepin P, He Z, Courrier E, Perrache C, Al Bourgol S, Lambert V, Maurin C, Saunier V, Gauthier A S, Gain P - Saint-Etienne

S071 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): Assessment of corneal biomechanics
SAUNIER V, Crouzet E, Legout P, Herbepin P, Thuret G, Touboul D, Gain P - Bordeaux

S072 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorization): study of a new intrastromal inlay for presbyopia
CROUZET E, Trone M C, Garcin T, Castignoles F, Dommanget C, Al Bourgol S, Perrache C, Forest F, Thuret G, Gain P - Saint-Etienne

S073 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorization): simulation of a DMEK
HE Z, Crouzet E, Perrache C, Garcin T, Trone M C, Forest F, Gain P, Thuret G - Saint-Etienne

S074 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): study of a retro-corneal implant for corneal edema
CROUZET E, Garcin T, Trone M C, Perrache C, Forest F, Daphan O, Marcovich A, Ferara N, Thuret G, Gain P - Saint-Etienne

S075 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): Kinetics of human cornea swelling and deswelling in the bioreactor as a function of IOP and endothelial status
PERRACHE C, Crouzet E, Guindolet D, Herbepin P, Garcin T, He Z, Courrier E, Gain P, Thuret G - Saint-Etienne

S076 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): study of new lyophilized amniotic membranes
GAIN P, Crouzet E, Al Bourgol S, Barnouin L, Perrache C, He Z, Forest F, Thuret G - Saint-Etienne

S077 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): regeneration of corneal and limbal epithelium of stored human corneas
GUINDOLET D, Crouzet E, Perrache C, Gabison E, He Z, Thuret G, Gain P - Paris

S078 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorization): simulation of the endothelial cells injection therapy for corneal edema
HE Z, Crouzet E, Perrache C, Garcin T, Forest F, Gain P, Thuret G - Saint-Etienne

S079 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): an ex vivo model of human Staphylococcus aureus keratitis
LAMBERT V, Courrier E, Maurin C, Charaoui S, Verhoeven P, Al Bourgol S, Crouzet E, Perrache C, Herbepin P, He Z, Gain P, Thuret G - Saint-Etienne

S080 The OBSERV platform (Ophthalmic Bioreactor Specialized in Experimental Research & Valorisation): an innovative ex vivo model of human herpetic keratitis
COURRIER E, Lambert V, Maurin C, Bourlet T, Verhoeven P, Charaoui S, Al Bourgol S, Crouzet E, Perrache C, Herbepin P, He Z, Gain P, Thuret G - Saint Priest en Jarez

POS

10:15 - 11:15 | POSTER AREA

ACB - Anatomy/Cell Biology

Poster S081-S102

KAUPPINEN A

S081 rf
Improved wound resolution for Entropion Surgery using a microscope-assisted 8'0' vicryl suture technique.
BALENDRA S, Rainsbury P, Makuloluwe S, Lockwood A, Maclean H - Portsmouth

S082
Increased TRAIL and TRAIL receptor expression in rat corneal stroma exposed to chemical burn damage
DRAGONI F, Amirkavei M, Kaarniranta K, Viiri J, Amadio M - Kuopio

S083 rf
Effect of Pseudomonas and Acanthamoeba infection upon inflammation produced by human cornea epithelial cells
BISEVAC J, Korhonen E, Noer A, Moe C. M, Kaarniranta K, Kauppinen A, Petrovski G - Oslo

S084
Effect of trypsin-EDTA on expression of DNA damage repair enzyme APE1 in human conjunctival epithelial cells
NICOLAISSEN B O, Nguyen G, Beraki K, Moe M C, Petrovski G, Nicolaissen B, Lorenzo Y - Drammen

S085 rf
The role of caspase-8 in inflammasome activation in RPE cells
RANTA-AHO S, Piippo N, Korhonen E, Hytti M, Kauppinen A, Kaarniranta K - Kuopio

S086
Morphologic and electroretinographic phenotype of NRF-2 and PGC-1α deficient mice: a novel model for dry age-related macular degeneration
SZÄSZUJFALUSI FELSZEGHY S, Johanna V, Koskela A, Chen M, Ferrington D, Kauppinen A, Kaarniranta K - Kuopio

S087
New nature-inspired hybrids activating the Nrf2-HO1 pathway in retinal pigment epithelial cells and their potential use in pathologies featured by oxidative stress
AMADIO M, Catanzaro M, D'Angelo I, Kaarniranta K, Kauppinen A, Rosini M, Govoni S, Lanni C - Pavia

S088 rf
Oxidative stress and mitochondrial damage overloads mitophagy in dry age-related macular degeneration like PGC-1α/Nrf-2 knockout mice model
SRIDEVI GURUBARAN R, Viiri J, Koskela A, Hyttinen J, Kauppinen A, Urtti A, Szäszujfalusi Felszeghy S, Kaarniranta K - Kuopio

S089 rf
Rab 7 characterization and its regulatory role on autophagy in retinal pigment epithelium cells
MYSORE Y, Piippo N, Hyttinen J M T, Kaarniranta K, Kauppinen A - Kuopio

S090
Ex vivo expansion of human primary RPEs for potential use in clinical transplantation studies
NAGYMIHALY R, Lytvynchuk L, Moe M, Bergersen L H, Petrovski G - Oslo

S091
Contribution of the monocyte-derived macrophages to retinal microglia response after a peripheral nerve injury
POZO LORENZO F J, Bográn-Rodríguez H R, David S, Vidal-Sanz M, Aviles-Trigueros M - El Palmar, Murcia

S092
TIM2: a new player in iron homeostasis in the retina
VALENÇA A, Ramos D, Catita J, Bonet A, Nacher V, Navarro M, Carretero A, Mendes-Jorge L, Ruberte J - Lisboa

S093
Sitagliptin, a dipeptidyl peptidase-IV inhibitor, attenuates retinal neurodegeneration in rd10 mice
KUTSYR O, Fernández-Sánchez L, Maneu V, Lax P, Ambrósio A F, Cuenca N - Alicante

S094 rf+
Neurogenesis detection in the adult human retina
ORTUÑO-LIZARÁN I, Peterson D A, Cuenca N - San Vicente del Raspeig

S095
Lactate: More than merely a metabolic waste product
VOHRA R, Aldana B I, Skytt D M, Waagepetersen H, Bergersen L H, Kolko M - Copenhagen

S096
Optic nerve remodeling event due to a retinal ganglion cell degeneration in patients with Parkinson disease
SÁNCHEZ SÁEZ X, Ortuño-Lizarán I, Beach T G, Serrano G E, Adler C H, Cuenca N - Sant vicent del Raspeig, Alicante

Saturday, October 6 - Poster session

POS

10:15 - 11:15 | POSTER AREA

ACB - Anatomy/Cell Biology

Poster S081-S102

KAUPPINEN A

S097 Prevention of glutamate-induced retinal ganglion cell death by UCCB01-144 treatment
BULLI G, VOHRA R, Skytt D M, Strømgaard K, Kolko M - Copenhagen*

S098 rf Cenupatide is an effective antiangiogenic in a novel mouse model of rubeosis iridis associated with neovascular glaucoma
ANDRE H, Locri F, Aronsson M, Maurizio C, Dal Monte M, Bagnoli P, De Rosa M, Pavone V, Kvanta A - Stockholm

S099 Aflibercept Treatment Leads to Vascular Abnormalization of the Choroidal Neovascularization
WYLEGALA A - Katowice

S100 MicroRNA regulation underlines an interplay between autophagy and neovascularization in wet AMD
KAARNIRANTA K, Watala C, Filip A, Winiarczyk M, Zmorzy ski S, Mackiewitcz J, Blasiak J - Kuopio

S101 Epiretinal membranes in a db/db model of diabetic retinopathy
BONET A, Valença A, Catita J, Nacher V, Navarro M, Carretero A, Mendes-Jorge L, Ramos D, Ruberte J - Bellaterra, Barcelona

S102 SIRT1 overexpression induces VEGF expression and pericyte recruitment in the retina
RAMOS D, Catita J, Valença A, Bonet A, Carretero A, Navarro M, Nacher V, Mendes-Jorge L, Ruberte J - Lisbon

POS

10:15 - 11:15 | POSTER AREA

LC - Lens and Cataract

Poster S103-S114

QUINLAN R , ROZEMA J

S103 Image registration demonstrates central lens thickness minimally changes during accommodation
GRZYBOWSKI A, Schachar R A, Gaca-Wysocka M, Schachar I H, Kamangar F, Pierscionek B K P - Olsztyn

S104 Comparison of collagen and alpha smooth muscle actin distribution in in-vitro and in-vivo developed posterior capsule opacification
D'ANTIN J C, Ribeiro Koch C, Tresserra F, I. Barraquer R, Michael R - Barcelona

S105 Calcium signaling in ex vivo cultured human anterior lens epithelial cells after mechanical stimulation
ANDJELIC S, Gosak M, Gojic D, Hawlina M - Ljubljana

S106 Intraocular lens surface roughness studied by atomic force microcopy in different environments in vitro
KETABI SHADVAR S, Gros-Otero J, Villa-Collar C, Garcia-Gonzalez M, Teus M A - Alcobendas

S107 Influence of steam and pressure and gamma radiation sterilization on drug loaded intraocular lenses for endophthalmitis prevention
PRIOR FILIPE H, Topete A, Saramago B, Serro A P - Lisbon

S108 Prediction of postoperative spherical equivalent after cataract surgery using a machine learning approach
DEBELLEMANIERE G, Dubois M, Gatinel D - Paris

S109 Correlations between subjective and objective preoperative assessment of cataract severity, and intraoperative ultrasound energy
GARCIN T, Grivet D, Thuret G, Gain P - Saint Etienne

S110 Phacoemulsification and zonular weakness: contribution of the wired capsular tension ring.
LAMBERT V, Courrier E, Renault D, Thuret G, Gain P, Malek Y, Oudjani N - Saint-Etienne

S111 Vivinex© toric lenses refractive results after cataract surgery, preliminary study including 50 eyes
VERRECCHIA S, Hussam E C, Elbany S, Agard E, Dot C - Lyon

S112 Implantation of toric intraocular lens and femtolaser arcuate keratotomy as ways for corneal astigmatism correction at single-stage phacoemulsification
MALGIN K - Orenburg

S113 Clinical outcomes after cataract surgery with a Precizon Multifocal intraocular lens
LEE G, Jun I H, Koh K M, Kim T I - Seoul

S114 Molecular genetic analysis in three cases with syndromic cataracts
DUDAKOVA L, Skalicka P, Magner M, Plevova P, Honzik T, Liskova P - Prague

Saturday, October 6 - Poster session

POS

10:15 - 11:15 | POSTER AREA

PO - Pathology/Oncology

Poster S115-S119

VAN GINDERDEUREN R , JAGER MJ

S115	Orbital cellulitis secondary to malignat neoplasia *LÓPEZ SANGRÓS I, Marco S, Bartolomé M I, Marta C B, Castillo J, Berniolles J, Dominguez A M, Montes P, Karlsruher G, Ascaso J - Zaragoza*
S116	Invasive retinoblastoma – case report *MRAZOVAC D, Juri Mandic J, Zimak Z, Vukojevic N - Zagreb*
S117	Tunisian retinoblastoma clinical and genetic profile *ROUATBI A, Chebbi A, Ben Selem M, Bouguila H - Tunis*
S118	Tunisian uveal melanoma's epidemiological study *ROUATBI A, Chebbi A, Ben Selem M, Bouguila H - Tunis*
S119	Tunisian experience with antimitotic agents in ocular surface squamous neoplasia *ROUATBI A, Chebbi A, Ben Selem M, Bouguila H - Tunis*

Saturday, October 6 - Second morning session

SIS

11:15 - 12:30 | HERMES

RV - Management of proliferative diabetic retinopathy

AIM: To present all the new facts regarding Proliferative Diabetic retinopathy
METHODS: We will provide lectures and questions and answers in the field of Proliferative Diabetic retinopathy pathophysiology, medical treatment , Surgical treatment, New Techniques, New Instrumentation.
RESULT: We believe that at the end of rhe session we will provide all the necessary knowledge for a safer and better management of the Proliferative Diabetic retinopathy .
CONCLUSION: Proliferative Diabetic retinopathy is a good proportion of a Vitreoretinal Surgeon's every day activity. The more you know the better management you can provide

PAPPAS G , POURNARAS J

3311	11:15	Laser or Anti-VEGF for prolipherative diabetic retinopathy *PARIKAKIS E - Kifissia, Athens*
3312	11:30	Investigation techniques for proliferative diabetic retinopathy *PETROU P - Athens*
3313	11:45	27g for proliferative diabetic retinopathy *PAPPAS G - Heraklion*
3314	12:00	3D surgery for proliferative diabetic retinopathy *POURNARAS J A - Lausanne*
3315	12:15	Guidlines for the management of Proliferative Diabetic retinopathy *TBC*

SIS

11:15 - 12:30 | RHODES 1

G: ARVO@EVER - Advances in glaucoma

ARVO

This session will summarise the lates advances in the different aspects of glaucoma management including medicine, laser and surgery. Highlights of the newest treatments as well as the latest tthoughts on existing/best practice will be covered. Additionally, all speakers will cover future therapies/technologies in the field.

CORDEIRO M F , BRON A

3321	11:15	Medicine *CORDEIRO M F - London*
3322 *	11:40	Lasers *MEIER-GIBBONS F - Rapperswil*
3323	12:05	Can we individuaize glaucoma surgery? *SUNARIC MEGEVAND G - Geneva*

Saturday, October 6 - Second morning session

RF

11:15 - 12:30 | RHODES 2

EOVS - Rapid Fire session

LAWRENSON J , CASTELO-BRANCO M

33301	*rf*	11:15	The Rayleigh equation: reasons for a standard in application *KRASTEL H, Kirchhübel R, Bischoff P, Jonas J B - Neckargemünd*
33302	*rf*	11:21	Uncorrected refractive error and associated risk factors among socially vulnerable older adult population living in Armenia *GILOYAN A, Harutyunyan T, Petrosyan V - Yerevan*
33303	*rf*	11:27	Corneal astigmatism distribution at Indonesia National Eye Center Cicendo Eye Hospital *SUGANDA R, Renata Musa I, Wahyu M S, Virgana R - Jakarta utara*
33304	*rf*	11:33	Conservative Treatment of Newly Diagnosed Keratoconus *MRAZOVAC D, Jandrokovic S, Zimak Z, Petricek I - Zagreb*
33305	*rf*	11:39	A new reaction time test (Ocusweep® Reaction Time Test) for assessing visual performance and compliance *TIGCHELAAR I, Mäntysalo T, Leinonen M - Turku*
33306	*rf*	11:45	The influence of cataract light scatters on retinal vessel oxygen saturation *WAIZEL M, Türksever C, Todorova M G - Basel*
33307	*rf*	11:51	Correlating macular inner retinal layer thickness with photopic and mesopic contrast sensitivity in healthy young and older subjects. *PUELL M, Palomo-Álvarez C, Pérez-Carrasco M - Madrid*
33308	*rf*	11:57	Different retinal layers thickness measurements change with age in healthy eyes *RODRIGO M J, Vilades E, Orduna E, Gavin A - Zaragoza*
33309	*rf*	12:03	Electrophysiology and retinal thickness alterations in patients with multiple sclerosis with and without previous optic neuritis *ORDUNA HOSPITAL E, Vilades Palomar E, Rodrigo Sanjuan M J, Gavin Sancho A, Cipres Alastuey M, Larrea Samper J G, Satue Palacian M, Garcia Martin E - Zaragoza*
33310	*rf*	12:09	Pattern electroretinogram steady-steate in dyslexis and normal readers *CELLINI M, Campos E C - Bologna*
33311	*rf*	12:15	Investigating the movement of the centre of the multifocal hexagonal stimulus array using an electroretinogram function *SUZUKI N, Yamane K - Numazu*

JM

11:15 - 12:30 | RHODES 3

OOG Business Meeting

HEEGAARD S

Agenda

1. Financial update
2. OOG membership
3. Future meetings
4. Collaborative studies
5. Any other business

Saturday, October 6 - Second morning session

RF

11:15 - 12:30 | RHODES 4

IM/LC - Rapid Fire session

PICHI F , NERI P , MICHAEL R , BARRAQUER R I

33501	*rf*	11:15	Suclinical signs persistance in Vogt-Koyanagi-Harada disease (VKHD) patients treated with early high-dose corticosteroids and immunosuppressive therapy *YAMAMOTO TAKIUTI J H, Lavezzo M M, Sakata V M, Kanenobu C, Morita C, Oyamada M K, Hirata C E - Sao Paulo*
33502	*rf*	11:21	Fine-Tuning of therapy in stromal choroiditis using indocyanine green angiography (ICGA) *ELAHI S, Gillmann K, Gasc A, Jeannin B, Herbort Jr C P - Lausanne*
33503	* *rf*	11:27	EYS606 for the Treatment of Non-Infectious Uveitis (NIU) *BUGGAGE R - Paris*
33504	*rf*	11:33	Aciclovir-resistant HSV1 keratitis : a clinical and virological study *ROUSSEAU A, Burrel S, Gueudry J, Deback C, Bordereau S, Mouriaux F, Labalette P, Bazard M C, Gabison E, Bourcier T, Schweitzer C, Labetoulle M - Le Kremlin Bicêtre*
33505	*rf*	11:39	Association between visual function and quality of life in patients with Vogt-Koyanagi-Harada disease *YAMAMOTO TAKIUTI J H, Missaka R F, Souto F M, Marchiori B M, Caetano V M, Takiuti J T, Lavezzo M M, Oyamada M K, Hirata C E - Sao Paulo*
33506	*rf*	11:45	Interleukin-33 regulates mitochondrial function in the retinal pigment epithelium maintaining immune homeostasis *SCOTT L, Vincent E, Dick A, Theodoropolou S - Bristol*
33507	*rf*	11:51	Intraocular lens surface roughness studied by atomic force microcopy in different environments in vitro *KETABI SHADVAR S, Gros-Otero J, Villa-Collar C, Garcia-Gonzalez M, Teus M A - Alcobendas*
33508	*rf*	11:57	Influence of steam and pressure and gamma radiation sterilization on drug loaded intraocular lenses for endophthalmitis prevention *PRIOR FILIPE H, Topete A, Saramago B, Serro A P - Lisbon*
33509	*rf*	12:03	Implantation of toric intraocular lens and femtolaser arcuate keratotomy as ways for corneal astigmatism correction at single-stage phacoemulsification *MALGIN K - Orenburg*
33510	*rf*	12:09	Molecular genetic analysis in three cases with syndromic cataracts *DUDAKOVA L, Skalicka P, Magner M, Plevova P, Honzik T, Liskova P - Prague*

Saturday, October 6 - Second morning session

SIS

11:15 - 12:30 | GALLIENI 1+2

MBGE - Genetic models to human ocular diseases

Genetic disorders are caused by multifactorial means, involving a combination of genetic and environmental factors. Many human diseases involve eye development, a complex and unique sense organ. For most vision pathologies, there is no satisfatory therapeutic tools. Therefore, there is a great need for vision research and design of cellular and animal models that recapitulate eye disorders. Such models will help studying the normal and pathological molecular pathways but also screening for small compounds that could become potential therapeutic tools. This session will bring European experts who design cellular and animal models of retinal and corneal disorders.

ASHERY-PADAN R , ABERDAM D

3361	11:15	Molecular mechanisms underlying retinal degeneration caused by cilia dysfunction *MAY SIMERA H, Patnaik S, Kretschmer V, Schneider S - Mainz*
3362	11:33	Inherited retinal dystrophies and regulated protein clearance *IVAN C - Pozzuoli (NA)*
3363	11:51	Stem cell tracking, loss and recovery in the corneal epithelium *SHALOM-FEUERSTEIN R - Haifa*
3364	12:09	Modeling of aniridia-related keratopathy by CRISPR/Cas9 of human limbal epithelial cells and rescue by recombinant PAX6 protein *ROUX, L - Paris*

Saturday, October 6 - Noon session

JM

12:30 - 13:45 | HERMES

FAN Club

Cases with retinal imaging are presented and discussed with a panel.
Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.
Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.
www.fan-int.org

VAN SCHOONEVELD M

SIS

12:30 - 13:45 | RHODES 1

EOVS - Scattered light and visual function

Any disturbance to the homogeneity of ocular media will cause a localised change in refractive index, which will consequently alter the optical pathway of incoming light, causing an increase in light scatter or retinal straylight. Forward light scatter originates predominantly in the cornea and the crystalline lens; it's known to produce veiling glare on the retina, which in turn affects retinal image contrast. Veiling glare is also reported to induce disability glare; haloes; and can adversely affect critical tasks such as driving. There has been an increasing interest in the influence of forward light scatter, particularly since the development of instruments which allow easy measurement of light scatter parameters.
This Special Interest Symposium aims to bring together researchers with specific interests in the impact of light scatter on retinal sensitivity, its relationship with intraocular lens glistening, measurement techniques, and will discuss functional effects of scattering versus morphology. We expect the symposium to draw interest from a broad range of vision researchers; including those with interests in retinal image quality, and refractive surgery.

NAGRA M , BARBUR J L

3421	*	12:30	Scattered light and retinal sensitivity to contrast *BARBUR J L - London*
3422	*	12:40	Straylight and the slitlamp image: functional effects of scattering versus morphology *VAN DEN BERG T J - Amsterdam*
3423		12:50	Is bigger better? Glistenings, forward light scatter and visual performance *HULL C, Stanojcic N, Philippaki E, O'Brart D - London*
3424		13:00	Comparison between two scatter parameters in a population under age 65 : the C-quant (Oculus) and the HD Analyser (Visiometrics) *VAN VERRE H - Halle*
3425		13:10	Factors influencing retinal straylight *ROZEMA J - Edegem*
3426		13:20	Disk halo size as a measurement of scattering and visual function *PUELL M, Pérez-Carrasco M, Palomo-Álvarez C - Madrid*
3427	*	13:30	Refractive error and forward light scatter *NAGRA M, Patel M, Barbur J - London*

Saturday, October 6 - Noon session

SIS

12:30 - 13:45 | RHODES 2

SOPREF - Eyelid and orbital tumors: diagnosis, treatment and biomarkers

LAGIER J

3431	12:30	Lymphoma highlights *ROBERT PY - Limoges*
3432	12:39	Sebaceous carcinoma highlights *FEVRIER E, Lagier J - Nice*
3433	12:48	Challenge in squamous cell carcinoma *MARTEL A, Lagier J - Nice*
3434	12:57	Radiotherapy of sebaceous carcinoma in 2018 *CLAREN A - Nice*
3435	13:06	IgG4 relationship with orbital malignant tumor *MOURIAUX F - Rennes*
3436	13:15	Challenge in eyelid melanoma combined with conjunctivitis melanoma challenge *DELAS J - Nice*
3437	13:24	Challenge in fibroblastic/myofibroblastic tumor in child *NAHON-ESTEVE S, Lasalle S - Nice*
3438	13:33	Outcomes of patients with conjunctival squamous cell carcinoma treated with proton beam therapy *Nahon-Esteve S, CAUJOLLE J P - Nice*

JM

12:30 - 13:45 | RHODES 3

OOG Ocular Oncology Group II - Uveal melanoma

DESJARDINS L , ZOGRAFOS L

3441	12:30	Rapid MR Imaging of Ocular Movement for Radiotherapy Planning *JAARSMA-COES M, Van Vught L, Koolstra K, Beenakker J W B - Leiden*
3442	12:40	Automated analysis of eye tumor MR-images for an improved treatment determination *BEENAKKER J W M, Hassan M K, Shamonin D P, Shahzad R, Webb A, Stoel B C, Luyten G P M - Leiden*
3443	12:50	Measuring eye deformation under different patient positions using MRI *JAARSMA-COES M, Schuurmans M S, Hassan M K M A, Marinkovic M, Luyten G P M, Beenakker J W B - Leiden*
3444	13:00	MR-Imaging enables accurate diagnosis and follow-up for vitrectomized eyes in uveal melanoma patients *JAARSMA-COES M, Goncalves Ferreira T A, Marinkovic M, Luyten G P M, Beenakker J W M - Leiden*
3445	13:10	Local tumourcontrol rate and late complications of fractionated stereotactic radiotherapy in uveal melanoma *VAN BEEK J, Van Rij C, Yavuzyigitoglu S, Paridaens D, Naus N, Kiliç E - Rotterdam*
3446	13:20	Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis *RANTALA E, Hernberg M, Kivelä T - Helsinki*

Saturday, October 6 - Noon session

RF

12:30 - 13:45 | RHODES 4

COS - Rapid Fire session

GICQUEL J , SZENTMARY N

34502	*rf*	12:36	Anti-inflammatory properties of corneal stroma-derived stem cells: Potential as a topical therapy for the ocular surface *SIDNEY L, Orozco Morales M L, Marsit N, Mcintosh O, Hopkinson A - Nottingham*
34503	*rf*	12:42	Phenotype-genotype correlation of p.R124S mutation in granular type 1 corneal dystrophy of Tunisian origin *FALFOUL Y, Bouyacoub Y, Munier F L, Sayeb M, Ouederni M, Chargui M, El Matri L, Abdelhak S, Cheour M - Tunis*
34504	*rf*	12:48	Keratoendotheliitis Fugax Hereditaria is Caused by a Mutation in the NLRP3 Gene *TURUNEN J, Wedenoja J, Repo P, Järvinen R S, Jäntti J, Mörtenhumer S, Riikonen A, Lehesjoki A E, Majander A, Kivelä T - Helsinki*
34505	*rf*	12:54	Non-contact millimeter-field imaging of in vivo corneal cells by full-field OCT *MAZLIN V, Xiao P, Grieve K, Sahel J A, Fink M, Boccara C - Paris*
34506	*rf*	13:00	Gender Differences in Symptoms and Signs of Dry Eye Disease in a Norwegian Cohort of Patients *TELLEFSEN S, Badian R A, Stojanovic A, Paaske Utheim T, Aas Utheim Ø, Tashbayev B, Raeder S, Chen X - Oslo*
34507	* *rf*	13:06	Developement of a safe and biocompatible powder to be reconstituted as keystone for dry eye syndrome treatment *Barnouin L, MICHEL A - MIONS*
34508	*rf*	13:12	Ocular surface temperature, blinking rate and corneal sensitivity in young contact lens wearers *Pastor-Zaplana J Á, Morales-Villellas M, Monteserín-Rodríguez M, GALLAR J, Acosta M C - San Juan de Alicante*
34509	*rf*	13:18	Orbital biomechanical changes in Graves' disease and Thyroid eye disease: application of Corvis ST *VIEIRA M, Neves A, Carvalheira F, Batista A, Santos M, Sousa J - Leiria*
34510	*rf*	13:24	Effect of intracorneal ring segment implantation on tear film properties in patients with keratoconus *SAGRI D, Thabit A, Elalfy M, Hamada S, Goldblum D, Scholl H, Gatzioufas Z - Zurich*

JM

12:30 - 13:45 | GALLIENI 1+2

Women in EVER

VOTRUBA M , KAWASAKI A

3461	12:30	Moving from academia to industry *PURSLOW C - Monmouth*
3462	12:46	Having it all? *TSANGARIDES SA - London*
3463	13:02	The long way from basic sciences to patient's care (and return) *D'ESPOSITO F - London*
3464	13:18	Women in Vision UK- a movement for gender equality in ophthalmology and vision sciences *MOOSAJEE M - London*
	13:34	Q & A and conclusions & next steps by the moderators

Saturday, October 6 - First afternoon session

RF

14:15 - 15:30 | HERMES

Young investigators' award session I

POURJAVAN S , NERI P

3511		14:15	ACB - Neurogenesis detection in the adult human retina *ORTUÑO-LIZARÁN I, Peterson D A, Cuenca N - San Vicente del Raspeig*
3512		14:24	EOVS - New analysis of the Farnsworth D-15 test *EVANS B, Barbur J, Rodriguez-Carmona M - London*
3513		14:33	G - Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer's disease *SHAMSHER E, Davis B, Dev P, Grgic L, Somavarapu S, Guo L, Cordeiro F - London*
3514		14:42	G - Peripapillary vascular analysis from optical coherence tomography angiography to differentiate glaucoma and normal eyes *MARQUES M, Cabral D, Rodrigues P, Alves S, Valadares J, Barrão S - Lisboa*
3515		14:51	RV - A morphological study and expression patterns of iron regulatory proteins in aging Wistar rats retina after iron overload *KUMAR P, Nag T C, Velpandian T, Toy T S, Wadhwa S - New Delhi*
3516		15:00	RV - The incidence of rhegmatogenous retinal detachment in France from 2010 to 2016: seasonal and geographical variations *BEN GHEZALA I, Benzenine E, Mariet A S, Gabrielle P H, Bron A, Quantin C, Creuzot C - Dijon*

14:15 - 15:30 | RHODES 1

SIS

G/NSPH - Biomarkers in ophthalmology and beyond

Neurodegenerative disorders present ocular manifestations which could precede general signs and symptoms. Correlation between the eye and the brain has been confirmed by recent advances in ophthalmic technologies. Furthermore, ocular biomarkers have increasingly been used as surrogate indicators of disease activity and treatment response.
The aim of this SIS is to generate a multidisciplinary discussion around biomarkers in ophthalmology with a particular focus on:
1. What is the State-of-the-Art
2. New advances in structural biomarkers for ophthalmic and neurological conditions
3. Genetic biomarkers in ophthalmology.

NORMANDO E M , CORDEIRO M F

3521		14:15	Biomarkers in glaucoma *YAP T - London*
3522		14:30	Biomarkers in optic neuritis *BARBONI P - Bologna*
3523		14:45	Structural Biomarkers in neurodegeneration *CUNHA J P, Ferreira J, Dias-Santos A - Lisbon*
3524		15:00	Genetic biomarkers in ophthalmology *VOTRUBA M - Cardiff*
3525	*	15:15	New and emerging ocular biomarkers *CORDEIRO M F - London*

Saturday, October 6 - First afternoon session

SIS

14:15 - 15:30 | RHODES 2

PO - New treatments in eye melanomas

Ocular melanoma have a high tendency to metastasize, and a lack of efficient treatments. It is important to get more insight in the molecular pathways and the immunological characteristics of conjunctival and uveal melanoma in order to develop treatments for metastases. Another option is to prevent the development of melanoma by early treatment of high-risk nevi. Different approaches will be discussed.

JAGER M J , MOULIN A

3531	14:15	Treatment targets in conjunctival melanoma *MOULIN A - Lausanne*
3532	14:27	Immunology of conjunctival and uveal melanoma *JAGER M J - Oegstgeest*
3533	14:39	Differential diagnosis of intraocular tumors *ROMANOWSKA DIXON B - Krakow*
3535	14:51	Treatment of uveal melanoma metastases: a surgeon's view *CASSOUX N - Paris*
3536	15:03	Treatment of uveal melanoma: an oncologist's view *PIPERNO-NEUMANN S - Paris*

SIS

14:15 - 15:30 | RHODES 3

LC/COS - Customized intraocular lenses – challenges and limitations

Beside the classical spherical lens designs there are aspherical (aberration free and aberration correcting), toric and multifocal IOLs on the market. None of them are really customized to the optical aberration of the cornea, which means that after implantation there are residual optical aberrations left in the eye.Customized intraocular lenses offer the capability to individually correct optical aberrations of the eye. Calculations are performed based on the shape of the corneal front and back surface, the shape of the pupil and standard biometric measures. Optical surfaces are characterized by a global definition or local splines. In general, the potential deterioration of the retinal image performance gains with the degree of customization if customized lenses are not properly positioned in the eye or biometric parameters change over time.In this course we would like to address which preoperative measurements are necessary, the workflow of customized IOL calculation, and the postoperative monitoring in terms of quality check.

LANGENBUCHER A , EPPIG T

3541	14:15	The basic concept behind customized IOLs – optical aberrations and correction options *LANGENBUCHER A, Schröder S, Schrecker J, Eppig T - Homburg*
3542	14:33	Calculation of customized IOLs – from corneal tomography and biometry to the lens shape *EPPIG T, Schröder S, Schrecker J, Langenbucher A - Homburg/Saar*
3543	14:51	Robustness towards position uncertainties – the forgotten factor *SCHRÖDER S, Eppig T, Schrecker J, Langenbucher A - Homburg*
3544	15:09	First clinical results with customized IOLs *SCHRECKER J - Glachau*

Saturday, October 6 - First afternoon session

RF

14:15 - 15:30 | RHODES 4

RV - Rapid Fire session

POURNARAS J , POURNARAS C

35501	* *rf*	14:15	Strain differences in the rat streptozotocin-induced model of diabetic retinopathy *JÄÄSKELÄINEN N, Tenhunen A, Thapa R, Ragauskas S, Dunlop T, Ziniauskaite A, Haapaniemi A M, Räsänen H, Kaja S, Kalesnykas G, Cerrada-Gimenez M - Kuopio*
35502	*rf*	14:21	In vivo retinal cells visible without adaptive optics using a novel full-field OCT *MAZLIN V, Xiao P, Scholler J, Grieve K, Sahel J A, Fink M, Boccara C - Paris*
35503	*rf*	14:27	Choriocapillaris changes during development of CNV – an OCT Angiography quantitative analysis *RODRIGUES C, Cabral D, Coscas F, Pereira T, Cachado F, Geraldes C, Sellam A, Barrão S, Papoila A, Coscas G, Souied E - Lisbon*
35504	*rf*	14:33	Analysis of choroidal structure changes in diabetic patients without diabetic retinopathy: a longitudinal study *FIGUEIREDO R, Luís M E, Hipólito Fernandes D, Cunha J P, Alves M, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Coimbra*
35505	*rf*	14:39	Retinal neurodegeneration in patients with type 2 diabetes mellitus without diabetic retinopathy *MOURA-COELHO N, Alves M, Dias Santos A, Costa L, Oliveira Santos B, Cunha J P, Papoila A L, Abegão Pinto L, Tavares Ferreira J - Lisbon*
35506	*rf*	14:45	Predictive biomarkers in OCT-Angiography of peripheral nonperfusion in retinal venous occlusions *REIS CABRAL D, Coscas F, Glacet-Bernard A, Pereira T, Geraldes C, Papoila A, Vila Franca M, Coscas G, Souied E - Lisboa*
35507	* *rf*	14:51	Topical Treatment for Ocular Diseases of the Posterior Segment: Non-Invasive Delivery of Large Therapeutics such as Bevacizumab and Ranibizumab *DE COGAN F, Slope L, Berwick M, Peacock A, Scott R, Xu H, Chen M - Birmingham*
35508	*rf*	14:57	Evaluation of an Artificial Inteligence clinical decision support suite for Diabetic Retinopathy and Age related macular degeneration screening *TRANOS P, Karassavidou E, Tsirampidou E, Stavrakas P, Chrissafis C - Thessaloniki*
35509	*rf*	15:03	Development and validation of a risk-prediction nomogram for good functional response one year after treatment with anti-VEGF in naive-Diabetic macular edema *GABRIELLE P H, Massin P, Arnould L, Bouche-pillon J, Maupin E, Bron A, Kodjikian L, Creuzot C - Dijon*
35510	*rf*	15:09	Acute endophthalmitis after intravitreal injections of corticosteroids or anti-vascular growth factor agents. A nationwide study in France from 2012 to 2015 *BAUDIN F, Benzenine E, Mariet A S, Bron A, Daien V, Korobelnik J F, Quantin C, Creuzot C - Dijon*

Saturday, October 6 - First afternoon session

RF

14:15 - 15:30 | GALLIENI 1+2

MBGE - Rapid Fire session

LISKOVA P , GRAW J

3561	*rf*	14:15	Phenotype in homozygous and heterozygous carriers of BEST1 mutations in autosomal recessive Bestrophinopathy *EL MATRI K, Falfoul Y, Habibi I, Turki A, Chebil A, Schorderet D, El Matri L - Tunis*
3562	*rf*	14:21	A possible novel TGFBI mutation Ser591Phe in a Finnish family with lattice corneal dystrophy *JAAKKOLA A M, Järventausta P, Repo P, Kivelä T, Turunen J - Helsinki*
3563	*rf*	14:27	The 100,000 Genomes Project and the Western Eye Hospital Experience *D'ESPOSITO F, Miodragovic S, Normando E, Bonetti P, Cordeiro M F - London*
3564	*rf*	14:33	Vision-Related and Health-Related Quality of Life in Patients with Giant Cell Arteritis *NÍ MHÉALÓID Á, Conway R, Molloy E, Murphy C C - Dublin*
3565	*rf*	14:39	Clinical and Genetic Characteristics of enhanced S-cone syndrome in a Tunisian cohort: experience of the oculogenetic laboratory LR14SP01 *FALFOUL Y, Turki A, Habibi I, Hassairi A, El Matri K, Chebil A, Schorderet D, El Matri L - Tunis*
3566	*rf*	14:45	Mapping of proteomic profile and effect of the spongy layer in the human amniotic membrane *NAZARI HASHEMI P, Bisson A, Chaventre F, Guillou C, Cosette P, Boyer O, Muraine M - Rouen*
3567	*rf*	14:51	Cornea donation for research versus for transplantation: a one year prospective study of acceptance rates in a French University Hospital *GARCIN T, Pugniet J L, Peyragrosse T, Barallon M, Rogues F, Acquart S, Thuret G, Gain P - Saint Etienne*
3568	*rf*	14:57	Heritability of corneal curvature and Pentacam topometric indices: a population based study *YEKTA A A, Hashemi H, Khabazkhoob M, Heydarian S, Ostadimoghaddam H, Derakhshan A, Heravian J, Azimi Khorasani A, Momeni-Moghaddam H, Yekta R - Mahhad*

Saturday, October 6 - Second afternoon session

RF

15:30 - 16:45 | HERMES

Young investigators' award session II

FUCHSLUGER T , BARRAQUER R

3611		15:30	COS - Immunolabeling of nerves by anti-neurofilament and anti- III-Tubulin in the different compartments of the human ocular surface *HE Z, Lambert V, Forest F, Bergandi F, Garcin T, Perrache C, Gain P, Thuret G - Saint-Etienne*
3612		15:39	COS - Clinical signs in dry eye: a multicentric cross-sectional study *CANTALAMESSA E, Villani E, Nucci P, Rolando M - Milan*
3613		15:48	IM - Treatment of corticosteroid resistant Grave's orbitopathy with tocilizumab *GRIVET D, Perillat N, Gain P, Thuret G - Saint-Etienne*
3614		15:57	LC - Prediction of postoperative spherical equivalent after cataract surgery using a machine learning approach *DEBELLEMANIERE G, Dubois M, Gatinel D - Paris*
3615		16:06	MBGE - Clinical and Genetic Characteristics of Leber Congenital Amaurosis in the Tunisian Population: experience of the oculogenetic laboratory LR14SP01 *EL MATRI K, Falfoul Y, Habibi I, Turki A, Hassairi A, Chebil A, Schorderet D, El Matri L - Tunis*
3616		16:15	PBP - Retinal ganglion cells loss and caspase 3 activation after ocular hypertension *VALIENTE-SORIANO F J, Sánchez-Migallón Carreras M C, Agudo-Barriuso M, Vidal-Sanz M - Murcia*

Saturday, October 6 - Second afternoon session

RF

15:30 - 16:45 | RHODES 1

G - Rapid Fire session

NORMANDO E , POURJAVAN S

36201	*rf*	15:30	Diagnostic accuracy of a new thresholding glaucoma screening programme using temporally modulated flicker *JINDAL A, Fidalgo B, Ctori I, Tyler C, Lawrenson J - London*
36202	*rf*	15:36	Transconjunctival bleb sutures for post-trabeculectomy hypotony *RULE E, Beer F, Manns R, Ambrose I, Walker L, Lockwood A, Kirwan J - Portsmouth*
36203	*rf*	15:42	The Role of the αvβ3 Integrin in Lamina Cribrosa Cells and the Possible Role in Glaucoma Pathogenesis *HOPKINS A, Murphy R, Irnaten M, Wallace D, Brennan D, Clarke A, O'Brien C - Dublin*
36204	*rf*	15:48	Intravitreal rituximab for the treatment of ocular lymphoma and glaucoma *LOCKWOOD A, Farnworth D, Rainsbury P, Balendra S - Portsmouth*
36205	*rf*	15:54	Peripapillary microvasculature and Lamina cribrosa: is there a role in the diagnosis of primary open-angle glaucoma? *RODRIGUES C, Sousa Silva R, Cabral D, Rodrigues P, Marques M, Camacho P, Valadares J, Segurado J, Fernandes J, Barrão S - Lisbon*
36206	* *rf*	16:00	Results from an international observatory survey on the management of glaucoma treatments and its impact on the ocular surface disease (OSD), an ECOS-G (European Club of Ocular Surface in Glaucoma) initiative *KOLKO M, Iliev M E, Benitez Del Castillo J M, Thygesen J, Baudouin C - Glostrup*
36207	*rf*	16:06	Incidence and prevalence of glaucoma in native and immigrant groups living in Denmark *HORWITZ A, Klemp M, Torp-Pedersen C, Kolko M - Copenhagen*
36208	*rf*	16:12	Comparing the mid-term efficacy and safety of the Stegmann Canal Expander Canaloplasty with the prolene suture Canaloplasty in cases of open angle glaucoma *ADLJU R, Brazitikos I, Stangos A, Mameletzi A, Sunaric Mégevand G - Geneva*
36209	*rf*	16:18	Anatomical position of the raphe in the human retina *JANSONIUS N, Schiefer U - Groningen*
36210	*rf*	16:24	Effects of acute ocular hypertension on the adult rat retina: in vivo an ex vivo retinal analysis *GALLEGO ORTEGA A, Segura-Castro P, Gómez-Serna C, De La Villa P, Di Pierdomenico J, Bernal-Garro J, Villegas-Pérez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia*
36211	*rf*	16:30	Potential metabolic markers in glaucoma and their regulation in response to hypoxia *TIEDEMANN D, VOHRA R, Marie Dalgaard L, Vibæk Jensen J, Hildegaard Bergersen L, Vidiendal Olsen N, Hassel B, Abbas Chaudhry F, Kolko M - Copenhagen*

Saturday, October 6 - Second afternoon session

SIS

15:30 - 16:45 | RHODES 2

PO - Genetics in uveal melanoma

Uveal melanoma is characterised by a high rate of metastases. The development of metastases is associated with a wide range of tumor characteristics, which include tumor size, chromosome changes and mutations. Mutations in a gene located on chromosome 3, BAP1, are especially associated with a high mutation rate. Prognostication may be based on any of these characteristics, and optimal determinants are being sought.

In addition to somatic mutations in the BAP1 gene, germ-line mutations have been identified. It has been known for a long time that uveal melanoma can occur in families with multiple malignancies. Studies are now ongoing to determine the role of BAP1 germ line mutations in such families.

HEEGAARD S , KILIC E

3631	15:30	Occurrence of BAP1 mutations in families *LUYTEN G, Chau C, Marinkovic M, Bleeker J C, Jager M J, De Klein A, Van Doorn R, Nielsen M - Leiden*
3632	15:42	Analysing the function of BAP1 in uveal melanoma *TURUNEN J, Kivelä T - Helsinki*
3633	15:54	BAP1 in iris lesions *VERDIJK R M - Rotterdam*
3634	16:06	Mutations as prognostic factor in uveal melanoma *KILIC E - Rotterdam*
3635	16:18	Size and chromosomes in uveal melanoma *KIILGAARD J F - Copenhagen*
3636	16:30	Ethical issues of prognostication in uveal melanoma *VAFLARD P, Cassoux N, Mamzer-Bruneel M F, Rodrigues M - Paris*

RF

15:30 - 16:45 | RHODES 3

ACB - Rapid Fire session

KAUPPINEN A , KAARNIRANTA K

36401	*rf*	15:30	Improved wound resolution for Entropion Surgery using a microscope-assisted 8'0' vicryl suture technique. *BALENDRA S, Rainsbury P, Makuloluwe S, Lockwood A, Maclean H - Portsmouth*
36402	*rf*	15:36	Effect of Pseudomonas and Acanthamoeba infection upon inflammation produced by human cornea epithelial cells *BISEVAC J, Korhonen E, Noer A, Moe C. M, Kaarniranta K, Kauppinen A, Petrovski G - Oslo*
36403	*rf*	15:42	Cenupatide is an effective antiangiogenic in a novel mouse model of rubeosis iridis associated with neovascular glaucoma *ANDRE H, Locri F, Aronsson M, Maurizio C, Dal Monte M, Bagnoli P, De Rosa M, Pavone V, Kvanta A - Stockholm*
36404	*rf*	15:48	Rab 7 characterization and its regulatory role on autophagy in retinal pigment epithelium cells *MYSORE Y, Piippo N, Hyttinen J M T, Kaarniranta K, Kauppinen A - Kuopio*
36405	*rf*	15:54	The role of caspase-8 in inflammasome activation in RPE cells *RANTA-AHO S, Piippo N, Korhonen E, Hytti M, Kauppinen A, Kaarniranta K - Kuopio*
36406	*rf*	16:00	Oxidative stress and mitochondrial damage overloads mitophagy in dry age-related macular degeneration like PGC-1α/Nrf-2 knockout mice model *SRIDEVI GURUBARAN R, Viiri J, Koskela A, Hyttinen J, Kauppinen A, Urtti A, Szäszujfalusi Felszeghy S, Kaarniranta K - Kuopio*

Saturday, October 6 - Second afternoon session

RF

15:30 - 16:45 | RHODES 4

PBP - Rapid Fire session

OSBORNE N , VIDAL-SANZ M

3651	*rf*	15:30	Effect of flicker stimulation on retinal and optic nerve head blood flow as measured by Laser Speckle Flowgraphy *SCHMIDL D, Fondi K, Bata A, Luft N, Witkowska K, Werkmeister R, Schmetterer L, Garhofer G - Vienna*
3652	*rf*	15:36	Evaluation of sex differences in flicker light induced vasodilation and central retinal thickness in healthy young subjects *SZEGEDI S, Malin A G, Witkowska K J, Fondi K, Bata A M, Schmidl D, Garhofer G, Schmetterer L - Vienna*
3653	*rf*	15:42	Effects of focal light-emitting diode (LED)-induced phototoxicity in the albino rat retina *MIRALLES DE IMPERIAL OLLERO J A, Di Phierdomenico J, Gallego-Ortega A, Villegas-Perez M P, Valiente-Soriano F J, Vidal-Sanz M - Murcia*
3654	*rf*	15:48	Unilateral optic nerve axotomy at different distances from the optic disk cause the same course of retinal ganglion cells death *GALINDO-ROMERO C, Lucas-Ruiz F, Albadalejo-García V, Ros-Alcobas L, Vidal-Sanz M, Agudo-Barriuso M - Murcia*
3655	*rf*	15:54	Different aetiologies cause distinct patterns of cone degeneration *GARCÍA-AYUSO D, Di Pierdomenico J, Martínez-Vacas A, Hadj-Said W, Hernandez-Muñoz D, Marie M, Agudo-Barriuso M, Vidal-Sanz M, Picaud S, Villegas-Pérez M P - Murcia*
3656	*rf*	16:00	Microglial cell inhibition improves photorreceptor survival in two animal models of inherited retinal degeneration *DI PIERDOMENICO J, García-Ayuso D, Agudo-Barriuso M, Vidal-Sanz M, Villegas-Pérez M P - Murcia*

JM

15:30 - 16:45 | GALLIENI 1+2

Update in ophthalmology

FUCHSLUGERT

3661	15:30	ACB - Autophagy hot topic in AMD pathogenesis *KAARNIRANTA K - Kuopio*
3662	15:40	COS - Cornea & ocular surface *SZENTMARY N - Budapest*
3663	15:50	G - Updates in Glaucoma *LIM K. S - London*
3664	16:00	MBGE - how to find out the most frequently cited article in molecular biology, genetics and epidemiology of the eye *GRAW J - Neuherberg*

Saturday, October 6 - Prize Award Ceremony & Closing Remarks

PS

16:45 - 18:00 | HERMES

Prize Award Ceremony & Closing Remarks

Agenda

Chair: Rafael Barraquer, President EVER 2019

Introduction of the Award Ceremony by Francesca M. Cordeiro, Programme Secretary

Travel awards presentation by the section chairs

Poster prize presentations by the section chairs

Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2018 Alain Bron

EUPO 2018

European University Professors of Ophthalmology

October 3-4 in NICE, France

Retina, Intraocular Inflammation & Uveitis

Course Directors:

Prof. Catherine Creuzot-Garcher, University of Dijon, France

Prof. Bahram Bodaghi, University of Pierre and Marie Curie, Paris, France

The 2018 EUPO course is the first in a series redesigned to match the topics of the four viva voces that each candidate will face when they take the EBO Diploma Examination to become a FEBO.

2018: Retina, Intraocular Inflammation & Uveitis - Nice, October 3-4, 2018 with EVER
2019: Glaucoma, Cataract & Refractive Surgery - Nice, June 15-16, 2019 with SOE
2020: Refraction, Strabismus, Pediatric Ophthalmology & Neuro-ophthalmology - with EVER
2021: Cornea, External Diseases & Orbit - with SOE

For those not planning to take a EBO Diploma Examination, the 2018 EUPO Course provides an update on what is new and current, and thus will help in differential diagnosis and in choosing treatment in their offices and practices.

The redesigned course has a new syllabus based not only on short lectures, which will highlight what is new after the previous EUPO course on the same topic, but also on round table discussions that will prepare participants to respond in viva voces.

- **Anatomy and imaging techniques**
- **What to do when I see…?**
- **Round table: How do you diagnose these cases?**
- **How does it work?**
- **Round table: How do you treat these cases?**
- **My children cannot see because…**
- **Surgical diseases and special cases**
- **Round table: my job is difficult!**

Wednesday, October 3 - EUPO Course

8:00 - 8:30 | HERMES

Introduction of the EUPO Course

Introduction EUPO by President Tero KIVELÄ

Introduction EUPO 2018 course by Bahram BODAGHI

8:30 - 9:45 | HERMES

EUPO session 1 - Anatomy and imaging techniques

DICK Andrew

8:30	Blood retinal barrier *BEHAR-COHEN F - Paris*
8:45	Fluorescein angiography and ICG *PILOTTO E - Padova*
9:00	OCT: from anatomy to imaging *MIERE A - Creteil*
9:15	OCT angiography *STAURENGHI G - Milan*
9:30	Immune tolerance and its alteration *DICK A - Bristol*

09:45 - 10:15

Break

10:15 - 12:00 | HERMES

EUPO session 2 - What to do when I see?

KIVELÄ Tero

10:15	Serious retinal detachment *MIDENA E - Padova*
10:30	Atrophy of the retina *CREUZOT C - Dijon*
10:45	Detachment of pigment epithelium *DELYFER M - Bordeaux*
11:00	Black and white dots *NERI P - Abu Dhabi*
11:15	Vasculitis *KHAIRALLAH M - Monastir*
11:30	Inflammatory marcular edema *JONES N P - Manchester*
11:45	Pigmented tumor *KIVELÄ T - Helsinki*

Wednesday, October 3 - EUPO Course

12:00 - 13:15 | HERMES

EUPO Round table 1 - How do you diagnose these cases

BAILLIF Stephanie , BARISANI-ASENBAUER Talin

Cases of AMD, DME, DEP, dome shape, myopic choroidal nevascularisation, bruch rupture, VKH, Sarcoidosis, Syphilis are discussed.

Panel: Stephanie Baillif; Alexandra Miere; Piergiogio Neri; Marie-Noelle.Delyfer;Tero Kivela; Moncef Khairallah

13:15 - 14:15 | MYKONOS BAR

Lunch bags

14:15 - 15:45 | HERMES

EUPO session 3 - How does it work?

GRZYBOWSKI Andrzej

14:15	AntiVEGF *GRZYBOWSKI A - Olsztyn*
14:30	Steroids *WILLERMAIN F - Bruxelles*
14:45	Laser *LARSEN L M - Glostrup*
15:00	PDT *PARODI Maurizio B - Trieste*
15:15	Radiotherapy *PARROZZANI R - Padova*
15:30	IS and biologics *BODAGHI B - Paris*

15:45 - 17:15 | HERMES

EUPO Round table 2 - How do you diagnose these cases

NERI Piergiorgio

Cases : AMD 3 cases, DME 2 cases, DME + ischemic DR, ME due to VO, Ischemic vein occlusion, mac tel, Inflammatory choroidal neovascularization, Behçet's disease, Birdshot retinochoroidopathy, Acute retinal necrosis syndrome, sympathetic ophthalmia, IRVAN syndrome are discussed.

Panel : Piergiorgio Neri ; Maurizio Battaglia Parodi; Bahram Bodaghi; Nicholas Jones; François Willermain; Catherine Creuzot

17:15 - 17:45 | HERMES

EUPO Best case reports

Thursday, October 03 - EUPO Course

9:15 - 10:30 | HERMES

EUPO session 4 - My children cannot see

AUDO Isabelle

9:15	Inherited disease: from diagnosis to treatment *AUDO I - Paris*
9:30	Macular edema *AUDO I - Paris*
9:45	Toxoplasmosis *KODJIKIAN L - Lyon*
10:00	Exudative diseases *DE SMET M D - Mont sur Lausanne*
10:15	ROP *BREMOND-GIGNAC D - Paris*

10:30 - 11:00

Break

11:00 - 11:30 | HERMES

EVER lectures

11:30 - 12:15 | HERMES

EUPO session 5 - Surgical diseases and miscellaneous

VAN MEURS Jan C

11:30	Vitreomacular interface: new disease or new classification *VAN MEURS JC - Rotterdam*
11:39	Retinal detachment in myopic patients *MEIER P - Leipzig*
11:48	Central serous chorioretinopathy and ERD *BOUSQUET E - Paris*
11:57	Pars planitis *MISEROCCHI E - Milano*
12:06	Lymphoma *TOUITOU V - Paris*

12:15 - 12:45 | HERMES

EUPO Round table 3 - My job is difficult!

POURNARAS Constantin

Metastasis, choroidal ischemia, endophthalmitis, serpiginous discussed by the panel:
Leonidas Zografos, Moncef Khairallah; Alain Bron; Constantin Pournaras; Frédéric Mouriaux

12:45 - 12:50 | HERMES

EUPO Closure

CREUZOT Catherine



www.ever-f.eu

European Association for Vision and Eye Research Foundation

Santen

A Clear Vision For Life®

Ophthalmology Is Our Singular Focus

Protecting the World's Vision

Our commitment to eye care will always endure. As a specialised ophthalmology company, we are focused on improving ocular health to enrich patients' lives worldwide. That's Santen's Clear Vision for Life.

Discover more at www.santen.com

ARVO 2019

APRIL 28 – MAY 2 | VANCOUVER



Make plans to join ARVO in Vancouver!

Early Registration:
Opens by Oct. 15, 2018

Abstract submission:
Oct. 15 – Nov. 30 2018

New Deadline!

ARVO.org/AM

ARVO
The Association for Research in Vision and Ophthalmology

ARVO IMAGING IN THE EYE CONFERENCE

April 27, 2019
Vancouver Convention Centre
Vancouver, BC, Canada

Abstract submissions:
Jan. 4 – Feb. 15, 2019

ARVO.org/Imaging

ARVO
The Association for Research in Vision and Ophthalmology

Vision in focus

New Editor as from 2019

H. Scholl, Basel

Ophthalmic Research features original papers and reviews reporting on translational and clinical studies in the field of ophthalmology and vision research. The journal emphasizes hypothesis-based clinical and laboratory research with statistically valid results that clearly advance the fields of ophthalmic and vision research. It also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.

www.karger.com/ore

KARGER

Visit the Wisepress Booth and browse through recently published Karger books

KI18286

Presenting first authors

Four digit numbers refer to oral presentations

Day | Timeslot | Hall | Order in session

One letter and three digit numbers refer to posters

Day | Order in the postersession

Presenting first authors

Presenting first authors

Presenting first authors

Presenting first authors

All authors

All authors of abstracts are listed alphabetically

One letter and three digit numbers refer to posters
Four or five digit numbers refer to oral presentations
The digit numbers marked in **bold** indicate a first author abstract

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

All authors

Authors by country

EVER 2018
SPONSORS AND EXHIBITORS

SILVER SPONSORS

Santen

Théa

CIS SPONSOR

Théa

Dr.C 金眼科

SIS SPONSORS

Groupe AGRICA

CCAH ENSEMBLE, HANDICAP ET SOCIÉTÉ

IRCEM GROUPE

malakoff médéric SANTÉ • PRÉVOYANCE • RETRAITE

BAYER

Théa

EXHIBITORS

diagnosys

DICE

EXPERIMENTICA

Horus PHARMA

iris PHARMA

METROVISION

NOVARTIS

Quantel medical

santhera Pharmaceuticals

Théa

WISEPRESS

ZEISS

WEDNESDAY, OCTOBER 3

08:00 - 17:45	JM EUPO Course 2018 on Retina, Intraocular Inflammation & Uveitis	Hermes

THURSDAY, OCTOBER 4

	HERMES	RHODES 1	RHODES 2	RHODES 3	RHODES 4	GALLIENI 1&2
08:30 - 08:45	P Welcome by the President EVER 2018 - *BRON A*					Hermes
08:45 - 09:15	P EVER-Acta Lecture: OCT-A all what we need? - *SOUBRANE G*					Hermes
09:15 - 10:30	EUPO Course 2018 on Retina, Intraocular Inflammation & Uveitis JM	G/ACB - Novel models to study glaucomatous neurodegeneration SIS *KOLKO M - CORDEIRO MF*	EOVS - Basic principles of state-of-the-art ophthalmic instrumentation C *IRSCH K - BERNARDES R*	MBGE - I have received a mutation report for my patient, but i don't know what it means! C *LISKOVA P - DUDAKOVA L*	ACB - How to study mitochondria function, structure and clearance? C *KAARNIRANTA K - BLASIAK J*	G/COS - Ocular surface in glaucoma – why bother? SIS *NORMANDO EM - RATNARAJAN G*
10:30 - 11:00	SOC Coffee break					Exhibition area
11:00 - 11:30	KN EVER Lecture: Ocular Inflammation - delivered by the Past President - *DICK A*					Hermes
11:30 - 12:45	EUPO Course 2018 on Retina, Intraocular Inflammation & Uveitis & closure JM	G/LC - P+p (phaco 'plus' procedures) - revolutionising glaucoma care SIS *BLOOM P - AHMED F*	COS - Corneal nerves in health and disease C *GALLAR J - KOVACS I*	PBP - Cone photoreception in huma retina: structure and functional evaluation of the human fovea SIS *DE LA VILLA P - VIDAL-SANZ M*	ACB - Proteomics- a tool to find relevant biomarkers for ocular diseases, drug development and safety C *UUSITALO H - BEUERMAN R*	IM - Don't miss the diagnosis! how to survive against the worst enemies in your daily practice SIS *NERI P - KHAIRALLAH M*
12:45 - 14:00	CIS Lunchtime CIS: Nothing to fear about Demodex - *JAMES T*					Rhodes 2
14:15 - 14:45	KN Keynote Lecture: An eye on aging and disease - *APTE RS*					Hermes
14:45 - 16:00	RV - Bionic eye - where are we now? SIS *LYTVYNCHUK L*	G/LC - Simulated ocular surgery - part II SIS *SUNARIC MEGEVAND G - PRIOR FILIPE H*	COS/ACB - Aniridia-associated keratopathy (aak): from disease mechanisms to treatments SIS *LAGALI N - WYLEGALA E*	PBP - Pathogenic role of the micro-glia in neuroretinal diseases SIS *RAMIREZ JM - VIDAL-SANZ M*	ACB - Crosstalk of mitochondria and lysosomes in the degeneration of rpe SIS *KAARNIRANTA K - UUSITALO H*	MBGE - Controversies in epidemiology: beneficial or harmful effects of nutritional supplements in the prevention of AMD? SIS *GRAW J - MCCARTY C*
16:00 - 17:00	SOC Coffee break					Exhibition area
16:00 - 17:00	SOC Coffee with Profs					Poster area
16:00 - 17:00	POS Poster session: Retina/Vitreous - Physiology/Biochemistry/Pharmacology - Immunology/Microbiology					Poster area
17:00 - 18:15	RV - Oct-angiography biomarkers in choroidal and retinal disease SIS *BAILLIF S - SOUBRANE G*	G - Laser treatments for glaucoma -old headlines or breaking news? SIS *CRAWLEY L - AMEEN S*	G -YOS - Landmark papers in ophthalmology – how to do one! C *JÓHANNESSON G*	PO - Genetic predisposition syndromes in ophthalmology SIS *KIVELÄT - MOURIAUX F*	ACB - Ocular surface as a target for drug development SIS *UUSITALO H - BEUERMAN R*	MBGE - Grand rounds in animal & human genetics SIS *LEROY B - GRAW J*
18:30 - 19:30	SIS Evening SIS: What does TFOS DEWS II bring to your clinical practice? - *ROLANDO M*					Rhodes 2

FRIDAY, OCTOBER 5

08:30 - 09:45	RV - Ischemic ocular diseases: raise the red flag! SIS *AMBRESIN A - POURNARAS JA*	G - Maximising information extraction from biological data SIS *DAVIS B - NORMANDO EM*	COS - Optical imaging techniques for the cornea and anterior eye segment – pearls and pitfalls C *SZENTMARY N - WYLEGALA E*	IM - Therapeutic update: biologic agents in uveitis SIS *VAN CALSTER J - BODAGHI B*	LC/RV - New approaches in myopia diagnosis, prevention and treatment SIS *GRZYBOWSKI A - ASCASO F*	MBGE/NSPH - Understanding retinal ganglion cell loss — from genes to disease mechanisms SIS *VOTRUBA M - YU-WAI-MAN P*
09:45 - 10:15	KN Keynote Lecture: The Axon is dead: long live the Axon! - *LEVIN L*					Hermes
10:15 - 10:45	SOC Coffee break					Exhibition area
10:45 - 12:00	RV - Laser photocoagulation of capillary macro-aneuvrysms in retinal vascular diseases SIS *DUPAS B - PAQUES M*	G - EVER Obergurgl optic-nerve-conference symposium 2017 SIS *GRUS F - CROWSTON J*	COS - Diagnosis and treatment of infectious keratitis in the clinical practice today C *SZENTMARY N - SEITZ B*	IM/PO - Uveitis: translational insights in invasive diagnostics SIS *VAN CALSTER J - VAN GINDERDEUREN R*	LC - Optical and refractive changes with aging SIS *MICHAEL R - ROZEMA J*	LC/MBGE - Cholesterol, oxysterols and eye disease SIS *QUINLAN R*
12:00 - 12:30	KN European Ophthalmology Heritage Lecture: A brief history of cataract surgery - *DE LAEY JJ*					Hermes
12:30 - 13:30	CIS Lunchtime CIS: Innovations & Novel Products in Ophthalmology (INPO)					Hermes
12:30 - 13:30	SIS COS/MBGE - TFOS DEWS II: Dry Eye redefined - *VILLANI E - SULLIVAN DA*					Rhodes 1
12:30 - 13:30	CIS Lunchtime CIS: GuangDong Ophthalmologist Association (GDOA)					Rhodes 3
13:30 - 14:45	RV - Macular interface surgery SIS *PAPPAS G - POURNARAS JA*	G/IM - The latest update on uveitic glaucoma SIS *POURJAVAN S - NERI P*	COS - New approaches for unmet needs in anterior segment diseases SIS *FUCHSLUGERT - FERRARI G*	PO - Conjunctival tumors C *DESJARDINS L - MOULIN A*	PBP/ACB - Modern tools to examine the retina SIS *VIDAL-SANZ M - SALINAS NAVARRO MA*	MBGE - New insights in ocular developmental dysgenesis SIS *CALVAS P - ROZET JM*
14:45 - 15:45	SOC Coffee break					Exhibition area
14:45 - 15:45	SOC Coffee with Profs					Poster area
14:45 - 15:45	POS Poster session: Glaucoma - Neuro-ophthalmology/Strabismology/Paediatric/History - Electrophysiology, physiological Optics, Vision Sciences - Molecular Biology/Genetics/Epidemiology					Poster area
15:45 - 16:15	BM Business Meeting RV/LC	BM Business Meeting G/EOVS	BM Business Meeting COS/NSPH	BM Business Meeting PO/PBP	BM Business Meeting IM/MBGE	BM Business Meeting ACB
16:15 - 17:30	RV - Advanced oct and oct-angiography in challenging cases SIS *POURNARAS C - ZOGRAFOS L*	G - Neuroprotection in glaucoma – challenges and opportunities SIS *DAVIS B - DE GROEF L*	COS -Translational concepts in ophthalmology SIS *JUENEMANN A - SEITZ B*	PO - Orbital inflammation C *MOURIAUX F - KIVELÄT*	ACB/COS - Scleral contact lenses: hands on - fitting, maintenance & clinical advantages - it´s no magic ! SIS *KNOP E*	MBGE - Gene regulation in eye development and disease SIS *CVEKL A - KOZMIK Z*
17:30 - 18:00	KN Keynote Lecture: Microarchitecture and timeline of geographic atrophy: the x,y,z,t of AMD - *CURCIO C*					Hermes
18:00 - 19:15	RV - Adaptive optics: clinical applications and beyond SIS *PAQUES M - GRIEVE K*	NSPH - From Francisco de Goya's eyesight difficulties to famous one-eyed warriors SIS *GRZYBOWSKI A - ASCASO F*	COS - Keratoconus – from molecular biological background through corneal stabilization to keratoplasty SIS *SZENTMARY N - SEITZ B*	PO - Intravitreal pharmacotherapy in ocular oncology SIS *ZOGRAFOS L - DESJARDINS L*	ACB/COS - Keratoconus in all its states under a contact lens SIS *KNOP E - MEKKI MB*	NSPH - Understanding ocular anterior dysgenesis phenotype genotype SIS *BREMOND-GIGNAC D - ATILLA H*
19:15 - 19:45	GA EVER General Assembly					Hermes

SATURDAY, OCTOBER 6

08:30 - 09:45	RV - Controversies in new technology for the diagnosis and management of retinal and choroidal disease SIS *PAPASTEFANOU V - XIROUT*	G - Ocular imaging in glaucoma SIS *GARHOFER G - SCHMETTERER L*	COS - Visual rehabilitation in keratoconus beyond keratoplasty SIS *GATZIOUFAS Z - SZENTMARY N*	OOG Ocular Oncology Group I - Ocular adnexa, imaging and intraocular tumors JM *HEEGAARD S - KIVELÄT*	ACB/RV - Functional hypoxia in the eye: a role for hypoxia-inducible factors SIS *ANDRE H - KAUPPINEN A*	MBGE -The role of non-coding variants in ocular disease SIS *LISKOVA P - DE BAERE E*
09:45- 10:15	KN Ophthalmic Research Lecture: DARC Development and Translation - *CORDEIRO MF*					Hermes
10:15 - 11:15	SOC Coffee break					Exhibition area
10:15 - 11:15	POS Poster session: Cornea/Ocular Surface - Anatomy/Cell Biology - Lens and Cataract - Pathology/Oncology					Poster area
11:15 - 12:30	RV - Management of proliferative diabetic retinopathy SIS *PAPPAS G - POURNARAS JA*	ARVO@EVER - Advances in glaucoma SIS *CORDEIRO MF - BRON A*	EOVS - Rapid Fire session RF *LAWRENSON J - CASTELO-BRANCO M*	OOG Business Meeting JM *HEEGAARD S*	IM/LC - Rapid Fire session RF *PICHI F - NERI P - MICHAEL R - BARRAQUER R*	MBGE - Genetic models to human ocular diseases SIS *ASHERY-PADAN R - ABERDAM D*
12:30 - 13:45	FAN Club JM *VAN SCHOONEVELD M*	EOVS - Scattered light and visual function SIS *NAGRA M - BARBUR JL*	SOPREF - Eyelid and orbital tumors: diagnosis, treatment and biomarkers SIS *LAGIER J*	OOG Ocular Oncology Group II - Uveal melanoma JM *DESJARDINS L - ZOGRAFOS L*	COS - Rapid Fire session RF *GICQUEL JJ - SZENTMARY N*	Women in EVER JM *VOTRUBA M- KAWASAKI A*
13:45 - 14:15	SOC Coffee break					Exhibition area
14:15 - 15:30	Young investigators' award session I RF *POURJAVAN S - NERI P*	G/NSPH - Biomarkers in ophthalmology and beyond SIS *NORMANDO EM - CORDEIRO MF*	PO - New treatments in eye melanomas SIS *JAGER MJ - MOULIN A*	LC/COS - Customized intraocular lenses – challenges and limitations SIS *LANGENBUCHER A - EPPIGT*	RV - Rapid Fire session RF *POURNARAS JA - POURNARAS C*	MBGE - Rapid Fire session RF *LISKOVA P - GRAW J*
15:30 - 16:45	Young investigators' award session II RF *FUCHSLUGERT - BARRAQUER RI*	G - Rapid Fire session RF *NORMANDO EM - POURJAVAN S*	PO - Genetics in uveal melanoma SIS *HEEGAARD S - KILIC E*	ACB - Rapid Fire session RF *KAUPPINEN A - KAARNIRANTA K*	PBP - Rapid Fire session RF *OSBORNE N - VIDAL-SANZ M*	Update in ophthalmology JM
16:45 - 18:00	P Prize Award Ceremony & Closing Remarks					Hermes

BM Business Meeting
C Course
CIS Industry Sponsored Symposium
RF Rapid Fire session
GA General Assembly
JM Joint Meeting
KN Keynote lecture
SIS Special Interest Symposium
SOC Social
POS Poster session
P Plenary session

ACB: Anatomy / Cell Biology
COS: Cornea / Ocular Surface
EOVS: Electrophysiology / Physiological Optics / Vision Sciences
G: Glaucoma
IM: Immunology / Microbiology
LC: Lens and Cataract
MBGE: Molecular Biology / Genetics / Epidemiology
NSPH: Neuro-ophthalmology / Strabismology / Paediatric / History
PBP: Physiology / Biochemistry / Pharmacology
PO: Pathology / Oncology
RV: Retina / Vitreous
SOPREF: Société Ophtalmologique Plastique Reconstructive et Esthetique Française